,index,Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL,arms,arm1,arm2,arm1_included,arm2_included,arm1_to_remove,arm2_to_remove,also_arm1_to_remove,also_arm2_to_remove,new_arm1,new_arm2,arm1_has_approved_drugs,arm2_has_approved_drugs
3,24,25,NCT00112346,Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer,,Completed,No Results Available,Non-Small-Cell Lung Carcinoma,Drug: Cetuximab + platinum + gemcitabine|Drug: Platinum + Gemcitabine,"tumor response per treatment arm|disease control, symptom response, symptomatic progression, & progression free survival.",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA225-100,January 2005,December 2006,December 2006,"June 2, 2005",,"October 28, 2015","Local Institution, Mobile, Alabama, United States|Local Institution, Anchorage, Alaska, United States|Local Institution, Bakersfield, California, United States|Local Institution, Corona, California, United States|Local Institution, Oxnard, California, United States|Local Institution, San Diego, California, United States|Local Institution, Whittier, California, United States|Local Institution, Lakewood, Colorado, United States|Local Institution, Boynton Beach, Florida, United States|Local Institution, Brooksville, Florida, United States|Local Institution, Inverness, Florida, United States|Local Institution, Pembroke Pines, Florida, United States|Local Institution, Austell, Georgia, United States|Local Institution, Honolulu, Hawaii, United States|Local Institution, Skokie, Illinois, United States|Local Institution, Muncie, Indiana, United States|Local Institution, Annapolis, Maryland, United States|Local Institution, Frederick, Maryland, United States|Local Institution, Rockville, Maryland, United States|Local Institution, Plymouth, Massachusetts, United States|Local Institution, Farmington, New Mexico, United States|Local Institution, Armonk, New York, United States|Local Institution, Stony Brook, New York, United States|Local Institution, Gastonia, North Carolina, United States|Local Institution, Wilmington, North Carolina, United States|Local Institution, Bismarck, North Dakota, United States|Local Institution, Cincinnati, Ohio, United States|Local Institution, Portland, Oregon, United States|Local Institution, Charleston, South Carolina, United States|Local Institution, Dallas, Texas, United States|Local Institution, Vancouver, Washington, United States|Local Institution, Edmonton, Alberta, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Montreal, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Windsor, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00112346,2,cetuximab + platinum + gemcitabine,platinum + gemcitabine,1,1,False,False,False,False,cetuximab + platinum + gemcitabine,platinum + gemcitabine,1,1
11,65,66,NCT00173888,Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC),,Completed,No Results Available,Non-small Cell Lung Cancer,"Drug: Docetaxel, Cisplatin|Drug: Gemcitabine, Cisplatin","The primary objective of this study is to evaluate the 1-year treatment failure rate of two sequential chemotherapy regimens.|To evaluate the response rate for each regimen, the toxicity of each arm, and the duration of response",National Taiwan University Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,15.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,920303,July 2003,November 2012,November 2012,"September 15, 2005",,"December 6, 2012","Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT00173888,2,"docetaxel, cisplatin","gemcitabine, cisplatin",1,1,False,False,False,False,"docetaxel, cisplatin","gemcitabine, cisplatin",1,1
20,113,114,NCT00950365,Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),,Unknown status,No Results Available,Non-small Cell Lung Cancer,Drug: Pemetrexed|Drug: pemetrexed and erlotinib,Progression-free survival|Objective response rate|Disease control rate|Safety profile of pemetrexed and erlotinib combination|Assessment of molecular markers for biologic effects and predictive response,Montefiore Medical Center|Eli Lilly and Company|OSI Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,82.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pemetrexed/Erlotinib,May 2006,May 2011,,"July 31, 2009",,"July 31, 2009","University of Massachusetts, Worcester, Massachusetts, United States|Albert Einstein Cancer Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00950365,2,pemetrexed,pemetrexed and erlotinib,1,1,False,False,False,False,pemetrexed,pemetrexed and erlotinib,1,1
33,158,159,NCT00771563,Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES),SYRINGES,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: cisplatin + docetaxel|Drug: cisplatin + docetaxel + enoxaparin,Progression Free Survival|Symptom control evaluated with the Lung Cancer Symptoms Scale (LCSS)|Overall Survival|Best Overall Response|Incidence of total documented thromboembolic and hemorrhagic events|Overall safety and tolerability,"University Hospital, Antwerp|Universiteit Antwerpen",All,"18 Years and older   (Adult, Older Adult)",Phase 3,104.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TOGA 0601|EudraCT 2007-007696-16,June 2008,October 2012,October 2012,"October 13, 2008",,"June 28, 2013","University Hospital Antwerp, Edegem, Antwerp, Belgium|Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium",,https://ClinicalTrials.gov/show/NCT00771563,2,cisplatin + docetaxel,cisplatin + docetaxel + enoxaparin,1,1,False,False,False,False,cisplatin + docetaxel,cisplatin + docetaxel + enoxaparin,1,1
52,225,226,NCT00702182,Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer,,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: Vinorelbine (Navelbine)|Drug: Erlotinib,Define the recommended dose of oral navelbine with erlotinib,"National Cancer Centre, Singapore",All,"21 Years and older   (Adult, Older Adult)",Phase 1,30.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPCTG-VEP1,April 2008,April 2012,October 2012,"June 20, 2008",,"October 19, 2012","National Cancer Center Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT00702182,2,vinorelbine (navelbine),erlotinib,1,1,False,False,False,False,vinorelbine (navelbine),erlotinib,1,1
56,230,231,NCT00440414,Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC),,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Erlotinib (Tarceva)|Drug: Pemetrexed (Alimta),Time to Tumor Progression|Overall response rate|Overall survival between the two treatment arms|Quality of life assessment|Toxicity profile between the two treatment arms,Hellenic Oncology Research Group|University Hospital of Crete,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,320.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/06.05,April 2006,April 2010,April 2010,"February 27, 2007",,"August 19, 2010","University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece|401 Military Hospital, Medical Oncology Unit, Athens, Greece|Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece|IASO General Hospital of Athens, 1st Department of Medical Oncology, Athens, Greece|Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece|Sismanogleio General Hospital, 1st, 2nd Department of Pulmonary Diseases, Athens, Greece|Sotiria General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases, Athens, Greece|Metaxa's Anticancer Hospital of Piraeus,1st Dep of Medical Oncology, Piraeus, Greece|Theagenion Anticancer Hospital of Thessaloniki, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00440414,2,erlotinib (tarceva),pemetrexed (alimta),1,1,False,False,False,False,erlotinib (tarceva),pemetrexed (alimta),1,1
75,329,330,NCT00871403,Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer,,Completed,Has Results,"Lung Cancer, Non-Small Cell",Drug: pazopanib and pemetrexed|Drug: pemetrexed and cisplatin,"Progression-free Survival (PFS)|Overall Survival (OS)|Best Overall Response, Assessed as the Number of Participants With the Indicated Tumor Response: Investigator Assessed Only|Percentage of Participants With a Complete Response or a Partial Response",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,107.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,111128,July 2009,March 2011,March 2011,"March 30, 2009","February 16, 2012","June 20, 2013","GSK Investigational Site, Herlev, Denmark|GSK Investigational Site, Sutton, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT00871403,2,pazopanib and pemetrexed,pemetrexed and cisplatin,1,1,False,False,False,False,pazopanib and pemetrexed,pemetrexed and cisplatin,1,1
76,333,334,NCT03624309,Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer,,Not yet recruiting,No Results Available,Non-small Cell Lung Cancer,Drug: Anlotinib Plus Docetaxel|Drug: Docetaxel,PFS|OS|ORR|DCR|Safety (Number of Participants with Adverse Events as a Measure of Safety and Tolerability),Hunan Cancer Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,84.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALTER-L018,"October 15, 2018","October 1, 2019","October 1, 2020","August 10, 2018",,"September 17, 2018",,,https://ClinicalTrials.gov/show/NCT03624309,2,anlotinib plus docetaxel,docetaxel,1,1,False,False,False,False,anlotinib plus docetaxel,docetaxel,1,1
86,368,369,NCT00908336,Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen,,Unknown status,No Results Available,Non-Small Cell Lung Cancer,Drug: Docetaxel and Erlotinib|Drug: Erlotinib,Percentage of patients without disease progression after 6 months of treatment.|Progression-free survival|Duration of Response|Overall Response Rate|Disease Control Rate|Overall survival|Safety profile,Hospital Arnau de Vilanova,All,"18 Years and older   (Adult, Older Adult)",Phase 2,70.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML25033,March 2009,August 2010,December 2010,"May 25, 2009",,"May 25, 2009","Hospital Virgen de los Lirios, Alcoy, Alicante, Spain|Hospital Clínica de Benidorm, Benidorm, Alicante, Spain|Hospital General de Elda, Elda, Alicante, Spain|Hospital Provincial de Castellón, Castellón de la Plana, Castellón, Spain|Hospital de Sagunto, Sagunto, Valencia, Spain|Hospital San Juan de Alicante, Alicante, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT00908336,2,docetaxel and erlotinib,erlotinib,1,1,False,False,False,False,docetaxel and erlotinib,erlotinib,1,1
128,477,478,NCT01652820,Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer,GECP0008,Completed,No Results Available,Non Small-cell Lung Cancer,"Drug: Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day|Drug: Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d",Overall response rate|Local control rate at 1 year|Time to progression|Overall Survival,Spanish Lung Cancer Group|Aventis Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,140.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GECP 00-08 / TAX.ES1.209,October 2001,July 2006,December 2007,"July 30, 2012",,"July 30, 2012",,,https://ClinicalTrials.gov/show/NCT01652820,2,docetaxel 20mg/m2/week + carboplatin auc 2/weekly - concomitant chemoradiation 2gy/day,"docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin auc 2/w+ concomitant rdt 2gy/d",1,1,False,False,False,False,docetaxel 20mg/m2/week + carboplatin auc 2/weekly - concomitant chemoradiation 2gy/day,"docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin auc 2/w+ concomitant rdt 2gy/d",1,1
134,509,510,NCT01196078,A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer,,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: erlotinib [Tarceva]|Drug: vinorelbine,Percentage of Participants Achieving a Best Overall Response of Complete Response (CR) or Partial Response (PR)|Percentage of Participants Achieving Disease Control|Duration of Response Among Participants Who Achieved Either a CR or PR|Percentage of Participants With Disease Progression|Time to Disease Progression|Overall Survival: Percentage of Participants With an Progressive Disease or Death|Overall Survival: Time to Event|Quality of Life as Measured by the Functional Assessment of Cancer Therapy (FACT) Questionnaire|Changes in Quality of Life as Measured by the FACT Questionnaire|Percentage of Participants With Changes in Quality of Life as Measured by FACT Questionnaire Scores by Category of Change|Changes in Quality of Life as Assessed by FACT-L (Lung Symptoms) Questionnaire|Percentage of Participants With Changes in FACT-L (Lung Symptoms) by Category of Change,Hoffmann-La Roche,All,70 Years and older   (Older Adult),Phase 4,114.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML20322,February 2007,December 2010,December 2010,"September 8, 2010","July 27, 2015","July 27, 2015","Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01196078,2,erlotinib [tarceva],vinorelbine,1,1,False,False,False,False,erlotinib [tarceva],vinorelbine,1,1
139,553,554,NCT01350817,Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer,TARSEQ,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Erlotinib + docetaxel|Drug: Docetaxel,Progression free survival at 15 weeks.|Free survival at 12 months|Toxicities and feasibility,"University Hospital, Limoges|Hoffmann-La Roche",All,"18 Years and older   (Adult, Older Adult)",Phase 2,156.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,I10004,May 2011,March 2013,January 2014,"May 10, 2011",,"April 3, 2015","Service de Pneumologie, CHU Angers, Angers, France|Service de pneumologie; Centre Hospitalier d'Annecy, Annecy, France|Service de Pneumologie; Centre Hospitalier, Beauvais, France|Service de Pneumologie, Beauvais, France|Service de Pneumologie, Bordeaux, France|CHU Brest, Brest, France|Service de Pneumologie, Charleville Mezière, France|Service de Pneumologie ; Centre hospitalier, Charleville-Mezieres, France|Service de Pneumologie, Créteil, France|Service de Pneumologie; Centre Hospitalier, Draguignan, France|Service de Pneumologie, Draguignan, France|Service de Pneumologie, Elbeuf, France|Service de Pneumologie, Gap, France|Département de Pathologie Respiratoire du CHU de Limoges, Limoges, France|Service de Pneumologie, Hôpital de la Croix Rousse, Lyon, France|Service de Pneumologie-Neurologie ; Centre Hospitalier F. Quesnay, Mantes La Jolie, France|Département des Maladies Respiratoires ; Hôpital Sainte Marguerite, Marseille, France|CH de Meaux, Meaux, France|Service de Pneumologie, Meaux, France|Service de Pneumologie, Mulhouse, France|Service de Pneumologie - Hôpital St Antoine, Paris, Paris, France|Service de Pneumologie-Allergologie; Centre Hospitalier Général, Perigueux, France|CHU Reims, Reims, France|Service de Pneumologie, Hôpital Pontchailloux, Rennes, France|Service de Pneumologie; CHG de Roanne, Roanne, France|Clinique Pneumologique; Hôpital Charles Nicolle, Rouen, France|Service de Pneumologie; Hôpital Bois Guillaume, Rouen, France|Hôpital Charles Nicolle, Service de Pneumologie, Rouen, France|Service de Pneumologie, Hôpital Nord, saint Etienne, France|Service de Pneumologie, Villefranche, France",,https://ClinicalTrials.gov/show/NCT01350817,2,erlotinib + docetaxel,docetaxel,1,1,False,False,False,False,erlotinib + docetaxel,docetaxel,1,1
153,601,602,NCT00976456,Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer,65plus,Completed,Has Results,Non-squamous Non-small Cell Lung Cancer,Drug: Bevacizumab + Pemetrexed|Drug: Bevacizumab + Pemetrexed + Carboplatin,Progression Free Survival|Overall Survival,PD Dr. med. Wolfgang Schuette|Roche Pharma AG|Eli Lilly and Company|Martha-Maria Krankenhaus Halle-Dölau gGmbH,All,65 Years and older   (Older Adult),Phase 3,271.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,65 plus|ML21896,September 2009,October 2014,October 2014,"September 14, 2009","March 10, 2016","March 10, 2016","Krankenhaus Martha-Maria Halle-Doelau, Halle, Germany",,https://ClinicalTrials.gov/show/NCT00976456,2,bevacizumab + pemetrexed,bevacizumab + pemetrexed + carboplatin,1,1,False,False,False,False,bevacizumab + pemetrexed,bevacizumab + pemetrexed + carboplatin,1,1
154,603,604,NCT01348126,Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer,GALAXY,Terminated,No Results Available,Non-small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV|Non-small Cell Lung Cancer Metastatic,Drug: Docetaxel|Drug: Combination of ganetespib and docetaxel,Progression-free survival in two co-primary populations|Overall Response Rate|Determine qualitative and quantitative toxicities|Determine plasma drug concentrations of the combination|Evaluate Quality of Life|Disease Control Rate|Tumor size change|Overall survival,Synta Pharmaceuticals Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,385.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9090-08,May 2011,April 2014,October 2015,"May 5, 2011",,"November 5, 2015","Synta Pharmaceuticals Investigative Site, Tucson, Arizona, United States|Synta Pharmaceuticals Investigative Site, Santa Monica, California, United States|Synta Pharmaceuticals Investigative Site, Atlanta, Georgia, United States|Synta Pharmaceuticals Investigative Site, Chicago, Illinois, United States|Synta Pharmaceutials Investigative Site, Boston, Massachusetts, United States|Synta Pharmaceuticals Investigative Site, Winston-Salem, North Carolina, United States|Synta Pharmaceuticals Investigative Site, Kettering, Ohio, United States|Synta Pharmaceuticals Investigative Site, Portland, Oregon, United States|Synta Pharmaceuticals Investigative Site, Brussels, Belgium|Synta Pharmaceuticals Investigative Site, Jette, Belgium|Synta Pharmaceuticals Investigative Site, Yvoir, Belgium|Synta Pharmaceuticals Investigative Site, Banja Luka, Bosnia and Herzegovina|Synta Pharmaceuticals Investigative Site, Mostar, Bosnia and Herzegovina|Synta Pharmaceuticals Investgative Site, Sarajevo, Bosnia and Herzegovina|Synta Pharmaceuticals Investigative Site, Sarajevo, Bosnia and Herzegovina|Synta Pharmaceuticals Investigative Site, Tuzla, Bosnia and Herzegovina|Synta Pharmaceuticals Investigative Site, Hamilton, Canada|Synta Pharmaceuticals Investigative Site, Montreal, Canada|Synta Pharmaceuticals Investigative Site, Montreal, Canada|Synta Pharmaceuticals Investigative Site, Ottawa, Canada|Synta Pharmaceuticals Investigative Site, Pula, Croatia|Synta Pharmaceuticals Investigative Site, Split, Croatia|Synta Pharmaceuticals Investigative Site, Zagreb, Croatia|Synta Pharmaceuticals Investigative Site, Prague, Czech Republic|Synta Pharmaceuticals Investigative Site, Halle, Germany|Synta Pharmaceuticals Investigative Site, Hamburg, Germany|Synta Pharmaceuticals Investigative Site, Mainz, Germany|Synta Pharmaceuticals Investigative Site, Mannheim, Germany|Synta Pharmaceuticals Investigative Site, Offenbach, Germany|Synta Pharmaceuticals Investigative Site, Krakow, Poland|Synta Pharmaceuticals Investigative Site, Olsztyn, Poland|Synta Pharmaceuticals Investigative Site, Prabuty, Poland|Synta Pharmaceuticals Investigative Site, Szczecin, Poland|Synta Pharmaceuticals Investigative Site, Cluj - Napoca, Romania|Synta Pharmaceuticals Investigative Site, Cluj - Napoca, Romania|Synta Pharmaceuticals Investigative Site, Craiova, Romania|Synta Pharmaceuticals Investigative Site, Suceava, Romania|Synta Pharmaceuticals Investigative Site, Kazan, Russian Federation|Synta Pharmaceuticals Investigative Site, Moscow, Russian Federation|Synta Pharmaceuticals Investigative Site, Moscow, Russian Federation|Synta Pharmaceuticals Investigative Site, Saint-Petersburg, Russian Federation|Synta Pharmaceuticals Investigative Site, Saint-Petersburg, Russian Federation|Synta Pharmaceuticals Investigative Site, Sochi, Russian Federation|Synta Pharmaceuticals Investigative Site, Voronezh, Russian Federation|Synta Pharmaceuticals Investigative Site, Belgrade, Serbia|Synta Pharmaceuticals Investigative Site, Sremska Kamenica, Serbia|Synta Pharmaceuticals Investigative Site, Badalona, Spain|Synta Pharmaceuticals Investigative Site, Barcelona, Spain|Synta Pharmaceuticals Investigative Site, Madrid, Spain|Synta Pharmaceuticals Investigational Site, Leicester, United Kingdom|Synta Pharmaceuticals Investigative Site, London, United Kingdom|Synta Pharmaceuticals Investigational Site, London, United Kingdom|Synta Pharmaceuticals Investigational Site, Sutton, United Kingdom",,https://ClinicalTrials.gov/show/NCT01348126,2,docetaxel,combination of ganetespib and docetaxel,1,1,False,False,False,False,docetaxel,combination of ganetespib and docetaxel,1,1
156,622,623,NCT00678964,Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),TIE,Unknown status,No Results Available,Non-Small Cell Lung Cancer,Drug: Erlotinib|Drug: Vinorelbine and Carboplatin,"Evaluation of the progression free survival rate with the first-line therapy|Duration of remission|1-year survival|Overall survival|Response rate (CR/RR)|Quality of life, improvement of symptoms (FACT-L)|Simplified Charlsons´Comorbidity Score|Safety and Tolerability",LungenClinic Grosshansdorf,All,70 Years and older   (Older Adult),Phase 2,260.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EudraCT 2005-005827-32|ML19747,June 2006,November 2008,,"May 16, 2008",,"May 16, 2008","Gemeinschaftspraxis, Augsburg, Germany|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Charité - Campus Benjamin Franklin, Berlin, Germany|Helios Klinikum Emil von Behring, Berlin, Germany|Evangelische Lungenklinik Berlin, Berlin, Germany|Evang. Krankenhaus Bielefeld, Bielefeld, Germany|Johanniter-Krankenhaus Bonn, Bonn, Germany|Gemeinschaftspraxis, Celle, Germany|Fachkrankenhaus Coswig, Coswig, Germany|Fachklinik Diekholzen, Diekholzen, Germany|Klinikum Donaustauf, Donaustauf, Germany|Katholisches Klinikum Duisburg, Duisburg, Germany|Marien Hospital Düsseldorf, Düsseldorf, Germany|Universitätsklinik Essen, Essen, Germany|Klinikum Essen-Mitte, Essen, Germany|Krankenhaus Nordwest GmbH, Frankfurt/Main, Germany|Asklepios Fachkliniken München-Gauting, Gauting, Germany|Schwerpunktpraxis Onkologie, Goslar, Germany|Universitätsklinikum der Ernst-Moritz Arndt Universität Greifswald, Greifswald, Germany|Krankenhaus Großhansdorf, Großhansdorf, Germany|Georg-August-Universität Göttingen, Göttingen, Germany|Allgemeines Krankenhaus Harburg, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Lungenklinik Hemer, Hemer, Germany|Universitätsklinik des Saarlandes, Homburg/Saar, Germany|Klinikum der Friedrich-Schiller-Universität, Jena, Germany|Klinikum Kassel, Kassel, Germany|Malteser Krankenhaus St. Hildegardis Köln, Köln, Germany|Klinikum Leverkusen gGmbH, Leverkusen, Germany|Klinik Löwenstein gGmbH, Loewenstein, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|Katholisches Klinikum Mainz, Mainz, Germany|Klinikum der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Mannheim gGmbH, Mannheim, Germany|Zweckverband Kliniken im Mühlenkreis, Minden, Germany|Medizinische Klinik - Innenstadt, München, Germany|Ruppiner Kliniken GmbH, Neuruppin, Germany|Johanniter-Krankenhaus im Fläming gGmbH, Treuenbrietzen, Germany|Universitätsklinikum Ulm, Ulm, Germany",,https://ClinicalTrials.gov/show/NCT00678964,2,erlotinib,vinorelbine and carboplatin,1,1,False,False,False,False,erlotinib,vinorelbine and carboplatin,1,1
171,675,676,NCT03127319,A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases,,Recruiting,No Results Available,Non-squamous Non-small Cell Lung Cancer,Drug: apatinib docetaxel zoledronic|Drug: docetaxel zoledronic,Progression free survival|Overall survival|DCR (Disease control rate)|ORR (Objective response rate)|SREs（Skeletal-related events）|Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0,Affiliated Hospital of Hebei University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,40.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AHHU-2017AMZ01,"July 3, 2017",April 2019,December 2019,"April 25, 2017",,"January 17, 2018","Affiliated Hospital of Hebei university, BaoDing, Hebei, China",,https://ClinicalTrials.gov/show/NCT03127319,2,apatinib docetaxel zoledronic,docetaxel zoledronic,1,1,False,False,False,False,apatinib docetaxel zoledronic,docetaxel zoledronic,1,1
177,699,700,NCT00940875,A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer,,Terminated,Has Results,Non-Small Cell Lung Cancer,Drug: erlotinib [Tarceva]|Drug: gemcitabine,Percentage of Participants With Disease Progression or Death|PFS|Percentage of Participants Who Achieved Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST V 1.0|Percentage of Participants With Non-Progression at Weeks 8 and 16|Percentage of Participants Who Died|Overall Survival (OS)|Duration of Response,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,54.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML22429,June 2009,September 2011,September 2011,"July 16, 2009","April 2, 2015","April 2, 2015","Port Macquarie, New South Wales, Australia|Randwick, New South Wales, Australia|Sydney, New South Wales, Australia|Sydney, New South Wales, Australia|Tweed Heads, New South Wales, Australia|Wollongong, New South Wales, Australia|Brisbane, Queensland, Australia|Greenslopes, Queensland, Australia|Woolloongabba, Queensland, Australia|Richmond, South Australia, Australia|Terrace Gardens, South Australia, Australia|Hobart, Tasmania, Australia|Bendigo, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Wodonga, Victoria, Australia|Fremantle, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT00940875,2,erlotinib [tarceva],gemcitabine,1,1,False,False,False,False,erlotinib [tarceva],gemcitabine,1,1
180,727,728,NCT01498562,Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer,DATE,Completed,No Results Available,Non Small Cell Lung Cancer (NSCLC),Drug: Gefitinib and Nimotuzumab|Drug: Gefitinib,Progression free survival rate at 3 months|Progression free survival (PFS)|Overall survival (OS)|Overall safety profile|Objective response rate (ORR),Yonsei University,All,"20 Years and older   (Adult, Older Adult)",Phase 2,160.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4-2011-0662,December 2011,June 2014,June 2014,"December 23, 2011",,"December 2, 2014","Severance hospital, Yonsei Cancer Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01498562,2,gefitinib and nimotuzumab,gefitinib,1,1,False,False,False,False,gefitinib and nimotuzumab,gefitinib,1,1
183,731,732,NCT00700180,A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.,,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: bevacizumab [Avastin]|Drug: Carboplatin-based chemotherapy,"Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Dichotomized Baseline Plasma Marker Level|Progression-Free Survival - Percentage of Participants With an Event|Progression-Free Survival - Time to Event|Percentage of Participants With Objective Response|Percentage of Participants With Measurable Disease at Baseline Who Achieved CR, PR, or Stable Disease (SD) for at Least 6 Weeks|Duration of Response - Percentage of Participants With an Event|Duration of Response - Time to Event|Overall Survival - Percentage of Participants With an Event|Overall Survival - Time to Event",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,303.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO21015|2008-000662-23,September 2008,September 2012,September 2012,"June 18, 2008","September 25, 2014","September 25, 2014","St. Leonards, New South Wales, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Box Hill, Victoria, Australia|Fitzroy, Victoria, Australia|Antwerpen, Belgium|Liege, Belgium|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Ostrava, Czech Republic|Praha, Czech Republic|Odense, Denmark|Paris, France|Rouen, France|Bad Berka, Germany|Grosshansdorf, Germany|Hamburg, Germany|Oldenburg, Germany|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Budapest, Hungary|Edeleny, Hungary|Sopron, Hungary|Szombathely, Hungary|Torokbalint, Hungary|Milano, Italy|Milan, Italy|Orbassano, Italy|Roma, Italy|Den Haag, Netherlands|Enschede, Netherlands|Hoorn, Netherlands|Nieuwegein, Netherlands|Rotterdam, Netherlands|Poznan, Poland|Warszawa, Poland|Zabrze, Poland|Arkhangelsk, Russian Federation|Chelyabinsk, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Krasnodar, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|St Petersburg, Russian Federation|Barakaldo, Vizcaya, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Changhua, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Aberdeen, United Kingdom|Chelmsford, United Kingdom|London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00700180,2,bevacizumab [avastin],carboplatin-based chemotherapy,1,1,False,False,False,False,bevacizumab [avastin],carboplatin-based chemotherapy,1,1
185,737,738,NCT00891579,Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations,,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Pemetrexed (Alimta)|Drug: Gefitinib (IRESSA),Progression free survival (PFS)|Response rate (RR)|Overall survival (OS),Chinese Society of Lung Cancer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,161.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C-TONG0806,February 2009,September 2012,November 2012,"May 1, 2009",,"December 10, 2012","Lung Cancer Research Institute & Cancer Center of Guangdong General Hospital, Guangzhou, Guangdong, China|307 hospital of People's Liberation Army, Beijing, China|Peking Union Hospital, Beijing, China|Jilin Tumor Hospital, Changchun, China|Nanjing General Hospital of Nanjing Military Command, Nanjing, China|Shanghai Chest Hospital, Shanghai, China|The first hospital of China medical university, Shenyang, China",,https://ClinicalTrials.gov/show/NCT00891579,2,pemetrexed (alimta),gefitinib (iressa),1,1,False,False,False,False,pemetrexed (alimta),gefitinib (iressa),1,1
186,743,744,NCT00425191,Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.,,Completed,No Results Available,Non-small Cell Lung Cancer,Drug: Docetaxel and Gemcitabine|Drug: Gemcitabine cisplatin followed by docetaxel,Response Rate|Time to progression.,Sanofi,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,165.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XRP6976B_2501,July 2002,April 2005,,"January 22, 2007",,"December 7, 2009","Sanofi-Aventis, Milan, Italy",,https://ClinicalTrials.gov/show/NCT00425191,2,docetaxel and gemcitabine,gemcitabine cisplatin followed by docetaxel,1,1,False,False,False,False,docetaxel and gemcitabine,gemcitabine cisplatin followed by docetaxel,1,1
189,749,750,NCT00191191,To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC),,Completed,Has Results,Non-small Cell Lung Cancer,Drug: Pemetrexed 500 mg/m2|Drug: Pemetrexed 1000 mg/m2,Best Overall Response|Duration of Response|Progression-Free Survival (PFS)|Change From Baseline to 3 Months in Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD)|Change From Baseline to 3 Months in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Lung Cancer Subscale (LCS),Eli Lilly and Company,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,226.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5250|H3E-JE-NS01,October 2004,October 2008,October 2008,"September 19, 2005","November 25, 2009","December 9, 2009","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Gifu, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Gunma, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Miyagi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Niigata, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Okayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saitama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00191191,2,pemetrexed 500 mg/m2,pemetrexed 1000 mg/m2,1,1,False,False,False,False,pemetrexed 500 mg/m2,pemetrexed 1000 mg/m2,1,1
191,751,752,NCT00556322,"A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)",,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Alimta or Taxotere|Drug: erlotinib [Tarceva],Percentage of Participants Who Died (All Participants; Data Cutoff: 07 September 2010)|Duration of Overall Survival in All Participants (Data Cutoff 07 September 2010)|Probable Percentage of Participants Remaining Alive at 1 Year|Percentage of Participants Who Died in Epidermal Growth Factor Receptor (EGFR) Positive and Negative Population|Duration of OS in EGFR Positive and Negative Population|Probable Percentage of Participants Remaining Alive at 1 Year in the EGFR Positive and Negative Population|Percentage of Participants With Disease Progression or Death (All Participants; Data Cut Off 07 September 2010)|Progression-Free Survival (PFS) in All Participants (Data Cutoff 07 September 2010)|Probable Percentage of Participants Remaining Alive and Progression Free at 6 Months|Percentage of Participants With Disease Progression or Death in EGFR Positive and Negative Population (Data Cut Off 07 September 2010)|PFS in EGFR Positive and Negative Population (Data Cutoff 07 September 2010)|Probable Percentage of Participants Remaining Alive and Progression Free at 6 Months in EGFR Positive and Negative Population|Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator Using RECIST|Percentage of Participants With Deterioration in Quality of Life Determined Using Functional Assessment of Cancer Therapy - Lung (FACT-L)|Time to Deterioration in Quality of Life Using FACT-L|Probable Percentage of Participants Remaining Without Deterioration in Quality of Life at 6 Months as Assessed by FACT-L|Percentage of Participants With Symptomatic Progression Using FACT-L|Time to Symptomatic Progression Using FACT-L|Probable Percentage of Participants With Symptomatic Progression at 6 Months as Assessed by FACT-L|Percentage of Participants With Deterioration in the Trial Outcome Index (TOI)|Time to Deterioration in the TOI|Probable Percentage of Participants With Deterioration in the TOI at 6 Months as Assessed by FACT-L,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,424.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO18602,March 2006,June 2012,June 2012,"November 12, 2007","February 23, 2015","February 23, 2015","St. Leonards, New South Wales, Australia|Waratah, New South Wales, Australia|Adelaide, South Australia, Australia|East Bentleigh, Victoria, Australia|Fitzroy, Victoria, Australia|Geelong, Victoria, Australia|Melbourne, Victoria, Australia|Innsbruck, Austria|Klagenfurt, Austria|Wien, Austria|Wien, Austria|Antwerpen, Belgium|Winnipeg, Manitoba, Canada|Oshawa, Ontario, Canada|Sault Ste Marie, Ontario, Canada|Toronto, Ontario, Canada|Laval, Quebec, Canada|Montreal, Quebec, Canada|Santiago, Chile|Beijing, China|Guangzhou, China|Guangzhou, China|Shanghai, China|Ceské Budejovice, Czech Republic|Olomouc, Czech Republic|Plzen, Czech Republic|Herlev, Denmark|Odense, Denmark|Bayonne, France|Brest, France|Clermont-ferrand, France|Dijon, France|Le Mans, France|Lille, France|Limoges, France|Paris, France|PAU, France|Toulouse, France|Vandoeuvre-les-nancy, France|Bad Berka, Germany|Bochum, Germany|Halle (Saale), Germany|Herne, Germany|Neuruppin, Germany|Villingen-Schwenningen, Germany|Athens, Greece|Athens, Greece|Heraklion, Greece|Budapest, Hungary|Budapest, Hungary|Deszk, Hungary|Nyíregyháza, Hungary|Pecs, Hungary|Szombathely, Hungary|Torokbalint, Hungary|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Ancona, Marche, Italy|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Kuala Lumpur, Malaysia|Penang, Malaysia|Auckland, New Zealand|Christchurch, New Zealand|Lodz, Poland|Lodz, Poland|Otwock, Poland|Bucuresti, Romania|Cluj Napoca, Romania|Iasi, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Balashikha, Russian Federation|Chelyabinsk, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Kirov, Russian Federation|Krasnodar, Russian Federation|Krasnodar, Russian Federation|Kuzmolovo, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Perm, Russian Federation|Smolensk, Russian Federation|Soshi, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Yaroslavl, Russian Federation|Banska Bystrica, Slovakia|Bratislava, Slovakia|Nitra, Slovakia|Poprad, Slovakia|Golnik, Slovenia|Ljubljana, Slovenia|Maribor, Slovenia|Durban, South Africa|Johannesburg, South Africa|Pretoria, South Africa|Oviedo, Asturias, Spain|Santander, Cantabria, Spain|La Coruña, Spain|Zaragoza, Spain|Kharkov, Ukraine|Uzhgorod, Ukraine|Zaporozhye, Ukraine|Chelmsford, United Kingdom|Dundee, United Kingdom|Leicester, United Kingdom|Plymouth, United Kingdom|Caracas, Venezuela",,https://ClinicalTrials.gov/show/NCT00556322,2,alimta or taxotere,erlotinib [tarceva],1,1,False,False,False,False,alimta or taxotere,erlotinib [tarceva],1,1
192,758,759,NCT00783471,Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC),DOPERLO,Terminated,No Results Available,Advanced Non-Small Cell Lung Cancer,"Drug: Erlotinib, Docetaxel|Drug: Docetaxel, Erlotinib","Progression free survival (PFS)|To compare the Overall Survival (OS),the Objective Response Rate (ORR) and duration of response|Identify predictive signaling molecules of the EGFR pathway",Hellenic Cooperative Oncology Group,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,51.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HE 2D/07,November 2008,May 2010,June 2010,"October 31, 2008",,"June 16, 2010","Sotiria Hospital, Athens, Greece|""Alexandra"" Hospital, Athens, Greece|""Attikon"" University Hospital, 2nd Dept. of Internal Medicine, Propaedeutic, Oncology Section, Athens, Greece|Agii Anargiri Cancer Hospital, 3rd Dept. of Medical Oncology, Athens, Greece|Hygeia Hospital, Athens, Greece|University General Hospital of Ioannina, Medical Oncology Dept, Ioannina, Greece|Larissa University Hospital, Larissa, Greece|Metropolitan Hospital, Second Dept of Medical Oncology, Piraeus, Greece|Metropolitan Hospital, 1st Dept. of Medical Oncology, Pireaus, Greece|Patras University Hospital, Dept. of Internal Medicine, Oncology Section, Rio, Patras, Greece|Theagenio Cancer Hospital, 2nd Dept of Medical Oncology, Thessaloniki, Greece|Theagenio Cancer Hospital, 3rd Dept. of Medical Oncology, Thessaloniki, Greece|""Papageorgiou"" Hospital, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00783471,2,"erlotinib, docetaxel","docetaxel, erlotinib",1,1,False,False,False,False,"erlotinib, docetaxel","docetaxel, erlotinib",1,1
194,772,773,NCT00683904,Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer,,Completed,Has Results,Non-small Cell Lung Cancer (NSCLC),"Drug: Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|Drug: Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL","Number of Participants With Dose-limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose of Carboplatin in Combination With Ixabepilone, 32 mg/m^2|Number of Participants With Death as Outcome, Treatment-related Serious Adverse Events (SAEs), SAEs, Adverse Events (AEs), and Treatment-related AEs Leading to Discontinuation|Number of Participants With Grade 3 or Greater Treatment-related AEs|Number of Participants With Abnormalities in Hematology Laboratory Values by Worst CTC Grade|Number of Participants With Abnormalities in Serum Chemistry Laboratory Values by Worst CTC Grade|Number of Participants With Abnormalities in Urine Testing Results by Worst CTC Grade|Number of Participants With Abnormalities in Blood Pressure and Heart Rate|Number of Participants With Abnormalities in Weight and Eastern Cooperative Oncology Group (ECOG) Performance Status|Number of Participants at Each Response Evaluation Criteria in Solid Tumors (RECIST) Assessment|Maximum Observed Plasma Concentration of Ixabepilone|Time of Maximum Observed Plasma Concentration of Ixabepilone|Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinite Time of Ixabepilone|Volume of Distribution at Steady State of Ixabepilone|Total Body Clearance of Ixabepilone",R-Pharm,All,"20 Years and older   (Adult, Older Adult)",Phase 1,12.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CA163-160,June 2008,September 2009,September 2009,"May 26, 2008","April 15, 2011","March 10, 2016","Local Institution, Chuo-Ku, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00683904,2,"ixabepilone, 32 mg/m^2 + carboplatin, 5 mg/min/ml","ixabepilone, 32 mg/m^2 + carboplatin, 6 mg/min/ml",1,1,False,False,False,False,"ixabepilone, 32 mg/m^2 + carboplatin, 5 mg/min/ml","ixabepilone, 32 mg/m^2 + carboplatin, 6 mg/min/ml",1,1
199,786,787,NCT00370292,Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),,Completed,Has Results,Non Small Cell Lung Cancer,Drug: Pemetrexed - Before Protocol Amendment|Drug: Pemetrexed - After Protocol Amendment,"Mean Deoxycytidine Kinase (dCK) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3|Mean Human Equilibrative Nucleoside Transporter 1 (hENT) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3|Best Objective Tumor Response",Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,19.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10940|H3E-IT-S105,September 2006,September 2008,September 2008,"August 31, 2006","October 12, 2009","October 20, 2009","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy",,https://ClinicalTrials.gov/show/NCT00370292,2,pemetrexed - before protocol amendment,pemetrexed - after protocol amendment,1,1,False,False,False,False,pemetrexed - before protocol amendment,pemetrexed - after protocol amendment,1,1
200,792,793,NCT00330044,"Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer",,Completed,No Results Available,Inoperable Non Small Cell Lung Cancer,Drug: Premetrexed (Alimta)|Drug: Carboplatin,Response and Progression Free Survival,Sidney Kimmel Cancer Center at Thomas Jefferson University|Eli Lilly and Company|Thomas Jefferson University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,18.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,05C.276|2005-19,April 2006,August 2009,October 2009,"May 25, 2006",,"December 2, 2016","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00330044,2,premetrexed (alimta),carboplatin,1,1,False,False,False,False,premetrexed (alimta),carboplatin,1,1
206,803,804,NCT00050960,"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer",,Completed,Has Results,Non-small Cell Lung Cancer,Drug: bexarotene with carboplatin and paclitaxel|Drug: carboplatin and paclitaxel,Overall Survival,Eisai Inc.,All,"Child, Adult, Older Adult",Phase 3,612.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,L1069-48,May 2002,July 2004,March 2005,"January 3, 2003","August 24, 2010","July 13, 2012","Montgomery Cancer Center, L.L.C., Montgomery, Alabama, United States|Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Bay Area Cancer Research Group, LLC, Concord, California, United States|Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|Pacific Coast Hematology/Oncology Medical Group, Inc., Fountain Valley, California, United States|California Cancer Care, Inc., Greenbrae, California, United States|Coast Hematology and Oncology Associates, Long Beach, California, United States|Metropolitan Hematology/Oncology Medical Group, Los Angeles, California, United States|Sant P. Chawla, Inc., Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Sutter Gould Medical Foundation, Modesto, California, United States|Medical Oncology Care Associates, Orange, California, United States|Southern California Kaiser Permanente Medical Group, San Diego, California, United States|Sharp Health Care, San Diego, California, United States|UCSF/Mount Zion Comprehensive Cancer Center, San Francisco, California, United States|Medical Group of North County, Inc., San Diego Cancer Center, Vista, California, United States|Rocky Mountain Cancer Centers - Midtown, Denver, Colorado, United States|Eastern Connecticut Hematology & Oncology, Norwich, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Washington Cancer Institute, Washington, District of Columbia, United States|Comprehensive Cancer Care Specialists of Boca Raton, Boca Raton, Florida, United States|University of Florida/Jacksonville, Jacksonville, Florida, United States|Watson Clinic, Lakeland, Florida, United States|Oncology and Radiation Associates, Miami, Florida, United States|Florida Cancer Institute, New Port Richey, Florida, United States|Florida Oncology Associates, Orange Park, Florida, United States|Cancer Centers of Florida, P.A., Orlando, Florida, United States|South Florida Oncology & Hematology Consultants, Plantation, Florida, United States|Medical Oncology Associates of Augusta, Augusta, Georgia, United States|Georgia Oncology Partners Research & Education Foundation, Marietta, Georgia, United States|St. Luke's/Mountain State Tumor Institute (MSTI), Boise, Idaho, United States|Weiss Memorial Hospital, Chicago, Illinois, United States|Northwest Oncology and Hematology, SC, Elk Grove Village, Illinois, United States|Lutheran General Cancer Care Center, Park Ridge, Illinois, United States|Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States|Hematology Oncology Assoc. of Illinois, Skokie, Illinois, United States|Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Cancer Care Center, New Albany, Indiana, United States|Michiana Hematology-Oncology, South Bend, Indiana, United States|Kansas City Oncology and Hematology Group, Kansas City Cancer Centers, Overland Park, Kansas, United States|Drs. Carroll, Sheth, and Raghavan, Louisville, Kentucky, United States|Southwest Oncology Associates, Lafayette, Louisiana, United States|APMC, Metairie, Louisiana, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Chesapeake Oncology-Hematology Associates, Baltimore, Maryland, United States|Associates in Oncology/Hematology PC, Rockville, Maryland, United States|Berkshire Hematology Oncology, PC, Pittsfield, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Providence Cancer Institute, Southfield, Michigan, United States|St. Lukes Hospital, Duluth, Minnesota, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Hematology Oncology Centers of the Northern Rockies, Billings, Montana, United States|Montana Cancer & Infectious Disease Specialists, Missoula, Montana, United States|Cancer and Blood Specialists of Nevada, Henderson, Nevada, United States|Nevada Cancer Center, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Orange Medical Group, East Orange, New Jersey, United States|VA New Jersey Health Care System, East Orange, New Jersey, United States|Hematology-Oncology Associates of Northern NJ, PA, Morristown, New Jersey, United States|Somerset Hematology Oncology Associates, Somerset, New Jersey, United States|University of Medicine & Dentistry of NJ, School of Osteopathic Medicine, Stratford, New Jersey, United States|Overlook Oncology Center, Summit, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|New York Oncology Hematology, P.C., Capital District Hematology Oncology Associates, Albany, New York, United States|Erie Medical Center, Buffalo, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Arena Oncology Associates, Great Neck, New York, United States|Cancer Institute of Long Island, Inc., Great Neck, New York, United States|Cancer Research of Long Island, Inc., Great Neck, New York, United States|Broome Oncology, LLC, Johnson City, New York, United States|New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York, United States|Columbia Presbyterian Medical Center, New York, New York, United States|VA Medical Center, Northport, New York, United States|New York Oncology Hematology, P.C., Riverview Cancer Care Medical Associates, Rexford, New York, United States|South Shore Hematology Oncology Associates, PC, Rockville Centre, New York, United States|Raleigh Hematology Oncology Clinic, Cary, North Carolina, United States|Northwest Carolina Oncology and Hematology, P.A., Hickory, North Carolina, United States|Nashat Y. Gabrail, MD, Inc., Canton, Ohio, United States|University of Cincinnati, Barrett Cancer Center, Cincinnati, Ohio, United States|Columbus Community Clinical Oncology Program, Columbus, Ohio, United States|Dayton Oncology/Hematology Consultants, Dayton, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Cancer Care Associates - Mercy Campus, Oklahoma City, Oklahoma, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Oncology/Hematology, Kaiser Permanente Northwest, Portland, Oregon, United States|Oncology Hematology of Lehigh Valley, PC, Bethlehem, Pennsylvania, United States|Medical Oncology Associates of Wyoming Valley, PC, Kingston, Pennsylvania, United States|Charleston Hematology Oncology P.A., Charleston, South Carolina, United States|Liberty Hematology/Oncology, Columbia, South Carolina, United States|WJB Dorn VA Medical Center, Columbia, South Carolina, United States|Cancer Centers of the Carolinas, Seneca, South Carolina, United States|Santee Hematology/Oncology, Sumter, South Carolina, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Boston Baskin Cancer Group, Memphis, Tennessee, United States|Texas Oncology, P.A., Arlington, Texas, United States|South Austin Cancer Center, Austin, Texas, United States|Lone Star Oncology Consultants, P.A., Austin, Texas, United States|Cancer Specialists of South Texas, PA, Corpus Christi, Texas, United States|Texas Cancer Center at Medical City, Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|Texas Oncology, P.A., Garland, Texas, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Allison Cancer Center, Midland, Texas, United States|West Texas Cancer Center, Odessa, Texas, United States|Hope Oncology, Richardson, Texas, United States|Hematology & Oncology Associates of South Texas, San Antonio, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Texoma Cancer Center, Wichita Falls, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Arlington Fairfax Hematology Oncology, Arlington, Virginia, United States|Hematology Oncology Patient Enterprises, Center for Cancer Care, Charlottesville, Virginia, United States|Danville Hematology & Oncology, Inc., Danville, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Stark MD, PC, Portsmouth, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Yakima Regional Cancer Care Center, Internal Medicine Associates of Yakima, Inc., Yakima, Washington, United States|Morgantown Internal Medicine Group, Morgantown, West Virginia, United States|Allgemeines offentliches Krankenhaus der barmherzigen Schwestern vom Heiligen Kreuz Pneumologie, Wels, Austria|Sozialmedizinisches Zentrum, Wien, Austria|Kaiser-Franz-Josef-Spital, Wien, Austria|Algoma Regional Cancer Program - Sault Area Hospital, Sault Ste. Marie, Ontario, Canada|Humber River Regional Hospital, Weston, Ontario, Canada|S.M.B.D. Jewish General Hospital, Montreal, Quebec, Canada|Centre Hospitalier du Pays d'Aix, Aix en Provence, Cedex 01, France|Centre Hospitalier General de la Region Annecienne, Annecy Cedex, France|Centre Hospitalier d'Antibes-Juan-Les-Pins, Antibes Cedex, France|CHRU Hopital de Bois Guillaume, Bois Guillaume, France|DOP International, Creteil, France|Hopital de Draguignan, Draguignan, France|Centre Hospitalier General, Gap Cedex, France|Hopital du Cluzeau, Limoges Cedex, France|CHU Hopital St. Marguerite, Marseille, Cedex 09, France|Centre Regional de Lutte contre le Cancer (CRLC), Val d'Aurelle-Paul Lamarque, Montpellier, Cedex 05, France|Hopital Saint Antoine, Paris, Cedex 12, France|CHU - Hopital Nord, St. Etienne, Cedex 2, France|Hopital Saint Anne, Toulon Naval, France|Service de Pneumology, Hopital Adulte de Brabois, Vandoeuvre les Nancy, France|Centre Hospitalier, Villefranche sur Soane, France|Dept. of Internal Medicine, St. Nikolaus-Stiftshospital Andernach, Andernach, Germany|Aesklepios-Fachkliniken Muchen-Gauting, Gauting, Germany|Krankenhaus GroBhansdorf, Zentrum fur Pneumologie und Thoraxchirurgie, GroBhansdorf, Germany|Ludwig-Maximilians Universitat Munchen, Munchen, Germany|Charite Universitatsklinikum der Humboldt-Universitat zu Berlin, SchumannstraBe, Berlin, Germany|Hospital Provincial de Castellon, Castellon, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Universitario La Fe Servicio de Oncologia, Valencia, Spain|Hospital Arnau de Villanova, Servicio de Oncologia, Valencia, Spain|Hospital Clinico Universitario, Servicio Hematologia y Oncologia, Valencia, Spain|Hospital de Sagunto Servicio de Oncologia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT00050960,2,bexarotene with carboplatin and paclitaxel,carboplatin and paclitaxel,1,1,False,False,False,False,bexarotene with carboplatin and paclitaxel,carboplatin and paclitaxel,1,1
221,864,865,NCT01871480,CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer,,Terminated,No Results Available,Non-Small Cell Lung Cancer,Drug: Group A:cytokine-induced killer cell +gefitinib|Drug: Group B:Gefitinib,Progression-free survival|Overall survival,Kunming Medical University,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,50.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CIK plus gefitinib,May 2013,November 2015,May 2016,"June 6, 2013",,"December 30, 2013","Department of Cancer Biotherapy Center, The Third Affiliated Hospital of Kunming Medicine University, Kunming, Yunnan, China",,https://ClinicalTrials.gov/show/NCT01871480,2,group a:cytokine-induced killer cell +gefitinib,group b:gefitinib,1,1,False,False,False,False,group a:cytokine-induced killer cell +gefitinib,group b:gefitinib,1,1
226,903,904,NCT00231465,Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer,,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: docetaxel (Taxotere®)|Drug: ZD1839,Overall Response Rate (ORR)|Progression Free Survival (PFS) Rate|Overall Survival (OS) Rate,H. Lee Moffitt Cancer Center and Research Institute|AstraZeneca,All,70 Years and older   (Older Adult),Phase 2,44.0,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-12905|1839US/0205,July 2003,August 2012,August 2012,"October 4, 2005","November 30, 2012","March 3, 2017","H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT00231465,2,docetaxel (taxotere®),zd1839,1,1,False,False,False,False,docetaxel (taxotere®),iressa,1,1
231,920,921,NCT00881296,Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer,GEEP,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: gemcitabine and carboplatin|Drug: Gemcitabine,Efficacy (response rate)|The toxicity profile (adverse event profile),Hamamatsu University,All,76 Years and older   (Older Adult),Phase 2,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Hamamatsu 20-34,March 2008,March 2011,June 2011,"April 15, 2009",,"September 7, 2011","Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan",,https://ClinicalTrials.gov/show/NCT00881296,2,gemcitabine and carboplatin,gemcitabine,1,1,False,False,False,False,gemcitabine and carboplatin,gemcitabine,1,1
233,925,926,NCT01749072,Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients,,Unknown status,No Results Available,Non-small Cell Lung Cancer|Effects of Chemotherapy,"Drug: Gefitinib group|Drug: Vinorelbine, Ifosfamide, Mesna",Progression free survival|Overall survival|objective response rate|the score of functional assessment of cancer treatment-lung (FACT-L)|Number of participants with adverse events,Peking Union Medical College Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,120.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PUMCH-S464,December 2012,December 2016,December 2017,"December 13, 2012",,"December 13, 2012","Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing, Beijing, China",,https://ClinicalTrials.gov/show/NCT01749072,2,gefitinib group,"vinorelbine, ifosfamide, mesna",1,1,False,False,False,False,gefitinib group,"vinorelbine, ifosfamide, mesna",1,1
256,1079,1080,NCT00004096,Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: carboplatin|Drug: vinorelbine ditartrate,,Northwestern University|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,,Other|NIH,Interventional,Primary Purpose: Treatment,NU 99L2|NU-99L2|NCI-G99-1589,August 1999,March 2002,March 2002,"August 5, 2004",,"June 6, 2012","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00004096,2,carboplatin,vinorelbine ditartrate,1,1,False,False,False,False,carboplatin,vinorelbine ditartrate,1,1
262,1103,1104,NCT00004159,Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor,,Terminated,No Results Available,Lung Cancer,Drug: gemcitabine hydrochloride|Drug: paclitaxel,,University of Alabama at Birmingham|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,54.0,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000067399|UAB-9720|UAB-F970730006|NCI-G99-1624,February 2000,February 2000,February 2000,"July 26, 2004",,"November 20, 2013","University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT00004159,2,gemcitabine hydrochloride,paclitaxel,1,1,False,False,False,False,gemcitabine hydrochloride,paclitaxel,1,1
264,1124,1125,NCT00003447,Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,,Unknown status,No Results Available,Lung Cancer,Drug: gemcitabine hydrochloride|Drug: vinorelbine tartrate,,Istituto Nazionale per lo Studio e la Cura dei Tumori|National Cancer Institute (NCI),All,70 Years and older   (Older Adult),Phase 3,630.0,Other,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000066476|ITA-MILES|ITA-GOCSI-MILES|EU-98019,July 1998,,,"May 21, 2004",,"December 19, 2013","Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy",,https://ClinicalTrials.gov/show/NCT00003447,2,gemcitabine hydrochloride,vinorelbine tartrate,1,1,False,False,False,False,gemcitabine hydrochloride,vinorelbine tartrate,1,1
272,1167,1168,NCT00022646,Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: gemcitabine hydrochloride|Drug: pemetrexed disodium,tumor response rate|duration of response|time to treatment failure|survival|time to disease progression,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,157.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCCTG-N0026|NCI-2012-02399|CDR0000068838,August 2001,November 2003,October 2008,"January 27, 2003",,"December 7, 2016","CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, United States|CCOP - Wichita, Wichita, Kansas, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|CCOP - Duluth, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Health Plaza, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Medcenter One Health System, Bismarck, North Dakota, United States|CCOP - Merit Care Hospital, Fargo, North Dakota, United States|Altru Health Systems, Grand Forks, North Dakota, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT00022646,2,gemcitabine hydrochloride,pemetrexed disodium,1,1,False,False,False,False,gemcitabine hydrochloride,pemetrexed disodium,1,1
275,1189,1190,NCT00095225,A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer),,Completed,No Results Available,"Non-Small-Cell Lung Carcinoma|Neoplasm Recurrence, Local",Drug: Avastin (bevacizumab)|Drug: Tarceva (erlotinib HCl),To evaluate the safety and preliminary efficacy of combining bevacizumab with chemotherapy or Tarceva relative to chemotherapy alone on patients with previously treated advanced non-small cell lung cancer.,"Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,122.0,Industry,Interventional,Primary Purpose: Treatment,OSI2950g,July 2004,,November 2006,"November 2, 2004",,"January 29, 2008","Comprehensive Blood and Cancer Center (TORI), Bakersfield, California, United States|Bay Area Cancer Research Group, Concord, California, United States|Virginia K. Crosson Cancer Center (TORI), Fullerton, California, United States|California Cancer Center, Inc, Greenbrae, California, United States|Wilshire Oncology Medical Group (TORI), Laverne, California, United States|Pacific Shores Medical Group (TORI), Long Beach, California, United States|UCLA Medical Center PVUB 3360, Los Angeles, California, United States|Central Hematology Oncology Medical Group (TORI), Monterey Park, California, United States|North Valley Hematology/Oncology Medical Group (TORI), Northridge, California, United States|Ventura County Hematology-Oncology Specialists (TORI), Oxnard, California, United States|Cancer Care Associates Medical Group (TORI), Redondo Beach, California, United States|UC Davis Cancer Center, Sacramento, California, United States|Kaiser Permanente/ San Diego, San Diego, California, United States|Sansum Santa Barbara Medical Foundation Clinic (TORI), Santa Barbara, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc (TORI), Santa Barbara, California, United States|Kaiser Permanente Northern CA, Vallejo, California, United States|San Diego Cancer Center Medical Group (TORI), Vista, California, United States|Comprehensive Cancer Care Specialist at Boca Raton, Boca Raton, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|The Florida Cancer Institute(TORI), Orlando, Florida, United States|MD Anderson Cancer Ctr- Orlando, Orlando, Florida, United States|Hematology and Oncology of Northeast Georgia, PC (TORI), Athens, Georgia, United States|Medical Oncology Associates, PC (TORI), Augusta, Georgia, United States|Suburban Hematology-Oncology Associates (TORI), Lawrenceville, Georgia, United States|WellStar Cancer Research Office, Marietta, Georgia, United States|Atlanta Cancer Care (TORI), Roswell, Georgia, United States|Rush-Presbyteriam, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola Univ. Medical Center, Maywood, Illinois, United States|Hematology Oncology Consultants, Naperville, Illinois, United States|Oncoloy Hematology Associates of Central Illinois, PC (TORI), Peoria, Illinois, United States|Norton Healthcare Louisville Oncology, Louisville, Kentucky, United States|Ochsner Cancer Inst., New Orleans, Louisiana, United States|Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States|Methodist Cancer Center-Oncology Research, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada (TORI), Las Vegas, Nevada, United States|Summit Medical Group Overlook Oncology Center, Summit, New Jersey, United States|Cancer Research of Long Island, Great Neck, New York, United States|Northwestern Carolina Oncology and Hematology, Hickory, North Carolina, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Earle A. Chiles Research Institute, Portland, Oregon, United States|Kaiser Permanente Northwest Region, Portland, Oregon, United States|Univ. of Pittsburgh Cancer Center Inst., Pittsburgh, Pennsylvania, United States|University of Tenn. Cancer Ins, Memphis, Tennessee, United States|The West Cancer Clinic, Memphis, Tennessee, United States|M.D. Anderson, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Internal Medicine Associates of Yakima, Yakima, Washington, United States",,https://ClinicalTrials.gov/show/NCT00095225,2,avastin (bevacizumab),tarceva (erlotinib hcl),1,1,False,False,False,False,avastin (bevacizumab),tarceva (erlotinib hcl),1,1
283,1222,1223,NCT00003762,Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: docetaxel|Drug: gemcitabine hydrochloride,response rate|quality of life,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,106.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCCTG-982452|NCI-2012-02294|CDR0000066887,February 1999,February 2003,May 2008,"June 24, 2004",,"July 13, 2016","CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, United States|CCOP - Wichita, Wichita, Kansas, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|CCOP - Duluth, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Clinic, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Quain & Ramstad Clinic, P.C., Bismarck, North Dakota, United States|CCOP - Merit Care Hospital, Fargo, North Dakota, United States|Altru Health Systems, Grand Forks, North Dakota, United States|CCOP - Geisinger Clinical and Medical Center, Danville, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT00003762,2,docetaxel,gemcitabine hydrochloride,1,1,False,False,False,False,docetaxel,gemcitabine hydrochloride,1,1
287,1240,1241,NCT00407550,Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,,Completed,Has Results,Lung Cancer,Drug: gemcitabine HCL|Drug: pemetrexed disodium,Number of Patients With Confirmed Responses|Progression-free Survival|Overall Survival|Adverse Event,Mayo Clinic|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 2,19.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000516012|P30CA015083|RC0524|06-002282|H3E-US-S061,November 2006,January 2008,"May 12, 2010","December 5, 2006","June 13, 2012","May 2, 2019","Mayo Clinic Cancer Center, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00407550,2,gemcitabine hcl,pemetrexed disodium,1,1,False,False,False,False,gemcitabine hcl,pemetrexed disodium,1,1
293,1255,1256,NCT00054184,Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer,,Unknown status,No Results Available,Lung Cancer,Drug: docetaxel|Drug: paclitaxel poliglumex,Saftey|Efficacy,CTI BioPharma,All,"18 Years and older   (Adult, Older Adult)",Phase 3,350.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTI-PGT302|CDR0000269907|CWRU-CTI-1503,January 2003,December 2013,,"February 6, 2003",,"July 30, 2013","Clinical Research Consultants, Incorporated, Hoover, Alabama, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|Highlands Oncology Group - Springdale, Springdale, Arkansas, United States|Pacific Cancer Medical Center, Incorporated, Anaheim, California, United States|Synergy Hematology/Oncology Medical Associates, Encino, California, United States|California Cancer Care, Inc., Greenbrae, California, United States|California Hematology/Oncology Medical Group, Torrance, California, United States|Northwest Oncology and Hematology Associates, Coral Springs, Florida, United States|Florida Oncology Associates, Jacksonville, Florida, United States|Hematology Oncology Associates of theTreasure Coast - Port St. Lucie, Port Saint Lucie, Florida, United States|Suburban Hematology-Oncology, Snellville, Georgia, United States|Gross Point Medical Center, Skokie, Illinois, United States|Western Kentucky Hematology/Oncology Group, Paducah, Kentucky, United States|Kentucky Cancer Clinic, Pikeville, Kentucky, United States|Saint Joseph Oncology, Incorporated, Saint Joseph, Missouri, United States|Montana Cancer Specialists, Missoula, Montana, United States|Las Vegas Cancer Center, Las Vegas, Nevada, United States|Howell, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|New Mexico Oncology-Hematology Consultants, Limited, Albuquerque, New Mexico, United States|Queens Medical Associates, PC, Fresh Meadows, New York, United States|Piedmont Oncology Specialist, II, PLLC, Monroe, North Carolina, United States|Odyssey Research Services, Bismarck, North Dakota, United States|Gabrail Cancer Center - Canton Office, Canton, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Charleston Hematology-Oncology, P.A., Charleston, South Carolina, United States|Tri County Oncology Associates, Rock Hill, South Carolina, United States|Santee Hematology Oncology, Sumter, South Carolina, United States|Family Cancer Center, Collierville, Tennessee, United States|Southwest Regional Cancer Center, Austin, Texas, United States|Richardson, Texas, United States|Danville Hematology and Oncology, Incorporated, Danville, Virginia, United States|Virginia Oncology Care P.C., Richlands, Virginia, United States|Western Washington Medical Group, Everett, Washington, United States",,https://ClinicalTrials.gov/show/NCT00054184,2,docetaxel,paclitaxel poliglumex,1,1,False,False,False,False,docetaxel,paclitaxel poliglumex,1,1
306,1302,1303,NCT01303926,Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer,ERACLE,Unknown status,No Results Available,Non-squamous Nonsmall Cell Neoplasm of Lung,Drug: cisplatin pemetrexed|Drug: carboplatin paclitaxel bevacizumab,Difference in terms of quality of life (QOL) between treatment arms|treatment activity in terms of response rate|toxicity evaluation|Evaluation of QoL across time,Gruppo Oncologico Italia Meridionale,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,118.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Goim 2903|2009-015807-19,January 2010,June 2012,June 2012,"February 25, 2011",,"April 10, 2012","""Giovanni Paolo II"" Oncology Institute, Bari, BA, Italy|""San Paolo Hospital"" Oncology Service, Bari, BA, Italy|Division of Medical Oncology, ""Fatebenefratelli"" Hospital, Benevento, BN, Italy|Division of Medical Oncology, ""Sen. Perrino"" Hospital, Brindisi, Italy, Brindisi, BR, Italy|7 Division of Medical Oncology, ""Casa Sollievo della Sofferenza"" Hospital,, San Giovanni Rotondo, FG, Italy|Medical Oncology Division ""Vito Fazzi"" Hospital, Lecce, Le, Italy|Division of Medical Oncology, ""Buccheri-La Ferla"" Hospital, Palermo, PA, Italy|Division of Medical Oncology, ""La Maddalena"" Hospital, Palermo, PA, Italy|Division of Medical Oncology, Castellaneta Hospital, Castellaneta, TA, Italy|Division of Medical Oncology ""San Giuseppe Moscati Hospital"", Taranto, TA, Italy|Clinical Trials Office, Department of Medical Sciences, Azienda ULSS 13, Mirano, VE, Italy|National Cancer Institute ""G. Pascale"" Thoracic Dept., Napoli, Italy",,https://ClinicalTrials.gov/show/NCT01303926,2,cisplatin pemetrexed,carboplatin paclitaxel bevacizumab,1,1,False,False,False,False,cisplatin pemetrexed,carboplatin paclitaxel bevacizumab,1,1
319,1378,1379,NCT00268489,Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Biological: bevacizumab|Drug: pemetrexed disodium,Proportion of progression-free patients at 3 months|Response (complete and partial) as assessed by RECIST criteria|Overall survival|Progression-free survival|Duration of response|Time to treatment failure,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,48.0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCCTG-N0426|NCI-2012-02681|SWOG-N0426|CDR0000456427,May 2006,May 2007,April 2010,"December 22, 2005",,"July 6, 2016","Providence Cancer Center, Anchorage, Alaska, United States|Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Eden Medical Center, Castro Valley, California, United States|Saint Rose Hospital, Hayward, California, United States|Highland General Hospital at St. George's University School of Medicine, Oakland, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Valley Care Medical Center, Pleasanton, California, United States|Doctors Medical Center - San Pablo Campus, San Pablo, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Northside Hospital Cancer Center, Atlanta, Georgia, United States|Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|WellStar Cobb Hospital, Austell, Georgia, United States|Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Kennestone Cancer Center at Wellstar Kennestone Hospital, Marietta, Georgia, United States|Southern Regional Medical Center, Riverdale, Georgia, United States|Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States|Pearlman Comprehensive Cancer Center at South Georgia Medical Center, Valdosta, Georgia, United States|Saint Anthony's Hospital at Saint Anthony's Health Center, Alton, Illinois, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Galesburg Clinic, Galesburg, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hopedale Medical Complex, Hopedale, Illinois, United States|Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|Good Samaritan Regional Health Center, Mt. Vernon, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|St. Margaret's Hospital, Spring Valley, Illinois, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, Indiana, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|Reid Hospital & Health Care Services, Incorporated, Richmond, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Genesis Regional Cancer Center at Genesis Medical Center, Davenport, Iowa, United States|Mercy Capitol Hospital, Des Moines, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - North Iowa, Mason City, Iowa, United States|McCreery Cancer Center at Ottumwa Regional, Ottumwa, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Southwest Medical Center, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Cancer Research Center at Boston Medical Center, Boston, Massachusetts, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Green Bay Oncology, Limited - Iron Mountain, Iron Mountain, Michigan, United States|Foote Hospital, Jackson, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|Ted B. Wahby Cancer Center at Mount Clemens General Hospital, Mount Clemens, Michigan, United States|Seton Cancer Institute - Saginaw, Saginaw, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|Alexandria, Minnesota, United States|MeritCare Clinic - Bemidji, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller-Dwan Medical Center, Duluth, Minnesota, United States|St. Mary's - Duluth Clinic Cancer Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Fergus Falls, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Meeker County Memorial Hospital, Lichfield, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology Hematology, PA at Maplewood Cancer Center, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Chippewa County - Montevideo Hospital, Montevideo, Minnesota, United States|Hubert H. Humphrey Cancer Center at North Memorial Medical Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Saint Francis Cancer Center, Shakopee, Minnesota, United States|St. Joseph's Hospital, St Paul, Minnesota, United States|CentraCare Clinic - River Campus, St. Cloud, Minnesota, United States|Park Nicollet Health Services, St. Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, St. Paul, Minnesota, United States|United Hospital, St. Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States|Woodwinds Health Campus, Woodbury, Minnesota, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital, Gape Girardeau, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Arch Medical Services, Incorporated at Center for Cancer Care Research, Saint Louis, Missouri, United States|David C. Pratt Cancer Center at St. John's Mercy, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|Missouri Baptist Cancer Center, St. Louis, Missouri, United States|CCOP - St. Louis-Cape Girardeau, St. Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|St. Vincent Healthcare, Billings, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Deaconess Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|St. James Community Hospital, Butte, Montana, United States|Big Sky Oncology, Great Falls, Montana, United States|Sletten Regional Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Center, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Good Samaritan Cancer Center at Good Samaritan Hospital, Kearney, Nebraska, United States|Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Adirondack Cancer Care - Glens Falls, Glens Falls, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Moses Cone Regional Cancer Center at Wesley Long Community Hospital, Greensboro, North Carolina, United States|Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Annie Penn Cancer Center, Reidsville, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Cancer Care Center at Medcenter One Hospital, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center, Bismarck, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|MeritCare Medical Group, Fargo, North Dakota, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Riverside Cancer Services, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|Veterans Affairs Medical Center - Dayton, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Middletown Regional Hospital, Middletown, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|Mercy Medical Center, Springfield, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Mount Carmel Cancer Services at Mount Carmel St. Ann's Hospital, Westerville, Ohio, United States|United States Air Force Medical Center - Wright-Patterson, Wright-Patterson Afb, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Legacy Good Samaritan Hospital & Medical Center Comprehensive Cancer Center, Portland, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center & Children's Hospital, Portland, Oregon, United States|Salem Hospital Regional Cancer Care Services, Salem, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|Guthrie Cancer Center at Guthrie Clinic Sayre, Sayre, Pennsylvania, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sioux Valley Hospital and University of South Dakota Medical Center, Sioux Falls, South Dakota, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|Danville Regional Medical Center, Danville, Virginia, United States|St. Joseph Cancer Center, Bellingham, Washington, United States|Olympic Hematology and Oncology, Bremerton, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical, PLLC, Seattle, Washington, United States|Group Health Central Hospital, Seattle, Washington, United States|Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States|Polyclinic First Hill, Seattle, Washington, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Green Bay Oncology, Limited at St. Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Franciscan Skemp Healthcare, La Crosse, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States",,https://ClinicalTrials.gov/show/NCT00268489,2,bevacizumab,pemetrexed disodium,1,1,False,False,False,False,bevacizumab,pemetrexed disodium,1,1
331,1444,1445,NCT01513174,Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone,GOAL,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Gefitinib|Drug: Gefitinib plus olaparib,MTD (Maximum Tolerated Dose) defined as the highest dose level at which < 2 out of 6 patients experience a DLT|Progression-free survival|Overall response rate|Overall survival|Peak Plasma Concentration,Spanish Lung Cancer Group,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,186.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GECP10-03|2010-024178-21,August 2011,July 2016,July 2016,"January 20, 2012",,"April 26, 2017","H. Germans Trias i Pujol, Badalona, Barcelona, Spain|ICO Hospitalet, Hospitalet, Barcelona, Spain|H. Gen. Universitario de Alicante, Alicante, Spain|H. Vall d'Hebrón, Barcelona, Spain|H. Teresa Herrera, La Coruña, Spain",,https://ClinicalTrials.gov/show/NCT01513174,2,gefitinib,gefitinib plus olaparib,1,1,False,False,False,False,gefitinib,gefitinib plus olaparib,1,1
335,1457,1458,NCT00300885,A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC),,Terminated,Has Results,"Carcinoma, Non-Small Cell Lung","Drug: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel|Drug: Carboplatin plus Paclitaxel","Overall Survival (OS) in Patients Treated With Carboplatin, Paclitaxel and Sorafenib to OS in Patients Treated With Carboplatin, Paclitaxel and Placebo|Progression Free Survival (PFS)|Overall Best Response|Duration of Response|Patient Reported Outcome as Assessed by FACT-L Score. Change From Baseline in Total FACT-L at Cycles 3,5,7,9 and End of Treatment (EOT)|Patient Reported Outcome as Assessed by LCS Subscale Score. Change From Baseline in LCS Subscale at Cycles 2 Through 9 and at End of Treatment (EOT)",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 3,926.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,11961|2005-005245-19,February 2006,October 2007,February 2009,"March 10, 2006","September 20, 2010","November 4, 2014","Birmingham, Alabama, United States|Mobile, Alabama, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Springdale, Arkansas, United States|Anaheim, California, United States|Beverly Hills, California, United States|Burbank, California, United States|Corona, California, United States|Encinitas, California, United States|Highland, California, United States|Los Angeles, California, United States|Orange, California, United States|Sacramento, California, United States|Denver, Colorado, United States|Lakeland, Florida, United States|Merritt Island, Florida, United States|Orlando, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Savannah, Georgia, United States|Chicago, Illinois, United States|Skokie, Illinois, United States|Skokie, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Kokomo, Indiana, United States|Sioux City, Iowa, United States|Hutchinson, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Baton Rouge, Louisiana, United States|Metairie, Louisiana, United States|Boston, Massachusetts, United States|Pittsfield, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Hattiesburg, Mississippi, United States|Jefferson City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Morristown, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|Bismarck, North Dakota, United States|Fargo, North Dakota, United States|Columbus, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Dover, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pottsville, Pennsylvania, United States|Sayre, Pennsylvania, United States|Charleston, South Carolina, United States|Greenville, South Carolina, United States|Knoxville, Tennessee, United States|Nashville, Tennessee, United States|Trophy Club, Texas, United States|Salt Lake City, Utah, United States|Abingdon, Virginia, United States|Fairfax, Virginia, United States|Richlands, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Morgantown, West Virginia, United States|Milwaukee, Wisconsin, United States|El Palomar - Morón, Buenos Aires, Argentina|La Plata, Buenos Aires, Argentina|Mar del Plata, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Capital Federal-Buenos Aires, Argentina|Santa Fé, Argentina|Port Macquarie, New South Wales, Australia|Wollongong, New South Wales, Australia|Brisbane, Queensland, Australia|Adelaide, South Australia, Australia|Frankston, Victoria, Australia|Melbourne, Victoria, Australia|Perth, Western Australia, Australia|Bruxelles - Brussel, Belgium|Charleroi, Belgium|La Louviere, Belgium|Liege, Belgium|Salvador, Bahia, Brazil|Fortaleza, Ceará, Brazil|Fortaleza, Ceará, Brazil|Brasília, Distrito Federal, Brazil|Goiânia, Goiás, Brazil|Nova Lima, Minas Gerais, Brazil|Curitiba, Parana, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Joinville, Santa Catarina, Brazil|Barretos, Sao Paulo, Brazil|Jaú, Sao Paulo, Brazil|Ribeirao Preto, Sao Paulo, Brazil|Santo Andre, Sao Paulo, Brazil|Sorocaba, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Belo Horizonte, Brazil|North Vancouver, British Columbia, Canada|Barrie, Ontario, Canada|Brampton, Ontario, Canada|Montreal, Quebec, Canada|Regina, Saskatchewan, Canada|Santiago, Chile|Santiago, Chile|Santiago, Chile|Santiago, Chile|Bobigny Cedex, France|Caen, France|Clamart, France|Metz, France|Nancy, France|Nice Cedex 2, France|Strasbourg, France|Heidelberg, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Gauting, Bayern, Germany|München, Bayern, Germany|Hofheim, Hessen, Germany|Göttingen, Niedersachsen, Germany|Hannover, Niedersachsen, Germany|Oldenburg, Niedersachsen, Germany|Essen, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Hemer, Nordrhein-Westfalen, Germany|Leverkusen, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Großhansdorf, Schleswig-Holstein, Germany|Berlin, Germany|Hamburg, Germany|Hong Kong, Hong Kong|Budapest, Hungary|Deszk, Hungary|Gyula, Hungary|Matrahaza, Hungary|Torokbalint, Hungary|Orbassano, Torino, Italy|Bergamo, Italy|Genova, Italy|Milano, Italy|Parma, Italy|Pavia, Italy|Perugia, Italy|Roma, Italy|Torino, Italy|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Eindhoven, Noord-Brabant, Netherlands|Zwolle, Netherlands|Gdansk, Poland|Krakow, Poland|Olsztyn, Poland|Otwock, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|San Juan, Puerto Rico|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Elche, Alicante, Spain|Zaragoza, Aragón, Spain|Majadahonda, Madrid, Spain|Alicante, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Pontevedra, Spain|Zamora, Spain|Gävle, Sweden|Stockholm, Sweden|Uppsala, Sweden|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Plymouth, Devon, United Kingdom|Bornemouth, Dorset, United Kingdom|Leicester, Leicestershire, United Kingdom|London, United Kingdom|Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT00300885,2,"nexavar (sorafenib, bay43-9006) + carboplatin + paclitaxel",carboplatin plus paclitaxel,1,1,False,False,False,False,"nexavar (sorafenib, bay43-9006) + carboplatin + paclitaxel",carboplatin plus paclitaxel,1,1
336,1458,1459,NCT01187615,"Determination of Safety, Efficacy, and Pharmacokinetics of ""Regorafenib"" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer",,Terminated,No Results Available,Small Cell Lung Carcinoma,Drug: Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|Drug: Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed,"Number of participants with treatment related toxicities and adverse events and change from baseline in vitals signs and laboratory parameters|Pharmacokinetics assessments of Alimta, Cisplatin, and regorafenib in Cycle 1 and 2|Biomarkers (includes but not limited to plasma protein analysis of angiogenesis-related proteins, DNA mutational anaylsis of tumor tissue and plasma)|Tumor Assessments according to Response Evaluation Criteria in Solid Tumors (RECIST) every second cycle",Bayer,All,"18 Years and older   (Adult, Older Adult)",Phase 1,9.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,14458,August 2010,June 2012,June 2012,"August 24, 2010",,"July 8, 2014","New Haven, Connecticut, United States|Las Vegas, Nevada, United States|New York, New York, United States|Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01187615,2,regorafenib (bay73-4506) - sequential / cisplatin / pemetrexed,regorafenib (bay73-4506) - continuous / cisplatin / pemetrexed,1,1,False,False,False,False,regorafenib (bay73-4506) - sequential / cisplatin / pemetrexed,regorafenib (bay73-4506) - continuous / cisplatin / pemetrexed,1,1
338,1464,1465,NCT02364609,Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib,,"Active, not recruiting",No Results Available,Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,Drug: Afatinib Dimaleate|Biological: Pembrolizumab,Maximum tolerated dose (MTD) recommended dose of pembrolizumab in combination with lead in pembrolizumab and afatinib dimaleate|Recommended phase II dose|Overall response rate per RECIST 1.1|Progression free survival,"University of California, Davis|National Cancer Institute (NCI)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,38.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,704874|UCDCC#250|1200.237|P30CA093373|51657|NCI-2015-00126,September 2015,"October 21, 2019","October 21, 2019","February 18, 2015",,"May 2, 2019","University of California Davis Comprehensive Cancer Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT02364609,2,afatinib dimaleate,pembrolizumab,1,1,False,False,False,False,afatinib dimaleate,pembrolizumab,1,1
342,1487,1488,NCT00065182,Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer,,Completed,Has Results,"Lung Cancer, Non-Small Cell|Non-Small-Cell Lung Cancer",Drug: Topotecan/Docetaxel combination|Drug: Docetaxel,"Median Time of Overall Survival|Number of Participants With One-year Survival|Median Time to Progression|Response Rate|Response Duration|Time to Response-assessed Every 8 Weeks|Assessment of Quality of Life-assessed Every 4 Weeks|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Grade 1, 2, 3 or 4 Hematologic Toxicities|Number of Participants With Grade 3 or 4 Clinical Chemical Toxicities|Number of Participants With Clinically Significant Abnormal Vital Signs Data",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,399.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,104864/615|2004-002892-17,"August 14, 2003","August 30, 2007","August 30, 2007","July 18, 2003","June 24, 2019","June 24, 2019","GSK Investigational Site, Huntsville, Alabama, United States|GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Poway, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Boca Raton, Florida, United States|GSK Investigational Site, Boca Raton, Florida, United States|GSK Investigational Site, Lakeland, Florida, United States|GSK Investigational Site, Miami Shores, Florida, United States|GSK Investigational Site, Orange Park, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Stuart, Florida, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Decatur, Illinois, United States|GSK Investigational Site, Elk Grove Village, Illinois, United States|GSK Investigational Site, Skokie, Illinois, United States|GSK Investigational Site, Urbana, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Bowling Green, Kentucky, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Baton Rouge, Louisiana, United States|GSK Investigational Site, Lafayette, Louisiana, United States|GSK Investigational Site, Lake Charles, Louisiana, United States|GSK Investigational Site, Frederick, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Grosse Pointe Woods, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Robbinsdale, Minnesota, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Springfield, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Reno, Nevada, United States|GSK Investigational Site, Hackensack, New Jersey, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, East Syracuse, New York, United States|GSK Investigational Site, Manhasset, New York, United States|GSK Investigational Site, New Hyde Park, New York, United States|GSK Investigational Site, Nyack, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Fayetteville, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Dunmore, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Hilton Head Island, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Irving, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Abingdon, Virginia, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Sheboygan, Wisconsin, United States|GSK Investigational Site, Casper, Wyoming, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Moncton, New Brunswick, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, St. Catharines, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Weston, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Levis, Quebec, Canada|GSK Investigational Site, Sainte-Foy, Quebec, Canada|GSK Investigational Site, Kielce, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Szczecin Zdunowo 20, Poland",,https://ClinicalTrials.gov/show/NCT00065182,2,topotecan/docetaxel combination,docetaxel,1,1,False,False,False,False,topotecan/docetaxel combination,docetaxel,1,1
344,1499,1500,NCT00075517,Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer,,Unknown status,No Results Available,Lung Cancer,Drug: docetaxel|Drug: gemcitabine hydrochloride,Response rate|Progression-free survival|Overall survival|Tolerability|Quality of life,GERCOR - Multidisciplinary Oncology Cooperative Group|National Cancer Institute (NCI),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,,Other,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000346806|FRE-GERCOR-DOCEGEM-B00-2|EU-20331,September 2003,,,"January 12, 2004",,"July 24, 2008","Hopital Avicenne, Bobigny, France|Centre Jean Bernard, Le Mans, France|Hopital Perpetuel Secours, Levallois-Perret, France|Centre de Radiotherapie et Oncologie Saint-Faron, Mareuil Les Meaux, France|Clinique de Docteur Terrioux, Meaux, France|American Hospital of Paris, Neuilly Sur Seine, France|Hopital Tenon, Paris, France|Clinique les Bleuets, Reims, France|Polyclinique De Courlancy, Reims, France|Centre Rene Huguenin, Saint Cloud, France|Clinique Francois, Saint-Dizier, France|Hopital Paul Brousse, Villejuif, France",,https://ClinicalTrials.gov/show/NCT00075517,2,docetaxel,gemcitabine hydrochloride,1,1,False,False,False,False,docetaxel,gemcitabine hydrochloride,1,1
351,1531,1532,NCT00148798,Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX),FLEX,Completed,Has Results,Non Small Cell Lung Cancer (NSCLC),Drug: cetuximab + cisplatin + vinorelbine|Drug: cisplatin + vinorelbine,Overall Survival Time (OS)|Progression-free Survival Time|Best Overall Response Rate|Disease Control Rate|Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status|Quality of Life Assessment (EORTC QLQ-C30) Social Functioning|A Population Pharmacokinetic (PK) Analysis for Cetuximab in Non-Small Cell Lung Cancer (NSCLC) - Serum Cetuximab Concentrations|Safety - Number of Patients Experiencing Any Adverse Event,"Merck KGaA, Darmstadt, Germany",All,"18 Years and older   (Adult, Older Adult)",Phase 3,1861.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EMR 62202-046,October 2004,July 2007,May 2012,"September 8, 2005","October 4, 2011","June 25, 2014","Research Site, Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Adelaide, Australia|Research Site, Melbourne, Australia|Research Site, Randwick, Australia|Research Site, Sydney, Australia|Research Site, Wodonga, Australia|Research Site, Wien, Austria|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Liège, Belgium|Research Site, Porto Alegre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Pleven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Antofagasta, Chile|Research Site, Santiago de Chile, Chile|Research Site, Brno, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Pilsen, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Brest, France|Research Site, Caen, France|Research Site, Grenoble, France|Research Site, Marseille, France|Research Site, Paris, France|Research Site, Poitiers, France|Research Site, Rennes, France|Research Site, Rouen, France|Research Site, Strasbourg, France|Research Site, Augsburg, Germany|Research Site, Berlin, Germany|Research Site, Essen, Germany|Research Site, Freiburg, Germany|Research Site, Gauting, Germany|Research Site, Großhansdorf, Germany|Research Site, Göttingen, Germany|Research Site, Halle-Dölau, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Köln, Germany|Research Site, Löwenstein, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, München, Germany|Research Site, Stralsund, Germany|Research Site, Wuppertal, Germany|Research Site, Honh Kong, Hong Kong|Research Site, Budapest, Hungary|Research Site, Nyiregyháza, Hungary|Research Site, Szombathely, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Torokbalint, Hungary|Research Site, Zalegerzeg-Pózva, Hungary|Research Site, Dublin, Ireland|Research Site, Bologna, Italy|Research Site, Carpi, Italy|Research Site, Milano, Italy|Research Site, Rome, Italy|Research Site, Rozzano-Milano, Italy|Research Site, Treviglio, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Mexico-City, Mexico|Research Site, Monterrey, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Nieuwegeln, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Bydgoszcz, Poland|Research Site, Olsztyn, Poland|Research Site, Otwock, Poland|Research Site, Posnan, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Moscow, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Singapore, Singapore|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Nitra-Zobor, Slovakia|Research Site, Poprad, Slovakia|Research Site, Barakaldo (Bilbao), Spain|Research Site, Barcelona, Spain|Research Site, Elche Alicante, Spain|Research Site, Granollers, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Pontevedra, Spain|Research Site, San Sebastian, Spain|Research Site, Santander, Spain|Research Site, Terrassa, Spain|Research Site, Valencia, Spain|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Bern, Switzerland|Research Site, Thun, Switzerland|Research Site, Zürich, Switzerland|Research Site, Taipei, Tao Yuan County, Taiwan|Research Site, Taipei, Taiwan|Research Site, Ankara, Turkey|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Sumy, Ukraine|Research Site, Ternopol, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Aberdeen, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Wolverhampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00148798,2,cetuximab + cisplatin + vinorelbine,cisplatin + vinorelbine,1,1,False,False,False,False,cetuximab + cisplatin + vinorelbine,cisplatin + vinorelbine,1,1
353,1535,1536,NCT00085839,Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2,,Completed,Has Results,Non-Small Cell Lung Cancer,"Drug: Tarceva (Trademark) (erlotinib HCl, OSI-774)|Drug: Combination carboplatin and paclitaxel",Progression-free Survival|Overall Survival|Best Tumor Response,OSI Pharmaceuticals|Astellas Pharma Inc,All,"18 Years and older   (Adult, Older Adult)",Phase 2,103.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSI-774-201,February 2004,March 2007,March 2007,"June 17, 2004","April 22, 2011","August 9, 2012","California Cancer Care, Inc., Greenbrae, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Mount Sinai Cancer Center, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Evanston Northwestern Healthcare, Evanston, Illinois, United States|Oncology/Hematology Associates of Central Illinois, Peoria, Illinois, United States|Norton Healthcare, Inc., Louisville, Kentucky, United States|Maryland Hematology/Oncology Associates, Baltimore, Maryland, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Weill Medical College of Cornell University, New York, New York, United States|FEK Addo, PC, Bismarck, North Dakota, United States|Gabrail Cancer Center, Canton, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|East Tennessee Oncology/Hematology, PC, Knoxville, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00085839,2,"tarceva (trademark) (erlotinib hcl, osi-774)",combination carboplatin and paclitaxel,1,1,False,False,False,False,tarceva,combination carboplatin and paclitaxel,1,1
354,1536,1537,NCT00309998,Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Biological: bevacizumab|Drug: vinorelbine tartrate,"Median time to disease progression by imaging study every 6 weeks|Response rate by imaging study every 6 weeks|Median survival|Safety as measured by toxicity (e.g thromboembolism, bleeding, or bowel perforation) every three weeks or as required",University of Rochester,All,70 Years and older   (Older Adult),Phase 2,50.0,Other,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000465498|URCC-U1505|GENENTECH-AVF3328S,September 2005,May 2007,,"April 3, 2006",,"September 17, 2014","James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States",,https://ClinicalTrials.gov/show/NCT00309998,2,bevacizumab,vinorelbine tartrate,1,1,False,False,False,False,bevacizumab,vinorelbine tartrate,1,1
358,1561,1562,NCT00278460,Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: docetaxel|Drug: gemcitabine hydrochloride,patient response rate to weekly taxotere and gemcitabine|Evaluate toxicity of weekly Taxotere and Gemcitabine,Wake Forest University Health Sciences|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 2,49.0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000462116|CCCWFU-62199|AVENTIS-CCCWFU-62199|AG-CCCWFU-62199|CCCWFU-BG99-322,November 2000,February 2006,September 2007,"January 18, 2006",,"January 19, 2017",,,https://ClinicalTrials.gov/show/NCT00278460,2,docetaxel,gemcitabine hydrochloride,1,1,False,False,False,False,docetaxel,gemcitabine hydrochloride,1,1
359,1569,1570,NCT01063283,Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC,AVF4759,Completed,No Results Available,Advanced Non-squamous Non-Small Cell Lung Cancer,Drug: Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg|Drug: Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg,Does a higher dose of bevacizumab have any effect on changes in blood pressure|Response rate|Change in tumor size|Progression free survival,"University of Chicago|Genentech, Inc.",All,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,70.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-014-B,March 2010,June 2016,June 2016,"February 5, 2010",,"June 1, 2017","The University of Chicago Medical Center, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01063283,2,carboplatin and pemetrexed with bevacizumab 7.5 mg/kg,carboplatin and pemetrexed with bevacizumab 15 mg/kg,1,1,False,False,False,False,carboplatin and pemetrexed with bevacizumab,carboplatin and pemetrexed with bevacizumab,1,1
361,1577,1578,NCT01404260,Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer,ISCAN,Completed,Has Results,Non-small Cell Lung Cancer,Drug: Gefitinib|Drug: Gemcitabine +Carboplatin,Progression Free Survival,"Guangdong Association of Clinical Trials|First Hospital of Jilin University|Ruijin Hospital|Fudan University|Jiangsu Cancer Institute & Hospital|Nanjing PLA General Hospital|Wuxi No. 4 People's Hospital|The First Affiliated Hospital of Soochow University|Second Affiliated Hospital, School of Medicine, Zhejiang University|Sir Run Run Shaw Hospital|Henan Cancer Hospital|Changhai Hospital|NanJing PLA 81 Hospital|First People's Hospital of Hangzhou",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,219.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTONG 1102,June 2011,March 2015,October 2015,"July 28, 2011","January 27, 2017","January 27, 2017","Shanghai Lung Tumor Clinical Center,Shanghai Chest Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01404260,2,gefitinib,gemcitabine +carboplatin,1,1,False,False,False,False,gefitinib,gemcitabine +carboplatin,1,1
369,1606,1607,NCT00387322,Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors,,Completed,No Results Available,"Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: erlotinib hydrochloride|Drug: pemetrexed disodium,Safety and feasibility (Phase I)|Response rate (Phase II)|Toxicity (Phase I)|Maximum tolerated dose (Phase I)|Preliminary efficacy (Phase I)|Overall survival (Phase II)|Progression-free survival (Phase II)|Frequency and severity of toxicity (Phase II),"University of California, Davis|National Cancer Institute (NCI)",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,42.0,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000505895|P30CA093373|UCDCC-159|200412741,March 2005,October 2007,May 2009,"October 13, 2006",,"March 29, 2010","University of California Davis Cancer Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT00387322,2,erlotinib hydrochloride,pemetrexed disodium,1,1,False,False,False,False,erlotinib hydrochloride,pemetrexed disodium,1,1
372,1619,1620,NCT00787852,A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC),,Terminated,Has Results,Non-Small Cell Lung Cancer,"Drug: Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|Drug: Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38",Number of Patients Who Came Off Study for Toxicity Using CTC Version 3.0|Complete and Partial Response by CT Scan or MRI,Brown University|Rhode Island Hospital|Memorial Hospital of Rhode Island,All,"19 Years and older   (Adult, Older Adult)",Phase 1,11.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BrUOG-NSCL-216,March 2009,March 2011,December 2011,"November 10, 2008","September 25, 2013","July 30, 2014","Lifespan Hospitals, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00787852,2,"group 1: radiation, paclitaxel,carbo, dasatinib days 1-47","group 2: radiation, paclitaxel, carbo, dasatinib days 1-38",1,1,False,False,False,False,"group 1: radiation, paclitaxel,carbo, dasatinib days 1-47","group 2: radiation, paclitaxel, carbo, dasatinib days 1-38",1,1
377,1649,1650,NCT01023347,A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer,,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Paclitaxel (Genexol®)|Drug: Paclitaxel loaded polymeric micelle (Genexol-PM®),response rate|overall survival|progression-free survival|toxicity profiles,Samyang Biopharmaceuticals Corporation,All,"18 Years and older   (Adult, Older Adult)",Phase 2,276.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GPM-0801,June 2008,December 2009,June 2012,"December 2, 2009",,"May 9, 2017","Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01023347,2,paclitaxel (genexol®),paclitaxel loaded polymeric micelle (genexol-pm®),1,1,False,False,False,False,paclitaxel (genexol®),paclitaxel loaded polymeric micelle (genexol-pm®),1,1
379,1663,1664,NCT00446225,Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients With Mutations in the TK Domain of EGFR,,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: Erlotinib (Tarceva)|Drug: Carboplatin // Gemcitabine // Docetaxel //Cisplatin,Progression Free-survival|Objective Response|One year survival|Overall survival|Safety incidence|Life quality|Molecular markers related to EGFR and study pathology,Spanish Lung Cancer Group,All,"18 Years and older   (Adult, Older Adult)",Phase 3,174.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EURTAC-SLCG // GECP06/01|EudraCT:2006-003568-73,February 2007,December 2009,December 2012,"March 12, 2007",,"March 11, 2013","Centre Hospitalier Universitaire D'Angers, Angers, France|Hôpital Auguste Morvan, Brest, France|Centre François Baclesse, Caen, France|Centre Hospitalier René Dubos, Cergy Pontoise, France|Centre Hospitalier Intercommunal, Creteil, France|Hôpital A. Mignot, Le Chesnay, France|Centre Hospitalier Du Mans, Le Mans, France|Centre Oscar Lambret, Lille, France|Hôpital du Cluzeau, Limoges, France|Centre Hospitalier Régional, Longjumeau, France|Centre Hospitalier de Meaux, Meaux, France|Centre Hospitalier de Mulhouse, Mulhouse, France|Hôpital Saint Antoine, Paris, France|Centre Hospitalier, Perigueux, France|Centre Hospitalier de La Région D'Annecy, Pringy, France|CHU Rennes Hôpital Ponchaillou, Rennes, France|Centre Hosiptalier Genéral de Roanne, Roanne, France|Institut de Cancérologie de La Loire, St-Priest en Jarez, France|Hôpital Larrey, Toulouse, France|CRO di Aviano, Aviano, Italy|AO Materdomini, Catanzaro, Italy|AOU Policlinico G. Martino, Messina, Italy|AO Monaldi, Napoli, Italy|Casa di Cura ""La Maddalena"", Palermo, Italy|Istituti Fisioterapici Ospitalieri, Roma, Italy|AO S.Camillo Forlanini, Roma, Italy|Università di Roma ""La Sapienza"" Az.Policlinico Umb.I°, Roma, Italy|PO di SS.ma Annunziata, Sassari, Italy|H. Virgen de los Lirios, Alcoy, Alicante, Spain|H. Torrevieja Salud, Torrevieja, Alicante, Spain|ICO - H. Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital de Mataró, Mataró, Barcelona, Spain|H. Marqués de Valdecilla, Santander, Cantabria, Spain|F.H.Alcorcón, Alcorcon, Madrid, Spain|H. Fuenlabrada, Fuenlabrada, Madrid, Spain|H. Son Dureta, Palma de Mallorca, Mallorca, Spain|H. Ntra. Sra. de la Candelaria, Santa Cruz de Tenerife, Tenerife, Spain|Hospital de Cruces, Baracaldo, Vizcaya, Spain|H.G.U. Alicante, Alicante, Spain|H. Santa Creu i Sant Pau, Barcelona, Spain|Instituto Universitario Dexeus, Barcelona, Spain|H.U.Vall D´Hebrón, Barcelona, Spain|H. Clinic i Provincial, Barcelona, Spain|H. Althaia, Barcelona, Spain|H. Duran i Reynals-ICO, Barcelona, Spain|H. Provincial de Castellón, Castellón, Spain|H. Reina Sofía, Córdoba, Spain|ICO Girona -H. Dr. Josep Trueta, Girona, Spain|Hospital Insular Gran Canaria, Gran Canaria, Spain|H. Virgen de las Nieves, Granada, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Complejo Hosp. Univ. Juan Canalejo, La Coruña, Spain|Hospital San Millan Y San Pedro, Logroño, Spain|H. Arnau de Vilanova, Lérida, Spain|H. de la Princesa, Madrid, Spain|H. Gregorio Marañón, Madrid, Spain|H. Ruber Internacional, Madrid, Spain|H.U. Puerta de Hierro, Madrid, Spain|Fundación Jimenez Diaz, Madrid, Spain|Hospial Clinico San Carlos, Madrid, Spain|H. La Paz, Madrid, Spain|H. 12 de Octubre, Madrid, Spain|H. Ramon y Cajal, Madrid, Spain|H. Carlos Haya, Málaga, Spain|H.C.Universitario Virgen de la Victoria, Málaga, Spain|H. Son Llàtzer, Palma de Mallorca, Spain|Clinica Rotger, Palma de Mallorca, Spain|H. de Donostia, San Sebastian, Spain|H. Virgen del Rocío, Sevilla, Spain|H. Nuestra Sra. de Valme, Sevilla, Spain|H.C.U.Valencia, Valencia, Spain|H. General U. de Valencia, Valencia, Spain|H. Arnau de Vilanova Valencia, Valencia, Spain|H. Dr. Peset, Valencia, Spain|H. Miguel Servet, Zaragoza, Spain|H. Clínico Lozano Blesa, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT00446225,2,erlotinib (tarceva),carboplatin // gemcitabine // docetaxel //cisplatin,1,1,False,False,False,False,erlotinib (tarceva),carboplatin // gemcitabine // docetaxel //cisplatin,1,1
380,1669,1670,NCT03527108,"Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC",,Not yet recruiting,No Results Available,Non Small Cell Lung Cancer,"Drug: Nivolumab, ramucirumab|Drug: Nivolumab",Number of patients with progression free survival (PFS) at 6 months in IO naive patients.treated with nivolumab and ramucirumab combination therapy vs the nivolumab monotherapy|Disease control rate (DCR) in IO experienced patients.treated with nivolumab and ramucirumab combination therapy|Overall Response Rate (ORR) in IO naive patients treated with nivolumab and ramucirumab combination therapy|Overall Response Rate in IO naive patients treated with nivolumab monotherapy|Number of patients with treatment related toxicities in IO naive patients treated with nivolumab and ramucirumab combination therapy|Number of patients with treatment related toxicities in IO naive patients treated with nivolumab monotherapy|Overall survival in IO naive patients treated with nivolumab and ramucirumab combination.|Overall survival in IO naive patients treated with nivolumab monotherapy|Number of patients with PFS at 6 months in IO experienced patients treated with nivolumab and ramucirumab combination therapy .|ORR in IO experienced patients treated with nivolumab and ramucirumab combination therapy .|Number of patients with treatment related toxicities in IO experienced patients treated with nivolumab and ramucirumab combination therapy .|Overall survival in IO experienced patients treated with nivolumab and ramucirumab combination therapy .,Fox Chase Cancer Center|Bristol-Myers Squibb|Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,117.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-1026|TH-125,"December 1, 2019","April 1, 2023","April 1, 2024","May 16, 2018",,"June 18, 2019","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03527108,2,"nivolumab, ramucirumab",nivolumab,1,1,False,False,False,False,"nivolumab, ramucirumab",nivolumab,1,1
388,1713,1714,NCT00738881,Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer,MARVEL,Terminated,Has Results,Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,Drug: Erlotinib Hydrochloride|Drug: Pemetrexed Disodium,Progression-free Survival (PFS)|Time to Treatment Failure|Overall Survival|Confirmed Response Rate Defined as Complete Response (CR) or a Partial Response (PR) Per Response Evaluation Criteria In Solid Tumors (RECIST),National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group|Southwest Oncology Group,All,"18 Years and older   (Adult, Older Adult)",Phase 3,23.0,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2009-00663|CDR0000612010|NCCTG-N0723|CALGB-30802|CAN-NCIC-BRC4|N0723|U10CA180821|U10CA025224,October 2008,December 2011,December 2014,"August 21, 2008","October 2, 2014","October 29, 2015","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Sparks Regional Medical Center, Fort Smith, Arkansas, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Valley Care Health System - Pleasanton, Pleasanton, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Tahoe Forest Cancer Center, Truckee, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Exempla Saint Joseph Hospital, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program CCOP, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Bristol Hospital, Bristol, Connecticut, United States|Middlesex Hospital, Middletown, Connecticut, United States|Lynn Regional Cancer Center - West, Boca Raton, Florida, United States|Boca Raton Comprehensive Cancer Center, Boca Raton, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|MacNeal Hospital and Cancer Center, Berwyn, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Graham Hospital Association, Canton, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Hematology and Oncology Associates, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Eureka Hospital, Eureka, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Illinois CancerCare Galesburg, Galesburg, Illinois, United States|Illinois CancerCare-Cottage, Galesburg, Illinois, United States|Illinois CancerCare-Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hematology Oncology Associates of Illinois-Highland Park, Highland Park, Illinois, United States|Hopedale Medical Complex - Hospital, Hopedale, Illinois, United States|Midwest Center for Hematology Oncology, Joliet, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|NorthShore Hematology Oncology-Libertyville, Libertyville, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Mcdonough District Hospital, Macomb, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Holy Family Medical Center, Monmouth, Illinois, United States|Illinois CancerCare-Monmouth, Monmouth, Illinois, United States|DuPage Medical Group-Ogden, Naperville, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Bromenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Illinois CancerCare-Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Pekin Cancer Treatment Center, Pekin, Illinois, United States|Pekin Hospital, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois Oncology Research Association CCOP, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Hematology Oncology Associates of Illinois - Skokie, Skokie, Illinois, United States|Illinois CancerCare-Spring Valley, Spring Valley, Illinois, United States|Saint Margaret's Hospital, Spring Valley, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Franciscan St. Francis Health-Beech Grove, Beech Grove, Indiana, United States|Reid Hospital and Health Care Services, Richmond, Indiana, United States|McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, United States|Hematology Oncology Associates-Quad Cities, Bettendorf, Iowa, United States|Cedar Rapids Oncology Association, Cedar Rapids, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Genesis Medical Center - East Campus, Davenport, Iowa, United States|Genesis Medical Center - West Campus, Davenport, Iowa, United States|Mercy Capitol, Des Moines, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Covenant Medical Center, Waterloo, Iowa, United States|Hospital District Sixth of Harper County, Anthony, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Shawnee Mission Medical Center-KCCC, Shawnee Mission, Kansas, United States|Stormont-Vail Regional Health Center, Topeka, Kansas, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|The Memorial Hospital at Easton, Easton, Maryland, United States|Cancer Trials Support Unit, Rockville, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Steward Saint Elizabeth's Medical Center, Brighton, Massachusetts, United States|Cape Cod Hospital, Hyannis, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Michigan Cancer Research Consortium CCOP, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Spectrum Health Big Rapids Hospital, Big Rapids, Michigan, United States|Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Saint Joseph Mercy Port Huron, Port Huron, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Meeker County Memorial Hospital, Litchfield, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Minnesota Cooperative Group Outreach Program, Minneapolis, Minnesota, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Joseph Health Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Hospital, Liberty, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Center for Cancer Care and Research, Saint Louis, Missouri, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Frontier Cancer Center and Blood Institute-Billings, Billings, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Glacier Oncology PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Veterans Adminstration New Jersey Health Care System, East Orange, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County, Mount Holly, New Jersey, United States|Riverview Medical Center/Booker Cancer Center, Red Bank, New Jersey, United States|Virtua West Jersey Hospital Voorhees, Voorhees, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Syracuse Veterans Administration Medical Center, Syracuse, New York, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Southeast Cancer Consortium-Upstate NCORP, Winston-Salem, North Carolina, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Saint Alexius Medical Center, Bismarck, North Dakota, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|North Coast Cancer Care-Clyde, Clyde, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Dayton CCOP, Dayton, Ohio, United States|Hematology Oncology Center Incorporated, Elyria, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Saint Luke's Hospital, Maumee, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Clinton Memorial Hospital, Wilmington, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Mercy Hospital, Scranton, Pennsylvania, United States|Scranton Hematology Oncology, Scranton, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Mount Nittany Medical Center, State College, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|AnMed Health Hospital, Anderson, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Danville Regional Medical Center, Danville, Virginia, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Memorial Hospital Of Martinsville, Martinsville, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT00738881,2,erlotinib hydrochloride,pemetrexed disodium,1,1,False,False,False,False,erlotinib hydrochloride,pemetrexed disodium,1,1
390,1717,1718,NCT00026156,S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: docetaxel|Drug: vinorelbine tartrate,,Southwest Oncology Group|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,125.0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000068991|S0027|U10CA032102,November 2001,July 2004,November 2008,"January 27, 2003",,"February 15, 2013","MBCCOP - Gulf Coast, Mobile, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|Veterans Affairs Medical Center - Phoenix (Carl T. Hayden), Phoenix, Arizona, United States|Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Veterans Affairs Medical Center - Little Rock (McClellan), Little Rock, Arkansas, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, United States|David Grant Medical Center, Travis Air Force Base, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Veterans Affairs Medical Center - Denver, Denver, Colorado, United States|MBCCOP - Howard University Cancer Center, Washington, District of Columbia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|Dwight David Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States|CCOP - Central Illinois, Decatur, Illinois, United States|Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital), Hines, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Genesis Medical Center, Davenport, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Veterans Affairs Medical Center - Wichita, Wichita, Kansas, United States|Veterans Affairs Medical Center - Lexington, Lexington, Kentucky, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States|Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States|Boston Medical Center, Boston, Massachusetts, United States|St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Veterans Affairs Medical Center - Boston (Jamaica Plain), Jamaica Plain, Massachusetts, United States|Veterans Affairs Medical Center - Ann Arbor, Ann Arbor, Michigan, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|CCOP - Beaumont, Royal Oak, Michigan, United States|Providence Hospital - Southfield, Southfield, Michigan, United States|Veterans Affairs Medical Center - Biloxi, Biloxi, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Veterans Affairs Medical Center - Jackson, Jackson, Mississippi, United States|Keesler Medical Center - Keesler AFB, Keesler AFB, Mississippi, United States|Veterans Affairs Medical Center - Kansas City, Kansas City, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Veterans Affairs Medical Center - Albuquerque, Albuquerque, New Mexico, United States|MBCCOP - University of New Mexico HSC, Albuquerque, New Mexico, United States|Veterans Affairs Medical Center - Albany, Albany, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Veterans Affairs Medical Center - Cincinnati, Cincinnati, Ohio, United States|Barrett Cancer Center, Cincinnati, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Veterans Affairs Medical Center - Dayton, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Veterans Affairs Medical Center - Oklahoma City, Oklahoma City, Oklahoma, United States|Veterans Affairs Medical Center - Portland, Portland, Oregon, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Oregon Cancer Institute, Portland, Oregon, United States|Veterans Affairs Medical Center - Charleston, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Veterans Affairs Medical Center - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Veterans Affairs Medical Center - San Antonio (Murphy), San Antonio, Texas, United States|Veterans Affairs Medical Center - Temple, Temple, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Veterans Affairs Medical Center - Salt Lake City, Salt Lake City, Utah, United States|CCOP - Virginia Mason Research Center, Seattle, Washington, United States|Veterans Affairs Medical Center - Seattle, Seattle, Washington, United States|CCOP - Northwest, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00026156,2,docetaxel,vinorelbine tartrate,1,1,False,False,False,False,docetaxel,vinorelbine tartrate,1,1
392,1720,1721,NCT00190476,Elderly NSCLC/D vs DP (JCOG0207),,Terminated,No Results Available,Non-small-cell Lung Cancer,Drug: Weekly docetaxel alone|Drug: Weekly docetaxel + cisplatin combination,overall survival|Toxicity|Progression-free survival|Response rate|Symptom score,"Japan Clinical Oncology Group|Ministry of Health, Labour and Welfare, Japan",All,70 Years and older   (Older Adult),Phase 3,230.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JCOG0207|C000000146,April 2003,,April 2007,"September 19, 2005",,"September 12, 2016","Aichi Cancer Center Hospital, Nagoya,Chikusa-ku,Kanokoden,1-1, Aichi, Japan|Aichi Cancer Center,Aichi Hospital, Okazaki,Kake-machi,Kuriyado,18, Aichi, Japan|National Cancer Center Hospital East, Kashiwa,Kashiwanoha,6-5-1, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama,Horinouchi,13, Ehime, Japan|Kyushu University Hospital, Higashi-ku,Maidashi,3-1-1, Fukuoka, Japan|Gifu Municipal Hospital, Gifu,Kashima-cho,7-1, Gifu, Japan|Gunma Prefectural Cancer Center, Ota,Takabayashi-nishi-cho,617-1, Gunma, Japan|National Nishigunma Hospital, Shibukawa,Kanai,2854, Gunma, Japan|National Hospital Organization, Dohoku National Hospital, Asahikawa,Hanasaki,7-4048, Hokkaido, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo,Shiroishi-ku,Kikusui,4-2-3-54, Hokkaido, Japan|Hyogo Medical Center for Adults, Akashi,Kitaouji-cho,13-70, Hyogo, Japan|Hyogo College of Medicine, Nishinomiya,Mukogawa-cho,1-1, Hyogo, Japan|Ibaraki Kenritsu Chuo Hospital & Cancer Center, Nishi-ibarakigun,Tomobemachi,Koibuchi,6528, Ibaraki, Japan|Kanagawa Cancer Center, Yokohama,Asahi-ku,Nakao,1-1-2, Kanagawa, Japan|Yokohama Mucipical Citizen's Hospital, Yokohama,Hodogaya-ku,Okazawa-cho,56, Kanagawa, Japan|Kumamoto Regional Medical Center Hospital, Kumamoto,Honjo,5-16-10, Kumamoto, Japan|Niigata Cancer Center Hospital, Niigata,Kawagishi-cho, 2-15-3, Niigata, Japan|Osaka Prefectural Medical Center for Respiratory and Allergic Disease, Habikino,Habikino,3-7-1, Osaka, Japan|Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka,Higashinari-ku,Nakamichi,1-3-3, Osaka, Japan|Osaka City General Hospital, Osaka,Miyakojima-ku,Miyakojimahondori,2-13-22, Osaka, Japan|Kinki University School of Medicine, Osaka-Sayama,Ohno-higashi,377-2, Osaka, Japan|National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai,Nagasone,1180, Osaka, Japan|National Hospital Organization Toneyama National Hospital, Toyonaka,Toneyama,5-1-1, Osaka, Japan|Saitama Cancer Center, Kita-adachi,Ina,Komuro,818, Saitama, Japan|Sizuoka Cancer Center, Sunto-gun,Nagaizumi-cho,Shimonagakubo,1007, Shizuoka, Japan|Tochigi Cancer Center, Utsunomiya,Yohnan,4-9-13, Tochigi, Japan|National Cancer Center Hospital, Chuo-ku,Tsukiji,5-1-1, Tokyo, Japan|International Medical Center of Japan, Shinjuku-ku,Toyama,1-21-1, Tokyo, Japan|Yamagata Prefectural Central Hospital, Yamagata,Aoyagi,1800, Yamagata, Japan",,https://ClinicalTrials.gov/show/NCT00190476,2,weekly docetaxel alone,weekly docetaxel + cisplatin combination,1,1,False,False,False,False,weekly docetaxel alone,weekly docetaxel + cisplatin combination,1,1
397,1735,1736,NCT03663205,A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC,,"Active, not recruiting",No Results Available,Non-Small Cell Lung Cancer,"Drug: Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed|Drug: Cisplatin or Carboplatin,Pemetrexed","Progression Free Survival (PFS) assessed by Independent Review Committee(IRC)|Objective Response Rate (ORR) assessed by Independent Review Committee(IRC)|Duration Of Response (DOR) assessed by Independent Review Committee(IRC)|Overall Survival|Progression Free Survival (PFS) as assessed by the investigator|Objective response rate (ORR) as assessed by the investigator|Duration of response (DOR) as assessed by the investigator|health-related quality of life (HRQoL)- measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ LC13) as presented in patient-reported outcomes|health-related quality of life (HRQoL)- measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer Core 30 (EORTC QLQ-C30) as presented in patient-reported outcomes|Incidence and severity of treatment-emergent AEs (TEAEs) graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), v4.03|PD-L1 expression by IHC",BeiGene,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,334.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BGB-A317-304|CTR20180032,"July 23, 2018","June 21, 2020","September 23, 2020","September 10, 2018",,"November 4, 2019","Anhui Provincial Hospital, Hefei, Anhui, China|Beijing Hospital, Beijing, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|The second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|The Third Affiliated Hospital (Institute of Field Surgery) of PLA Army Medical University, Chongqing, Chongqing, China|Chongqing Three Gorges Central Hospital, Chongqing, Chongqing, China|Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|Cancer Hospital Of Shantou University Medical College, Shantou, Guangdong, China|Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China|The People's Hospital Of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Cancer Center of Guangzhou Medical University, Guangzhou, Guangzhou, China|Nanfang Hospital,Southern Medical University, Guangzhou, Guangzhou, China|Guizhou Cancer Hospital, Guiyang, Guizhou, China|Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou, China|Hainan General Hospital, Haikou, Hainan, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|Changsha Central Hospital, Changsha, Hunan, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|Xuzhou Central Hospital, Xuzhou, Jiangsu, China|The First Hospital of Jilin University, Changchun, Jilin, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|Liaoning Cancer Hospital, Shenyang, Liaoning, China|Weifang People's Hospital, Huaifang, Shandong, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Jinan Central Hospital, Jinan, Shandong, China|Jinan Military General Hospital, Jinan, Shandong, China|Shandong Cancer Hospital, Jinan, Shandong, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Fudan Universuty Shanghai Cancer Center, Shanghai, Shanghai, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|West China Hospital,Sichuan University, Chengdu, Sichuan, China|General Hospital, Tianjin Medical University, Tianjin, Tianjin, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China|Yunnan Cancer Hospital, &The Third Affiliated Hospital of Kunming Medical University&Yunnan Cancer Center &Yunnan Cancer Center, Kunming, Yunnan, China|The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China|Hangzhou First People's Hospital, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Shanghai Chest Hospital, Shanghai, China",,https://ClinicalTrials.gov/show/NCT03663205,2,"tislelizumab,cisplatin or carboplatin ,pemetrexed","cisplatin or carboplatin,pemetrexed",1,1,False,False,False,False,"tislelizumab,cisplatin or carboplatin ,pemetrexed","cisplatin or carboplatin,pemetrexed",1,1
400,1748,1749,NCT03732001,A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC,ALTER-L024,Recruiting,No Results Available,Non-small Cell Lung Cancer,Drug: Anlotinib combined Docetaxel|Drug: Docetaxel,PFS|OS|ORR|DCR|Safety and Tolerability: Number of Participants with Adverse Events,"China Medical University, China|Shengjing Hospital|The Second Affiliated Hospital of Dalian Medical University|General Hospital of Shenyang Military Region|The People's Hospital of Liaoning Province|Shenyang Chest Hospital|Anshan Tumor Hospital|The Affiliated Zhongshan Hospital of Dalian University|The First People's Hospital of Jingzhou|Benxi Cental Hospital|GEM flower hospital of Liaohe oil field|Panjin Central Hospital",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,80.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALTER-L024,"November 8, 2018","November 9, 2019","November 9, 2020","November 6, 2018",,"November 28, 2018","The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China",,https://ClinicalTrials.gov/show/NCT03732001,2,anlotinib combined docetaxel,docetaxel,1,1,False,False,False,False,anlotinib combined docetaxel,docetaxel,1,1
409,1794,1795,NCT02319577,GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial,,Unknown status,No Results Available,Non Small Cell Lung Cancer,Drug: oral vinorelbine|Drug: Gefitinib,"Progression-free survival (PFS) rate at 6 months|Overall survival (OS) rate at 1 year (1Y-OS), 2 years (2Y-OS), and 3 years (3Y-OS)|Response rate (RR)|Safety profile: Safety will be assessed by medical interview, physical examination, and blood collection for complete blood count on days 1 and 8 and biochemistry","IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",All,"18 Years and older   (Adult, Older Adult)",Phase 2,80.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Genoa trial,March 2012,June 2015,December 2015,"December 18, 2014",,"December 18, 2014","IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy",,https://ClinicalTrials.gov/show/NCT02319577,2,oral vinorelbine,gefitinib,1,1,False,False,False,False,oral vinorelbine,gefitinib,1,1
415,1813,1814,NCT02504489,Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC,DUBLIN-3,Recruiting,No Results Available,Non-Small Cell Lung Cancer,Drug: Docetaxel + Plinabulin (DP)|Drug: Docetaxel (D),Overall Survival|Grade 4 neutropenia|Neutrophil count|docetaxel dose reduction and/or docetaxel dose withheld|Quality of Life (EORTC QLQ-C30)|ORR|PFS|DoR,BeyondSpring Pharmaceuticals Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 3,554.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,BPI-2358-103,December 2015,October 2019,November 2019,"July 22, 2015",,"June 4, 2019","Ironwood Cancer & Research Centers, Chandler, Arizona, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Memorial Health Care System, Colorado Springs, Colorado, United States|Cancer Center of Central Connecticut, Plainville, Connecticut, United States|Peachtree Hematoloy-Oncology Consultants, PC, Atlanta, Georgia, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Kansas University Medical Center, Westwood, Kansas, United States|University of Louisville-Brown Cancer Center, Louisville, Kentucky, United States|Henry Ford Hospital, Detroit, Michigan, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States|Central Care Cancer Center, Bolivar, Missouri, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Toledo Cancer Center, Toledo, Ohio, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Cookeville Regional Medical Center Cancer Center, Cookeville, Tennessee, United States|Blacktown Cancer Centre, Blacktown, New South Wales, Australia|Border Medical Oncology Research Unit, East Albury, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Adult Mater Hospital, South Brisbane, Queensland, Australia|Peninsula and South East Oncology, Melbourne, Victoria, Australia|Epworth Hospital, Richmond, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Oncology/Mount Hospital, Perth, Western Australia, Australia|St John of God Hospital, Subiaco, Subiaco, Western Australia, Australia|Anhui Provincial Hospital, Hefei, Anhui, China|Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|The PLA General Hospital, Beijing, Beijing, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|Zhongshan Hospital Xiamen University, Xiamen, Fujian, China|Guizhou Provincial Hospital, Guiyang, Guizhou, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Affiliated Cancer Hospital of Harbin Medical Unive, Ha'erbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|The Second Xiangya Hospital of Central South Unive, Changsha, Hunan, China|Jiangyin People's Hospital, Jiangyin, Jiangsu, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Nantong Tumor Hospital, Nantong, Jiangsu, China|Jiangxi Provincial Tumor Hospital, Nanchang, Jiangxi, China|Jilin Province Cancer Hospital, Changchun, Jilin, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China|The First Affiliated Hospital of Xi'an Jiaotong U, Xi'an, Shaanxi, China|Shandong Cancer Hospital, Jinan, Shangdong, China|527-Linyi Cancer Hospital, Linyi, Shangdong, China|Yantai Yuhuangding Hospital, Yantai, Shangdong, China|Shanghai Chest Hospital, Shanghai Jiaotong Univers, Shanghai, Shanghai, China|The Fifth People's Hospital of Shanghai, Shanghai, Shanghai, China|West China Hospital of Sichuan University, Chendu, Sichuan, China|Tianjin People's Hospital, Tianjin, Tianjin, China|Affiliated Tumor Hospital of Xinjiang Medical Univ, Ürümqi, Xinjiang, China|Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The First Affiliated Hospital, Zhejiang University, Hanzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT02504489,2,docetaxel + plinabulin (dp),docetaxel (d),1,1,False,False,False,False,docetaxel + plinabulin (dp),docetaxel (d),1,1
423,1853,1854,NCT01401192,Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression,,Unknown status,No Results Available,Non-small Cell Lung Cancer,Drug: Gemcitabine plus cisplatin|Drug: pemetrexed plus cisplatin,predictive value of TS expression|response rate,Samsung Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,304.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2011-06-006,July 2011,December 2013,,"July 25, 2011",,"July 25, 2011","Samsung Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01401192,2,gemcitabine plus cisplatin,pemetrexed plus cisplatin,1,1,False,False,False,False,gemcitabine plus cisplatin,pemetrexed plus cisplatin,1,1
436,1928,1929,NCT01752023,A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.,NA_00067809,Terminated,Has Results,Non-small Cell Lung Cancer Metastatic,Drug: Cisplatin + Gemcitabine with SUBATM-itraconazole|Drug: Cisplatin + Gemcitabine,Objective Response Rates|Tumor Blood Flow.|Median Time to Progression|Adverse Effects|Itraconazole Exposure Parameters|Tumor Necrosis,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,All,"18 Years to 100 Years   (Adult, Older Adult)",Phase 2,3.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,J1230|NA_00067809,March 2013,April 2014,April 2014,"December 18, 2012","June 2, 2017","October 17, 2018","Bayview Medical Center at Johns Hopkins, Baltimore, Maryland, United States|Johns Hopkins University, SKCCC, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01752023,2,cisplatin + gemcitabine with subatm-itraconazole,cisplatin + gemcitabine,1,1,False,False,False,False,cisplatin + gemcitabine with subatm-itraconazole,cisplatin + gemcitabine,1,1
439,1934,1935,NCT01204697,A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN),,Completed,Has Results,Non-Squamous Non-Small Cell Lung Cancer,Drug: docetaxel|Drug: erlotinib [Tarceva],Percentage of Participants Free From Disease Progression or Death at 6 Months|Progression-free Survival (PFS)|Overall Survival (OS)|Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR)|Percentage of Participants With Disease Control|Duration of Response (DoR),Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,74.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML21869,November 2010,July 2014,July 2014,"September 17, 2010","November 16, 2015","November 16, 2015","Avellino, Campania, Italy|Napoli, Campania, Italy|Parma, Emilia-Romagna, Italy|Aviano (PN), Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Cremona, Lombardia, Italy|Milano, Lombardia, Italy|Monza, Lombardia, Italy|Pavia, Lombardia, Italy|Sondalo, Lombardia, Italy|Macerata, Marche, Italy|Lecce, Puglia, Italy|San Giovanni Rotondo, Puglia, Italy|Lido Di Camaiore, Toscana, Italy|Pisa, Toscana, Italy|Pontedera, Toscana, Italy|Treviso, Veneto, Italy|Vicenza, Veneto, Italy",,https://ClinicalTrials.gov/show/NCT01204697,2,docetaxel,erlotinib [tarceva],1,1,False,False,False,False,docetaxel,erlotinib [tarceva],1,1
446,1965,1966,NCT03126799,A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+),AvaTa,Recruiting,No Results Available,EGFR Positive Non-small Cell Lung Cancer,Drug: Erlotinib plus Bevacizumab|Drug: Erlotinib,PFS|ORR|OS,"National Cancer Center, Korea|Roche Korea co.,Ltd.",All,"19 Years and older   (Adult, Older Adult)",Phase 2,128.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCC-2016-0107,"November 1, 2016","December 31, 2019","December 31, 2020","April 24, 2017",,"June 18, 2018","National Cancer Center, Goyang-Si, Gyeonggi-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03126799,2,erlotinib plus bevacizumab,erlotinib,1,1,False,False,False,False,erlotinib plus bevacizumab,erlotinib,1,1
448,1970,1971,NCT00786331,Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC,,Unknown status,No Results Available,Advanced Non-Small Cell Lung Cancer,Drug: Pemetrexed|Drug: Pemetrexed plus carboplatin,To compare time to progression between the combination pemetrexed-carboplatin and pemetrexed alone in previously treated patients with locally advanced or metastatic NSCLC|To assess differences in terms of response rate between the combination pemetrexed-carboplatin and pemetrexed alone.|To assess differences in terms of duration of response between the combination pemetrexed-carboplatin and pemetrexed alone.|To assess differences in terms of toxicity between the combination pemetrexed-carboplatin and pemetrexed alone.|To assess differences in terms of survival between the combination pemetrexed-carboplatin and pemetrexed alone.,Gruppo Oncologico Italiano di Ricerca Clinica,All,"18 Years and older   (Adult, Older Adult)",Phase 2,230.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GOIRC 02/2006|EudraCT number 2006-004009-24,July 2007,July 2009,December 2009,"November 6, 2008",,"August 3, 2009","Azienda Ospedaliero-Universitaria Umberto I, Clinica di Oncologia Medica, Ancona, Italy|Azienda Ospedaliera Ospedali Riuniti di Bergamo, UO di Oncologia Medica, Bergamo, Italy|Azienda Istituti Ospitalieri di Cremona, UO di Oncologia Medica, Cremona, Italy|Azienda Sanitaria Ospedaliera S. Croce e Carle, UO di Oncologia Medica, Cuneo, Italy|Ospedale S. Croce, U.O. di Oncologia Medica, Fano, PU, Italy|Azienda Ospedaliera Careggi, UO di Oncologia Medica, Firenze, Italy|EO Ospedali Galliera, SC Oncologia Medica, Genova, Italy|Ospedale Versilia, UO di Oncologia Medica, Lido di Camaiore, LU, Italy|USL 6, Presidio Ospedaliero di Livorno, U.O. di Oncologia MedicaAzienda, Livorno, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-IRST, Oncologia Medica, Meldola, FC, Italy|Istituto Nazionale Tumori, SC di Oncologia 2, Milano, Italy|Azienda Ospedaliero-Universitaria di Modena-Policlinico, U.O. di Oncologia Medica ed Ematologia, Modena, Italy|AO S. Gerardo, Nuovo Ospedale S. Gerardo-settore A, Oncologia Medica, Monza, MI, Italy|Azienda Ospedaliero-Universitaria di Parma, UOC di Oncologia Medica, Parma, Italy|Ospedale Silvestrini, S.C. di Oncologia Medica, Perugia, Italy|Arcispedale Santa Maria Nuova, UO di Oncologia Medica, Reggio Emilia, Italy|Azienda Ospedaliera S. Camillo-Forlanini, U.O. di Oncologia Medica, Roma, Italy|Ospedale SS. Annunziata, UO di Oncologia Medica, Sassari, Italy|Azienda Sanitaria Ospedaliera Molinette, U.O. di Oncologia Medica, Torino, Italy|P.O. Treviglio-Caravaggio, U.O. di Oncologia Medica, Treviglio, BG, Italy|Policlinico ""G. B. Rossi""-Borgo Roma, U.O. di Oncologia Medica Clinicizzata, Verona, Italy",,https://ClinicalTrials.gov/show/NCT00786331,2,pemetrexed,pemetrexed plus carboplatin,1,1,False,False,False,False,pemetrexed,pemetrexed plus carboplatin,1,1
449,1972,1973,NCT00130780,Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC,,Completed,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: Pre-surgical Treatment with Bevacizumab plus Chemotherapy|Drug: Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab,The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas Improves Therapeutic Response/Outcome Assessment.,Memorial Sloan Kettering Cancer Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,71.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,05-052,August 2005,October 2012,October 2012,"August 16, 2005","January 25, 2016","January 25, 2016","Memorial Sloan Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00130780,2,pre-surgical treatment with bevacizumab plus chemotherapy,pre-surgical docetaxel and cisplatin and adjuvant bevacizumab,1,1,False,False,False,False,pre-surgical treatment with bevacizumab plus chemotherapy,pre-surgical docetaxel and cisplatin and adjuvant bevacizumab,1,1
464,2031,2032,NCT01951469,Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer,,Unknown status,No Results Available,Non-small Cell Lung Cancer|Brain Metastases|EGFR Mutation,Drug: Gefitinib and Pemetrexed/cisplatin|Drug: Gefitinib mono-therapy,comparing the difference of iPFS(intracranial progression free survival) in two arms|comparing the difference of Response rate(CR&PR) and in two arms,Sun Yat-sen University|Wu Jieping Medical Foundation,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,160.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NSCLC brain metastasis 01,June 2013,June 2018,June 2019,"September 26, 2013",,"October 26, 2017","Sun Yat-sen University of Cancer Center, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01951469,2,gefitinib and pemetrexed/cisplatin,gefitinib mono-therapy,1,1,False,False,False,False,gefitinib and pemetrexed/cisplatin,gefitinib mono-therapy,1,1
470,2057,2058,NCT01951482,Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer,,Recruiting,No Results Available,Non Squamous Non-small Cell Lung Cancer|Brain Metastases|Bevacizumab,Drug: Pemetrexed/cisplatin|Drug: Bevacizumab and Pemetrexed/cisplatin,Compare iPFS(intracranial progression free survival) in two arms|Response rate(CR&PR),Sun Yat-sen University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,108.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NSCLC brain metastasis 02,June 2013,December 2019,June 2020,"September 26, 2013",,"October 26, 2017","Sun Yat-sen University of Cancer Center, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01951482,2,pemetrexed/cisplatin,bevacizumab and pemetrexed/cisplatin,1,1,False,False,False,False,pemetrexed/cisplatin,bevacizumab and pemetrexed/cisplatin,1,1
497,2178,2179,NCT00600587,Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC),,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: neoadjuvant erlotinib therapy|Drug: neoadjuvant gemcitabine/carboplatin therapy,Response to Neoadjuvant Erlotinib Therapy|disease free survival|overall survival|complete resection rate|Toxicity of Neoadjuvant Erlotinib Therapy and postoperative complications,Guangdong Provincial People's Hospital|GuangdongPPH,All,"18 Years and older   (Adult, Older Adult)",Phase 2,24.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CSLC-0702|tarceva-123456-1,September 2007,June 2013,June 2013,"January 25, 2008",,"June 25, 2013","Guangdong General Hospital, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT00600587,2,neoadjuvant erlotinib therapy,neoadjuvant gemcitabine/carboplatin therapy,1,1,False,False,False,False,neoadjuvant erlotinib therapy,neoadjuvant gemcitabine/carboplatin therapy,1,1
507,2226,2227,NCT02004184,Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy,IDA,Terminated,No Results Available,"Carcinoma, Non-small-cell Lung",Drug: maintenance pemetrexed|Drug: pemetrexed at progression,overall survival|progression free survival|Toxicity|Health related quality of life,Norwegian University of Science and Technology|St. Olavs Hospital,All,"18 Years and older   (Adult, Older Adult)",Phase 3,230.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013/645|2013-001237-41,December 2013,March 2018,March 2018,"December 9, 2013",,"May 7, 2018","St Olavs Hospital, Trondheim, Norway",,https://ClinicalTrials.gov/show/NCT02004184,2,maintenance pemetrexed,pemetrexed at progression,1,1,False,False,False,False,maintenance pemetrexed,pemetrexed at progression,1,1
518,2272,2273,NCT02813785,A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy,IMpower210,"Active, not recruiting",No Results Available,"Carcinoma, Non-Small-Cell Lung","Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Drug: Docetaxel",Overall Survival (OS)|Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1|Percentage of Participants with Objective Response According to RECIST v1.1|Duration of Objective Response According to RECIST v1.1|Percentage of Participants with Adverse Events|Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to Atezolizumab|Minimum Observed Serum Concentration (Cmin) of Atezolizumab|Time to Deterioration (TTD) in Lung Cancer Symptoms According to European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 C30)|TTD in Lung Cancer Symptoms According to EORTC QLQ Lung Cancer Module (LC13)|Health-Related Quality of Life According to EORTC QLQ-C30 Score|Health-Related Quality of Life According to EORTC QLQ-LC13 Score,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,565.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,YO29232,"July 1, 2016","January 31, 2020","January 31, 2020","June 27, 2016",,"September 24, 2019","Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China|Beijing Cancer Hospital, Beijing, China|Beijing Chest Hospital; Oncology Department, Beijing, China|Affiliated Hospital of Bengbu Medical College, Bengbu, China|Jilin Cancer Hospital, Changchun, China|the First Hospital of Jilin University, Changchun, China|Changzhou First People's Hospital, Changzhou, China|West China Hospital, Sichuan University, Chengdu, China|Third Affiliated Hospital of Third Military Medical University, ChongQing, China|Second Affiliated Hospital of Third Military Medical University, Chongqing, China|Guangdong General Hospital, Guangzhou City, China|Sun Yet-sen University Cancer Center, Guangzhou, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China|Sir Run Run Shaw Hospital, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Jiangsu Cancer Hospital, Nanjing, China|The Affiliated Hospital of Medical College Qingdao University, Qingdao, China|Shanghai chest hospital, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, China|Liaoning cancer Hospital & Institute, Shenyang, China|Tianjin Medical University General Hospital, Tianjin (天津), China|The First Affiliated Hospital of Xian Jiao Tong University, Xi'an City, China|Henan Cancer Hospital, Zhengzhou, China|Kyungpook National University Medical Center, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Hospital Sultan Ismail; Oncology, Johor Bahru, Malaysia|Hospital Kuala Lumpur; Jabatan Radioterapi dan Onkologi, Kuala Lumpur, Malaysia|Sarawak General Hospital; Department of Radiotherapy, Oncology and Palliative care, Sarawak, Malaysia|National Cancer Centre; Medical Oncology, Singapore, Singapore|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|CHIANG MAI UNI HOSPITAL; FACULTY OF MEDICINE; Medical Oncology unit, Chiang Mai, Thailand|Khon Kaen University, Khon Kaen, Thailand",,https://ClinicalTrials.gov/show/NCT02813785,2,"atezolizumab (mpdl3280a), an engineered anti-pd-l1 antibody",docetaxel,1,1,False,False,False,False,"atezolizumab (atezolizumab), an engineered anti-pd-l1 antibody",docetaxel,1,1
522,2288,2289,NCT01082549,Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC),ECLIPSE,Completed,No Results Available,Squamous Cell Lung Cancer,Drug: gemcitabine/carboplatin|Drug: gemcitabine/carboplatin plus Iniparib,overall survival|progression free survival,Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,780.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EFC11553|20090321,March 2010,April 2013,April 2013,"March 8, 2010",,"March 17, 2016","Investigational Site Number 840306, Birmingham, Alabama, United States|Investigational Site Number 840207, Huntsville, Alabama, United States|Investigational Site Number 840351, Muscle Shoals, Alabama, United States|Investigational Site Number 840338, Anaheim, California, United States|Investigational Site Number 840353, Burbank, California, United States|Investigational Site Number 840341, Concord, California, United States|Investigational Site Number 840317, Duarte, California, United States|Investigational Site Number 840339, La Verne, California, United States|Investigational Site Number 840309, Loma Linda, California, United States|Investigational Site Number 840307, Los Angeles, California, United States|Investigational Site Number 840327, Maywood, California, United States|Investigational Site Number 840303, San Diego, California, United States|Investigational Site Number 840321, Santa Rosa, California, United States|Investigational Site Number 840326, Stockton, California, United States|Investigational Site Number 840310, Vallejo, California, United States|Investigational Site Number 840336, Denver, Colorado, United States|Investigational Site Number 840346, Norwich, Connecticut, United States|Investigational Site Number 840315, Newark, Delaware, United States|Investigational Site Number 840216, Ft. Lauderdale, Florida, United States|Investigational Site Number 840215, Jacksonville, Florida, United States|Investigational Site Number 840217, Lakeland, Florida, United States|Investigational Site Number 840205, Orlando, Florida, United States|Investigational Site Number 840104, Sarasota, Florida, United States|Investigational Site Number 840343, Athens, Georgia, United States|Investigational Site Number 840213, Augusta, Georgia, United States|Investigational Site Number 840347, Augusta, Georgia, United States|Investigational Site Number 840201, Gainesville, Georgia, United States|Investigational Site Number 840301, Lawrenceville, Georgia, United States|Investigational Site Number 840305, Marietta, Georgia, United States|Investigational Site Number 840314, Tucker, Georgia, United States|Investigational Site Number 840313, Chicago, Illinois, United States|Investigational Site Number 840218, Evansville, Indiana, United States|Investigational Site Number 840319, Indianapolis, Indiana, United States|Investigational Site Number 840329, South Bend, Indiana, United States|Investigational Site Number 840316, Wichita, Kansas, United States|Investigational Site Number 840320, Louisville, Kentucky, United States|Investigational Site Number 840308, Scarborough, Maine, United States|Investigational Site Number 840202, Bethesda, Maryland, United States|Investigational Site Number 840345, Salisbury, Maryland, United States|Investigational Site Number 840337, Royal Oak, Michigan, United States|Investigational Site Number 840328, St. Louis Park, Minnesota, United States|Investigational Site Number 840210, Bridgeton, Missouri, United States|Investigational Site Number 840212, Omaha, Nebraska, United States|Investigational Site Number 840318, Las Vegas, Nevada, United States|Investigational Site Number 840204, Morristown, New Jersey, United States|Investigational Site Number 840350, Chapel Hill, North Carolina, United States|Investigational Site Number 840330, Durham, North Carolina, United States|Investigational Site Number 840105, Cincinnati, Ohio, United States|Investigational Site Number 840302, Cleveland, Ohio, United States|Investigational Site Number 840348, Cleveland, Ohio, United States|Investigational Site Number 840335, Columbus, Ohio, United States|Investigational Site Number 840311, Bend, Oregon, United States|Investigational Site Number 840211, West Reading, Pennsylvania, United States|Investigational Site Number 840352, Charleston, South Carolina, United States|Investigational Site Number 840106, Columbia, South Carolina, United States|Investigational Site Number 840220, Spartanburg, South Carolina, United States|Investigational Site Number 840103, Chattanooga, Tennessee, United States|Investigational Site Number 840208, Chattanooga, Tennessee, United States|Investigational Site Number 840203, Collierville, Tennessee, United States|Investigational Site Number 840101, Nashville, Tennessee, United States|Investigational Site Number 840323, Fort Worth, Texas, United States|Investigational Site Number 840219, Newport News, Virginia, United States|Investigational Site Number 840102, Richmond, Virginia, United States|Investigational Site Number 840312, Seattle, Washington, United States|Investigational Site Number 840344, Tacoma, Washington, United States|Investigational Site Number 840322, Morgantown, West Virginia, United States|Investigational Site Number 840331, Wauwatosa, Wisconsin, United States|Investigational Site Number 056004, Brugge, Belgium|Investigational Site Number 056003, Brussel, Belgium|Investigational Site Number 056001, Liège, Belgium|Investigational Site Number 124003, Edmonton, Canada|Investigational Site Number 124006, Greenfield Park, Canada|Investigational Site Number 124005, London, Canada|Investigational Site Number 124007, Oshawa, Canada|Investigational Site Number 124004, Quebec, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 250007, Brest, France|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250009, Limoges Cedex, France|Investigational Site Number 250003, Marseille, France|Investigational Site Number 250004, Paris Cedex 13, France|Investigational Site Number 250010, Pierre Benite Cedex, France|Investigational Site Number 250008, Poitiers, France|Investigational Site Number 250001, Saint-Herblain Cedex, France|Investigational Site Number 250006, Strasbourg, France|Investigational Site Number 250005, Tours Cedex 1, France|Investigational Site Number 276002, Amberg, Germany|Investigational Site Number 276004, Berlin, Germany|Investigational Site Number 276007, Frankfurt Am Main, Germany|Investigational Site Number 276008, Großhansdorf, Germany|Investigational Site Number 276010, Halle/Saale, Germany|Investigational Site Number 276012, Heidelberg, Germany|Investigational Site Number 276009, Immenhausen, Germany|Investigational Site Number 276001, Löwenstein, Germany|Investigational Site Number 276006, München, Germany|Investigational Site Number 276003, Oldenburg, Germany|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348003, Budapest, Hungary|Investigational Site Number 348001, Mátraháza, Hungary|Investigational Site Number 348004, Nyíregyháza, Hungary|Investigational Site Number 376002, Kfar Saba, Israel|Investigational Site Number 376005, Petah-Tikva, Israel|Investigational Site Number 376003, Tel Hashomer, Israel|Investigational Site Number 376001, Tzrifin, Israel|Investigational Site Number 380006, Genova, Italy|Investigational Site Number 380001, Novara, Italy|Investigational Site Number 380008, Orbassano, Italy|Investigational Site Number 380002, Perugia, Italy|Investigational Site Number 380003, Roma, Italy|Investigational Site Number 380007, Roma, Italy|Investigational Site Number 442001, Luxembourg, Luxembourg|Investigational Site Number 528005, Breda, Netherlands|Investigational Site Number 528004, Eindhoven, Netherlands|Investigational Site Number 528001, Groningen, Netherlands|Investigational Site Number 528006, Maastricht, Netherlands|Investigational Site Number 528003, Zwolle, Netherlands|Investigational Site Number 616006, Bialystok, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616007, Lubin, Poland|Investigational Site Number 616004, Olsztyn, Poland|Investigational Site Number 616008, Torun, Poland|Investigational Site Number 616002, Warszawa, Poland|Investigational Site Number 616005, Wroclaw, Poland|Investigational Site Number 642002, Alba Iulia, Romania|Investigational Site Number 642006, Bucuresti, Romania|Investigational Site Number 642001, Cluj Napoca, Romania|Investigational Site Number 642004, Craiova, Romania|Investigational Site Number 642005, Hunedoara, Romania|Investigational Site Number 724009, Badalona, Spain|Investigational Site Number 724003, Barcelona, Spain|Investigational Site Number 724004, La Coruña, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724006, Madrid, Spain|Investigational Site Number 724002, Málaga, Spain|Investigational Site Number 724001, Palma De Mallorca, Spain|Investigational Site Number 724008, Sevilla, Spain|Investigational Site Number 724010, Valencia, Spain|Investigational Site Number 724007, Zaragoza, Spain|Investigational Site Number 826002, Glasgow, United Kingdom|Investigational Site Number 826005, Leeds, United Kingdom|Investigational Site Number 826001, Manchester, United Kingdom|Investigational Site Number 826006, Wolverhampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT01082549,2,gemcitabine/carboplatin,gemcitabine/carboplatin plus iniparib,1,1,False,False,False,False,gemcitabine/carboplatin,gemcitabine/carboplatin plus iniparib,1,1
528,2310,2311,NCT00729742,Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008),,Completed,No Results Available,"Carcinoma, Non-small Cell Lung",Drug: Comparator: erlotinib + dalotuzumab|Drug: Comparator: erlotinib monotherapy,"Validate imaging platform and molecular markers|Progression-free survival, overall survival",Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 1,49.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0646-008|2008_518|CTRI/2009/091/000139,February 2009,June 2010,May 2011,"August 7, 2008",,"April 4, 2016",,,https://ClinicalTrials.gov/show/NCT00729742,2,comparator: erlotinib + dalotuzumab,comparator: erlotinib monotherapy,1,1,False,False,False,False,comparator: erlotinib + dalotuzumab,comparator: erlotinib monotherapy,1,1
531,2322,2323,NCT01623102,Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer,,Unknown status,No Results Available,Lung Cancer,Drug: cisplatin and gemcitabine combination with Bevacizumab|Drug: Gemcitabine combined with cisplatin chemotherapy,disease-free time to progression|quality of life,Sichuan Cancer Hospital and Research Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,40.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WJP001,February 2013,August 2014,December 2014,"June 19, 2012",,"February 12, 2013","Sichuan Cancer Hospital, Chengdu, Sichuan, China|Sichuan Cancer Hospital, Chengdu, Sichuan, China",,https://ClinicalTrials.gov/show/NCT01623102,2,cisplatin and gemcitabine combination with bevacizumab,gemcitabine combined with cisplatin chemotherapy,1,1,False,False,False,False,cisplatin and gemcitabine combination with bevacizumab,gemcitabine combined with cisplatin chemotherapy,1,1
534,2335,2336,NCT00424853,ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC),,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Docetaxel and cisplatin followed by gemcitabine|Drug: docetaxel and cisplatin followed by gemcitabine,overall response rate assessed by RECIST criteria.|Time to progression|time to treatment failure|overall survival,Sanofi,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,88.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XRP6976B_2506|EudraCT # : 2004-001044-72,May 2005,August 2008,August 2008,"January 22, 2007",,"December 7, 2009","Sanofi-Aventis Administrative Office, Milan, Italy",,https://ClinicalTrials.gov/show/NCT00424853,2,docetaxel and cisplatin followed by gemcitabine,docetaxel and cisplatin followed by gemcitabine,1,1,False,False,False,False,docetaxel and cisplatin followed by gemcitabine,docetaxel and cisplatin followed by gemcitabine,1,1
537,2342,2343,NCT00087802,Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC),,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: gemcitabine/Eloxatin (GEMOX)|Drug: carboplatin/paclitaxel (CP),"To determine the relative efficacy, safety and clinical benefit of the GEMOX regimen compared to the standard combination regimen of CP as first-line treatment of Stage IIIB and IV NSCLC",Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,383.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,L_9210|SR96669,March 2004,May 2007,,"July 16, 2004",,"April 16, 2009","Birmingham Hematology and Oncology Associates, LLC, Birmingham, Alabama, United States|Birmingham Hematology and Oncology Associates, Birmingham, Alabama, United States|Hematology Oncology Associates, Phoenix, Arizona, United States|Northern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States|Arizona Oncology Associates - Hematology Oncology Physicians, Tucson, Arizona, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Florida Cancer Institute, New Port Richey, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Cancer Centers of Florida, P.A., Ocoee, Florida, United States|South Florida Oncology & Hematology Consultants, Plantation, Florida, United States|Hematology Oncology Associates of Illinois, Chicago, Illinois, United States|Northwest Medical Specialists, PC, Niles, Illinois, United States|Hematology Oncology Associates of Illinois, Skokie, Illinois, United States|Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Oncology Associates of Cedar Rapids, Cedar Rapids, Iowa, United States|Kansas City Oncology and Hematology Group, Overland Park, Kansas, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Berkshire Hematology Oncology, PC, Pittsfield, Massachusetts, United States|Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States|Minnesota Oncology Hematology, Minneapolis, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Arch Medical Services, Inc., St. Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New Mexico Cancer Care Associates, Santa Fe, New Mexico, United States|New York Oncology Hematology, P.C., Albany, New York, United States|New York Oncology Hematology, Latham, New York, United States|New York Oncology Hematology, P.C., Rexford, New York, United States|Interlakes Oncology & Hematology, P.C., Rochester, New York, United States|Raleigh Hematology Oncology Clinic, Cary, North Carolina, United States|Piedmont Hematology Oncology Associates, PLLC., Winston-Salem, North Carolina, United States|Dayton Oncology & Hematology, P.A., Kettering, Ohio, United States|Cancer Care Associates, Oklahoma City, Oklahoma, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Cancer Centers of the Carolinas, Seneca, South Carolina, United States|Texas Cancer Center - Abilene, Abilene, Texas, United States|Texas Oncology, P.A., Arlington, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Mamie McFaddin Ward Cancer Center, Beaumont, Texas, United States|Texas Oncology, P.A., Bedford, Texas, United States|Texas Cancer Center at Medical City, Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|The Texas Cancer Center, Dallas, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Cancer Center - Denton, Denton, Texas, United States|El Paso Cancer Treatment Ctr-East, El Paso, Texas, United States|Texas Oncology, P.A., Fort Worth, Texas, United States|San Antonio Tumor and Blood Clinic, Fredericksburg, Texas, United States|Texas Oncology, P.A., Garland, Texas, United States|Texas Oncology, P.A., Houston, Texas, United States|Texas Oncology, P.A., Irving, Texas, United States|Lake Vista Cancer Center, Lewisville, Texas, United States|Longview Cancer Center, Longview, Texas, United States|South Texas Cancer Center - McAllen, McAllen, Texas, United States|Texas Cancer Center of Mesquite, Mesquite, Texas, United States|Allison Cancer Center, Midland, Texas, United States|West Texas Cancer Center, Odessa, Texas, United States|Paris Regional Cancer Center, Paris, Texas, United States|Hematology Oncology Associates of South Texas, San Antonio, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Waco Cancer Care and Research Center, Waco, Texas, United States|Deke Slayton Cancer Center, Webster, Texas, United States|Fairfax Northern Virginia Hematology Oncology, PC, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., Salem, Virginia, United States|Puget Sound Cancer Centers, Edmonds, Washington, United States|Puget Sound Cancer Centers, Seattle, Washington, United States|Cancer Care Northwest, Spokane, Washington, United States|Northwest Cancer Specialists, P.C., Vancouver, Washington, United States",,https://ClinicalTrials.gov/show/NCT00087802,2,gemcitabine/eloxatin (gemox),carboplatin/paclitaxel (cp),1,1,False,False,False,False,gemcitabine/eloxatin (gemox),carboplatin/paclitaxel (cp),1,1
560,2416,2417,NCT00132639,Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC),,Completed,No Results Available,Pulmonary Neoplasms,Drug: Preoperative docetaxel-cisplatin combination chemotherapy|Drug: Preoperative docetaxel monotherapy,disease-free survival rate at 1 year|overall survival|disease-free survival|treatment compliance|response rate to chemotherapy|pathologic complete response (CR) rate|complete resection rate|post-surgical morbidity/mortality,"Haruhiko Fukuda|Ministry of Health, Labour and Welfare, Japan|Japan Clinical Oncology Group",All,"20 Years to 74 Years   (Adult, Older Adult)",Phase 2,80.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,JCOG 0204-MF|C000000032,October 2002,November 2008,November 2008,"August 22, 2005",,"September 22, 2016","National Cancer Center, Chuo-ku,Tsukiji,5-1-1, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00132639,2,preoperative docetaxel-cisplatin combination chemotherapy,preoperative docetaxel monotherapy,1,1,False,False,False,False,preoperative docetaxel-cisplatin combination chemotherapy,preoperative docetaxel monotherapy,1,1
569,2477,2478,NCT00657423,Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC),,Unknown status,No Results Available,Lung Neoplasms,Drug: Treated by endostar combined with docetaxel and cisplatin|Drug: Treated by docetaxel and cisplatin,mean survival time|objective response rate,Xijing Hospital|Yantai Medgenn Ltd.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,80.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,XJ-EnXS0802,April 2008,December 2008,April 2009,"April 14, 2008",,"September 17, 2010","Dept. Resp. Diseases, Xijing Hospital, Xi'an, Shaanxi, China",,https://ClinicalTrials.gov/show/NCT00657423,2,treated by endostar combined with docetaxel and cisplatin,treated by docetaxel and cisplatin,1,1,False,False,False,False,treated by endostar combined with docetaxel and cisplatin,treated by docetaxel and cisplatin,1,1
586,2570,2571,NCT03374280,Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC,,Recruiting,No Results Available,Non Small Cell Lung Cancer,Drug: pemetrexed/cisplatin intercalating gefitinib|Drug: pemetrexed/cisplatin,disease progression-free survival|overall survival|side-effects|overall response rate,Guangzhou Medical University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,178.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GuangzhouMC,"December 1, 2016","December 30, 2019","December 30, 2021","December 15, 2017",,"March 28, 2019","The first affiliated hospital of Guangzhou MC, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT03374280,2,pemetrexed/cisplatin intercalating gefitinib,pemetrexed/cisplatin,1,1,False,False,False,False,pemetrexed/cisplatin intercalating gefitinib,pemetrexed/cisplatin,1,1
597,2611,2612,NCT02655536,"Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial",BRILLIANT,Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung|Brain Neoplasms",Drug: Bevacizumab plus erlotinib|Drug: Erlotinib,Progression-free survival|overall survival|overall response rate|Time-to-central nervous system (CNS) progression|Time to extra-CNS progression|The PFS-2 in patients in patients with CNS progression only|Time to neurological symptom progression|Number of participants with treatment-related adverse events as assessed by CTCAE version 4.03,National Taiwan University Hospital,All,"20 Years to 99 Years   (Adult, Older Adult)",Phase 2,109.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201510073MIPB,"August 1, 2017",June 2019,December 2019,"January 14, 2016",,"July 10, 2018","Department of Oncology, Nationa Taiwan University Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02655536,2,bevacizumab plus erlotinib,erlotinib,1,1,False,False,False,False,bevacizumab plus erlotinib,erlotinib,1,1
619,2732,2733,NCT03726736,Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC,ACWDVDFPTAN,Recruiting,No Results Available,Non-small Cell Lung Cancer,Drug: Anlotinib combined Docetaxel|Drug: Docetaxel,PFS|OS|quality of life|ORR|DCR|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],Yong Fang|Zhejiang Provincial People’s Hospital|Zhejiang Cancer Hospital|Ningbo No. 1 Hospital|Ningbo No.2 Hospital|The First Hospital of Jiaxing|Huzhou Central Hospital|Sir Run Run Shaw Hospital,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,97.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALTER-L016,"December 21, 2018","November 1, 2019","November 1, 2020","October 31, 2018",,"June 7, 2019","Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China",,https://ClinicalTrials.gov/show/NCT03726736,2,anlotinib combined docetaxel,docetaxel,1,1,False,False,False,False,anlotinib combined docetaxel,docetaxel,1,1
620,2733,2734,NCT03654027,Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC,,Not yet recruiting,No Results Available,Non-small Cell Lung Cancer,Drug: Anlotinib Plus Docetaxel|Drug: Docetaxel,PFS|OS|ORR|DCR|Safety (Number of Participants with Adverse Events as a Measure of Safety and Tolerability),First Affiliated Hospital of Guangxi Medical University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,84.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ALTER-L019,"October 1, 2018","October 1, 2019","October 1, 2020","August 31, 2018",,"August 31, 2018",,,https://ClinicalTrials.gov/show/NCT03654027,2,anlotinib plus docetaxel,docetaxel,1,1,False,False,False,False,anlotinib plus docetaxel,docetaxel,1,1
627,2775,2776,NCT02001896,Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation,,Unknown status,No Results Available,Non-Small Cell Lung Cancer,Drug: gemcitabine; cisplatin or carboplatin; erlotinib|Drug: erlotinib,Progression-free survival|Overall Survival,Xinjiang Medical University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,60.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XJTHLC001,December 2013,June 2015,June 2015,"December 5, 2013",,"December 5, 2013","Xinjiang medical university, Urumqi, Xinjiang, China",,https://ClinicalTrials.gov/show/NCT02001896,2,gemcitabine; cisplatin or carboplatin; erlotinib,erlotinib,1,1,False,False,False,False,gemcitabine; cisplatin or carboplatin; erlotinib,erlotinib,1,1
636,2810,2811,NCT02959749,Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer,,Completed,No Results Available,Progression Free Survival,"Drug: Osimertinib|Drug: docetaxel, bevacizumab",progression free survival,Qingdao Central Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,147.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,QingdaoCH20161101,August 2015,October 2017,"December 31, 2017","November 9, 2016",,"February 14, 2018","Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China",,https://ClinicalTrials.gov/show/NCT02959749,2,osimertinib,"docetaxel, bevacizumab",1,1,False,False,False,False,osimertinib,"docetaxel, bevacizumab",1,1
641,2826,2827,NCT00283244,"Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC",,Completed,Has Results,Lung Cancer,Drug: erlotinib hydrochloride|Drug: gemcitabine hydrochloride,Progression-free Survival|Response Rate|Overall Survival|Toxicity|Quality of Life (QOL)- Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Trial Outcome Index-L (TOI-L),UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI),All,70 Years to 120 Years   (Older Adult),Phase 2,147.0,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LCCC 0512|P30CA016086|UNC-LCCC-0512,March 2006,September 2014,October 2014,"January 27, 2006","April 24, 2017","April 24, 2017","Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States|Summit Cancer Care, Savannah, Georgia, United States|Evanston Hospital, Evanston, Illinois, United States|Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Batte Cancer Center at Northeast Medical Center, Concord, North Carolina, United States|Cape Fear Valley Medical Center Cancer Center, Fayetteville, North Carolina, United States|Rex Cancer Center at Rex Hospital, Raleigh, North Carolina, United States|Kingsport Hematology-Oncology Associates, Kingsport, Tennessee, United States|University of Tennessee Cancer Institute - Memphis, Memphis, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00283244,2,erlotinib hydrochloride,gemcitabine hydrochloride,1,1,False,False,False,False,erlotinib hydrochloride,gemcitabine hydrochloride,1,1
657,2875,2876,NCT04042558,"A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies",GFPC 06-2018,Recruiting,No Results Available,NSCLC Stage IIIB|NSCLC Stage IV|EGFR Gene Mutation|ALK Gene Rearrangement Positive|ROS1 Gene Mutation,Drug: Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab|Drug: Carboplatin + Pemetrexed + Atezolizumab,Objective response rate (ORR) according to RECIST 1.1|The progression-free survival (PFS)|The overall survival|The duration of response,Centre Francois Baclesse|GFPC,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,149.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GFPC 06-2018,"September 26, 2019",June 2021,June 2023,"August 2, 2019",,"October 17, 2019","CHU, Angers, France|Centre Hospitalier, Annecy, France|CHU-Hôpital MORVAN, Brest, France|Centre François Baclesse, Caen, France|CHU Gabriel MONTPIED, Clermont-Ferrand, France|CHIC, Créteil, France|CHU, Grenoble, France|CHU Limoges, Limoges, France|Centre Léon Bérard, Lyon, France|Hôpital Nord, Marseille, France|Hopital Foch, Paris, France|institut Curie, Paris, France|HIA Percy, Percy, France|Hôpital Haut Lévêque,Centre François Magendie, Pessac, France|CHU, Pierre-Bénite, France|CHU, Rennes, France|CHU, Rouen, France|ICLN, St Priez en Jarez, Saint-Priest-en-Jarez, France|Centre Paul Strauss, Strasbourg, France|HIA St Anne, Toulon, France|CHU, Toulouse, France|Centre Hospitalier, Villefranche, France|HIA R.Picqué, Villenave-d'Ornon, France",,https://ClinicalTrials.gov/show/NCT04042558,2,carboplatin + pemetrexed + atezolizumab + bevacizumab,carboplatin + pemetrexed + atezolizumab,1,1,False,False,False,False,carboplatin + pemetrexed + atezolizumab + bevacizumab,carboplatin + pemetrexed + atezolizumab,1,1
661,2892,2893,NCT00445848,S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer,,Completed,Has Results,Lung Cancer,Biological: bevacizumab|Drug: erlotinib hydrochloride,Overall Survival|Progression-free Survival|Response Rate (Complete and Partial)|Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs,Southwest Oncology Group|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 2,89.0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000531056|S0636|U10CA032102,July 2007,August 2013,January 2014,"March 9, 2007","September 7, 2016","November 6, 2017","Kaiser Permanente - Deer Valley, Antioch, California, United States|Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States|Peninsula Medical Center, Burlingame, California, United States|Kaiser Permanente - Fremont, Fremont, California, United States|Marin Cancer Institute at Marin General Hospital, Greenbrae, California, United States|Kaiser Permanente Medical Center - Hayward, Hayward, California, United States|Tibotec Therapeutics - Division of Ortho Biotech Products, LP, Marysville, California, United States|Kaiser Permanente Medical Center - Oakland, Oakland, California, United States|Valley Medical Oncology Consultants - Pleasanton, Pleasanton, California, United States|Kaiser Permanente Medical Center - Redwood City, Redwood City, California, United States|Kaiser Permanente Medical Center - Richmond, Richmond, California, United States|Kaiser Permanente Medical Center - Roseville, Roseville, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|South Sacramento Kaiser-Permanente Medical Center, Sacramento, California, United States|Kaiser Permanente Medical Center - Sacramento, Sacramento, California, United States|Kaiser Permanente Medical Center - San Francisco Geary Campus, San Francisco, California, United States|California Pacific Medical Center - California Campus, San Francisco, California, United States|Kaiser Permanente Medical Center - Santa Teresa, San Jose, California, United States|Kaiser Foundation Hospital - San Rafael, San Rafael, California, United States|Sutter Health - Western Division Cancer Research Group, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara Kiely Campus, Santa Clara, California, United States|Kaiser Permanente Medical Center - Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente Medical Center - South San Francisco, South San Francisco, California, United States|Kaiser Permanente Medical Facility - Stockton, Stockton, California, United States|Tahoe Forest Cancer Center, Truckee, California, United States|Kaiser Permanente Medical Center - Vallejo, Vallejo, California, United States|Kaiser Permanente Medical Center - Walnut Creek, Walnut Creek, California, United States|University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States|Kaiser Permanente - Denver, Denver, Colorado, United States|Shaw Regional Cancer Center, Edwards, Colorado, United States|Valley View Hospital Cancer Center, Glenwood Springs, Colorado, United States|Kaiser Permanente - Lafayette, Lafayette, Colorado, United States|Montrose Memorial Hospital Cancer Center, Montrose, Colorado, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Broward General Medical Center Cancer Center, Fort Lauderdale, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Northside Hospital Cancer Center, Atlanta, Georgia, United States|Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|WellStar Cobb Hospital, Austell, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Kennestone Cancer Center at Wellstar Kennestone Hospital, Marietta, Georgia, United States|Southern Regional Medical Center, Riverdale, Georgia, United States|Harbin Clinic Cancer Center - Medical Oncology, Rome, Georgia, United States|Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler, Savannah, Georgia, United States|Kaiser Permanente - Moanalua Medical Center and Clinic, Honolulu, Hawaii, United States|Cancer Care Center of Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States|Edward Hospital Cancer Center, Naperville, Illinois, United States|Central Dupage Cancer Center, Winfield, Illinois, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Liberal, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas, United States|Cotton-O'Neil Cancer Center, Topeka, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Lucille P. Markey Cancer Center at University of Kentucky, Lexington, Kentucky, United States|Boston University Cancer Research Center, Boston, Massachusetts, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Battle Creek Health System Cancer Care Center, Battle Creek, Michigan, United States|Mecosta County Medical Center, Big Rapids, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Butterworth Hospital at Spectrum Health, Grand Rapids, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|Lacks Cancer Center at Saint Mary's Health Care, Grand Rapids, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Mercy General Health Partners, Muskegon, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Big Sky Oncology, Great Falls, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Good Samaritan Cancer Center at Good Samaritan Hospital, Kearney, Nebraska, United States|Highland Hospital of Rochester, Rochester, New York, United States|Interlakes Oncology/Hematology PC, Rochester, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Moses Cone Regional Cancer Center at Wesley Long Community Hospital, Greensboro, North Carolina, United States|Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Annie Penn Cancer Center, Reidsville, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|Adventist Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|St. Joseph Cancer Center, Bellingham, Washington, United States|Olympic Hematology and Oncology, Bremerton, Washington, United States|Columbia Basin Hematology, Kennewick, Washington, United States|Skagit Valley Hospital Cancer Care Center, Mount Vernon, Washington, United States|Harrison Poulsbo Hematology and Onocology, Poulsbo, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical, PLLC, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Group Health Central Hospital, Seattle, Washington, United States|Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States|Polyclinic First Hill, Seattle, Washington, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Evergreen Hematology and Oncology, PS, Spokane, Washington, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States",,https://ClinicalTrials.gov/show/NCT00445848,2,bevacizumab,erlotinib hydrochloride,1,1,False,False,False,False,bevacizumab,erlotinib hydrochloride,1,1
666,2905,2906,NCT00835471,2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC),NVALT10,Unknown status,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: erlotinib plus docetaxel or pemetrexed|Drug: erlotinib,Imaging|Safety,Dutch Society of Physicians for Pulmonology and Tuberculosis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,230.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NVALT10,March 2009,June 2013,June 2014,"February 3, 2009",,"July 26, 2010","VU medisch centrum, Amsterdam, Netherlands|Rode Kruis Ziekenhuis, Beverwijk, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Catharina-Ziekenhuis, Eindhoven, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Kennemer Gasthuis, Haarlem, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Universitair Medisch Centrum Sint Radboud, Nijmegen, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|Sint Franciscus Gasthuis, Rotterdam, Netherlands|HagaZiekenhuis, The Hague, Netherlands|Isala Klinieken, Zwolle, Netherlands",,https://ClinicalTrials.gov/show/NCT00835471,2,erlotinib plus docetaxel or pemetrexed,erlotinib,1,1,False,False,False,False,erlotinib plus docetaxel or pemetrexed,erlotinib,1,1
674,2951,2952,NCT00390429,Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors,,Completed,Has Results,"Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: docetaxel|Drug: erlotinib hydrochloride,Safety and Toxicity of Erlotinib Hydrochloride and Docetaxel as Measured by NCI CTC v3.0 on Day 8 of Course 1 and on Day 1 of Every Subsequent Course (Phase I [Completed as of 12/01/2004])|Response Rate (Phase II)|Comparison of Toxicity of Two Different Schedules of Erlotinib Hydrochloride and Docetaxel (Phase I [Completed as of 12/01/2004])|Maximum Tolerated Dose of Two Different Schedules of Erlotinib Hydrochloride and Docetaxel (Phase I [Completed as of 12/01/2004])|Overall Survival (Phase II)|Progression-free Survival (Phase II)|Frequency and Severity of Toxicities (Phase II)|Prognostic Significance of Epithelial Growth Factor Receptor (EGFR) Expression|Correlation of Baseline EGFR Levels With Clinical Outcome|Correlation of Basal Levels of p27 With Response Rate and Overall Survival|Correlation of Phospho-EGFR With Increased p27 and Clinical Outcome|Correlation of EGFR Polymorphisms With Treatment Response and Clinical Outcome,"University of California, Davis|National Cancer Institute (NCI)|Genentech, Inc.|Aventis Pharmaceuticals",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,81.0,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,273721|P30CA093373|UCDCC-128|UCDCC-200311717-5|AVENTIS-Z1001055|CDR0000505821,July 2002,August 2008,August 2012,"October 19, 2006","October 26, 2017","December 6, 2018","University of California Davis Cancer Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT00390429,2,docetaxel,erlotinib hydrochloride,1,1,False,False,False,False,docetaxel,erlotinib hydrochloride,1,1
688,2993,2994,NCT01107626,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,,"Active, not recruiting",No Results Available,Lung Cancer,Biological: bevacizumab|Drug: pemetrexed disodium,"Overall survival|Progression-free survival|Objective response as measured by RECIST|Toxicity|Association between bevacizumab and pemetrexed disodium population pharmacokinetics|Association between proteomic profiles and ICAM, VEGF, and FGF-beta with the clinical outcomes (Closed as of 04/01/2010)",Eastern Cooperative Oncology Group|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 3,1282.0,Other|NIH,Interventional,Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000666482|ECOG-E5508,August 2010,"July 31, 2019","May 8, 2020","April 21, 2010",,"December 13, 2018","Regional Medical Center, Anniston, Alabama, United States|Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|North Bay Cancer Center, Fairfield, California, United States|Todd Cancer Institute at Long Beach Memorial Medical Center, Long Beach, California, United States|Community Hospital of the Monterey Peninsula Comprehensive Cancer Center, Monterey, California, United States|Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States|Feather River Hospital Cancer Center, Paradise, California, United States|Sutter Cancer Center at Roseville Medical Center, Roseville, California, United States|Sutter Cancer Center, Sacramento, California, United States|Salinas Valley Memorial Hospital, Salinas, California, United States|Stanford Cancer Center, Stanford, California, United States|Aurora Presbyterian Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States|St. Anthony Central Hospital, Denver, Colorado, United States|Kaiser Permanente - Denver, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|CCOP - Colorado Cancer Research Program, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Kaiser Permanente - Lafayette, Lafayette, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|Praxair Cancer Center at Danbury Hospital, Danbury, Connecticut, United States|Helen and Harry Gray Cancer Center at Hartford Hospital, Hartford, Connecticut, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain, Connecticut, United States|Kaiser Permanente at Capitol Hill Medical Center, Washington, District of Columbia, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Veterans Affairs Medical Center - Washington, DC, Washington, District of Columbia, United States|North Broward Medical Center, Deerfield Beach, Florida, United States|Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital, Fort Lauderdale, Florida, United States|Broward General Medical Center Cancer Center, Fort Lauderdale, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Ella Milbank Foshay Cancer Center at Jupiter Medical Center, Jupiter, Florida, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States|Sacred Heart Cancer Center at Sacred Heart Hospital, Pensacola, Florida, United States|Sacred Heart Medical Oncology, Pensacola, Florida, United States|Cleveland Clinic Florida - Weston, Weston, Florida, United States|Phoebe Cancer Center at Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia, United States|Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler, Savannah, Georgia, United States|Pearlman Comprehensive Cancer Center at South Georgia Medical Center, Valdosta, Georgia, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|St. Joseph Regional Medical Center, Lewiston, Idaho, United States|Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Nampa, Idaho, United States|Mountain States Tumor Institute at St. Luke's, Twin Falls, Idaho, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|Hematology and Oncology Associates, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago Westside Hospital, Chicago, Illinois, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|Resurrection Medical Center, Chicago, Illinois, United States|Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States|Saint Joseph Hospital, Chicago, Illinois, United States|Elmhurst Memorial Hospital, Elmhurst, Illinois, United States|St. Francis Hospital, Evanston, Illinois, United States|Leonard C. Ferguson Cancer Center, Freeport, Illinois, United States|Delnor Hospital - Geneva, Geneva, Illinois, United States|Kellogg Cancer Care Center, Highland Park, Illinois, United States|Hinsdale Hematology Oncology Associates, Hinsdale, Illinois, United States|Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States|Provena St. Mary's Regional Cancer Center - Kankakee, Kankakee, Illinois, United States|La Grange Memorial Hospital, La Grange, Illinois, United States|North Shore Oncology and Hematology Associates, Limited - Libertyville, Libertyville, Illinois, United States|Cancer Care and Hematology Specialists of Chicagoland - Niles, Niles, Illinois, United States|West Suburban Center for Cancer Care, River Forest, Illinois, United States|Swedish-American Regional Cancer Center, Rockford, Illinois, United States|Center for Cancer Care at OSF Saint Anthony Medical Center, Rockford, Illinois, United States|Hematology Oncology Associates - Skokie, Skokie, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|Central Dupage Cancer Center, Warrenville, Illinois, United States|St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, Indiana, United States|Clarian Arnett Cancer Care, Lafayette, Indiana, United States|Suniti Medical Corporation, Merrillville, Indiana, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|Reid Hospital & Health Care Services, Richmond, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Hematology Oncology Associates of the Quad Cities, Bettendorf, Iowa, United States|Iowa Blood and Cancer Care, Cedar Rapids, Iowa, United States|St. Luke's Hospital, Cedar Rapids, Iowa, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates - West Des Moines, Clive, Iowa, United States|Mercy Cancer Center - West Lakes, Clive, Iowa, United States|Heartland Oncology and Hematology, Council Bluffs, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - North Iowa, Mason City, Iowa, United States|McCreery Cancer Center at Ottumwa Regional, Ottumwa, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Covenant Cancer Treatment Center, Waterloo, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Providence Medical Center, Kansas City, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's Hospital - South, Overland Park, Kansas, United States|CCOP - Kansas City, Prairie Village, Kansas, United States|Mitchell Memorial Cancer Center at Owensboro Medical Health System, Owensboro, Kentucky, United States|Mary Bird Perkins Cancer Center - Baton Rouge, Baton Rouge, Louisiana, United States|Ochsner Health Center - Bluebonnet, Baton Rouge, Louisiana, United States|Ochsner Health Center - Covington, Covington, Louisiana, United States|Louisiana State University Health Sciences Center - Monroe, Monroe, Louisiana, United States|MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, United States|Medical Center of Louisiana - New Orleans, New Orleans, Louisiana, United States|New Orleans Cancer Institute at Memorial Medical Center, New Orleans, Louisiana, United States|CCOP - Ochsner, New Orleans, Louisiana, United States|Ochsner Cancer Institute at Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|CancerCare of Maine at Eastern Maine Medical Center, Bangor, Maine, United States|Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States|Kaiser Permanente at Woodlawn Medical Center, Baltimore, Maryland, United States|Regional Cancer Center at Western Maryland Health System - Sacred Heart Campus, Cumberland, Maryland, United States|Frederick Memorial Hospital Regional Cancer Therapy Center, Frederick, Maryland, United States|Kaiser Permanente - Gaithersburg Medical Center, Gaithersburg, Maryland, United States|Kaiser Permanente Mid-Atlantic Medical Group-Largo Medical Facility, Largo, Maryland, United States|Peninsula Regional Medical Center, Salisbury, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Sturdy Memorial Hospital, Attleboro, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Jordan Hospital Club Cancer Center, Plymouth, Massachusetts, United States|Baystate Regional Cancer Program at D'Amour Center for Cancer Care, Springfield, Massachusetts, United States|UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Dickinson County Healthcare System, Iron Mountain, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Upper Michigan Cancer Center at Marquette General Hospital, Marquette, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|St. Joseph's Medical Center, Brainerd, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Immanuel St. Joseph's, Mankato, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Willmar Cancer Center at Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology - Woodbury, Woodbury, Minnesota, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|Central Care Cancer Center at Carrie J. Babb Cancer Center, Bolivar, Missouri, United States|Skaggs Cancer Center at Skaggs Regional Medical Center, Branson, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Goldschmidt Cancer Center, Jefferson City, Missouri, United States|St. John's Regional Medical Center, Joplin, Missouri, United States|Saint Luke's Cancer Institute at Saint Luke's Hospital, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology Oncology Associates, Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Parvin Radiation Oncology, Liberty, Missouri, United States|Mercy Clinic Cancer and Hematology - Rolla, Rolla, Missouri, United States|Phelps County Regional Medical Center, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology, Incorporated, Saint Joseph, Missouri, United States|St. Anthony's Cancer Center, Saint Louis, Missouri, United States|Missouri Baptist Cancer Center, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Good Samaritan Cancer Center at Good Samaritan Hospital, Kearney, Nebraska, United States|Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Immanuel Medical Center, Omaha, Nebraska, United States|Alegant Health Cancer Center at Bergan Mercy Medical Center, Omaha, Nebraska, United States|Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Renown Institute for Cancer at Renown Regional Medical Center, Reno, Nevada, United States|Seacoast Cancer Center at Wentworth - Douglass Hospital, Dover, New Hampshire, United States|Oncology Center at St. Joseph Hospital, Nashua, New Hampshire, United States|Veterans Affairs Medical Center - East Orange, East Orange, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton, Marlton, New Jersey, United States|Carol G. Simon Cancer Center at Morristown Memorial Hospital, Morristown, New Jersey, United States|UMDNJ University Hospital, Newark, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Frederick R. and Betty M. Smith Cancer Treatment Center, Sparta, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Franklin & Edith Scarpa Regional Cancer Center at South Jersey Healthcare, Vineland, New Jersey, United States|Fox Chase Virtua Health Cancer Program at Virtua West Jersey, Voorhees, New Jersey, United States|Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States|Maimonides Cancer Center at Maimonides Medical Center, Brooklyn, New York, United States|Bassett Healthcare Regional Cancer Program at Mary Imogene Bassett Hospital, Cooperstown, New York, United States|Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States|Nalitt Cancer Institute at Staten Island University Hospital, Staten Island, New York, United States|Stony Brook University Cancer Center, Stony Brook, New York, United States|Faxton Regional Cancer Center, Utica, New York, United States|Dickstein Cancer Treatment Center at White Plains Hospital Center, White Plains, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Moses Cone Regional Cancer Center at Wesley Long Community Hospital, Greensboro, North Carolina, United States|Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Kinston Medical Specialists, Kinston, North Carolina, United States|Annie Penn Cancer Center, Reidsville, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|MeritCare Broadway, Fargo, North Dakota, United States|Dakota Cancer Institute at Dakota Clinic - South University, Fargo, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|Roger Maris Cancer Center at MeritCare Hospital, Fargo, North Dakota, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Trinity CancerCare Center, Minot, North Dakota, United States|Cleveland Clinic Beachwood Family Health and Surgery Center, Beachwood, Ohio, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Mercy Cancer Center at Mercy Medical Center, Canton, Ohio, United States|Aultman Cancer Center at Aultman Hospital, Canton, Ohio, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Community Cancer Center, Elyria, Ohio, United States|Hematology Oncology Center, Elyria, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Cleveland Clinic Cancer Center, Independence, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|St. Rita's Medical Center, Lima, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|Hillcrest Cancer Center at Hillcrest Hospital, Mayfield Heights, Ohio, United States|Southwest General Health Center, Middleburg Heights, Ohio, United States|UHHS Chagrin Highlands Medical Center, Orange Village, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|Parma Community General Hospital, Parma, Ohio, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, United States|Cleveland Clinic Foundation - Strongsville, Strongsville, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|St. Anne Mercy Hospital, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|UHHS Westlake Medical Center, Westlake, Ohio, United States|Cleveland Clinic - Wooster, Wooster, Ohio, United States|United States Air Force Medical Center - Wright-Patterson, Wright-Patterson Air Force Base, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Cancer Care Associates - Norman, Norman, Oklahoma, United States|Cancer Care Associates - Mercy Campus, Oklahoma City, Oklahoma, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Mercy Fitzgerald Hospital, Darby, Pennsylvania, United States|Ephrata Cancer Center at Ephrata Community Hospital, Ephrata, Pennsylvania, United States|Regional Cancer Center - Erie, Erie, Pennsylvania, United States|Fox Chase Cancer Center Buckingham, Furlong, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|PinnacleHealth Regional Cancer Center at Polyclinic Hospital, Harrisburg, Pennsylvania, United States|Geisinger Hazleton Cancer Center, Hazleton, Pennsylvania, United States|Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Riddle Memorial Hospital Cancer Center, Media, Pennsylvania, United States|Cancer Center of Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States|Frankford Hospital Cancer Center - Torresdale Campus, Philadelphia, Pennsylvania, United States|Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States|Iris V. Henderson Cancer Center at Mercy Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Joseph Medical Center, Reading, Pennsylvania, United States|McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States|Guthrie Cancer Center at Guthrie Clinic Sayre, Sayre, Pennsylvania, United States|Mercy Hospital Cancer Center - Scranton, Scranton, Pennsylvania, United States|Hematology and Oncology Associates of Northeastern Pennsylvania, Scranton, Pennsylvania, United States|Grand View Hospital, Sellersville, Pennsylvania, United States|Geisinger Medical Group - Scenery Park, State College, Pennsylvania, United States|Mount Nittany Medical Center, State College, Pennsylvania, United States|Chester County Hospital, West Chester, Pennsylvania, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|Susquehanna Cancer Center at Divine Providence Hospital, Williamsport, Pennsylvania, United States|CCOP - Main Line Health, Wynnewood, Pennsylvania, United States|Lankenau Cancer Center at Lankenau Hospital, Wynnewood, Pennsylvania, United States|York Cancer Center at Apple Hill Medical Center, York, Pennsylvania, United States|AnMed Cancer Center, Anderson, South Carolina, United States|Cancer Centers of the Carolinas - Easley, Easley, South Carolina, United States|Bon Secours St. Francis Health System, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Faris Road, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Grove Commons, Greenville, South Carolina, United States|Greenville Hospital Cancer Center, Greenville, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Greer Medical Oncology, Greer, South Carolina, United States|Cancer Centers of the Carolinas - Seneca, Seneca, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Cancer Centers of the Carolinas - Spartanburg, Spartanburg, South Carolina, United States|Oncology Services of Aberdeen, Aberdeen, South Dakota, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|West Tennessee Cancer Center at Jackson-Madison County General Hospital, Jackson, Tennessee, United States|Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center, Kingsport, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Hendrick Cancer Center, Abilene, Texas, United States|Harrington Cancer Center, Amarillo, Texas, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|Community Cancer Center at Rutland Regional Medical Center, Rutland, Vermont, United States|Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States|Virginia Oncology Associates - Hampton, Hampton, Virginia, United States|Kaiser Permanente Tysons Corner Medical Center, McLean, Virginia, United States|Southwest Virginia Regional Cancer Center at Wellmonth Health, Norton, Virginia, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|Auburn Regional Center for Cancer Care, Auburn, Washington, United States|Overlake Cancer Center at Overlake Hospital Medical Center, Bellevue, Washington, United States|Providence Centralia Hospital, Centralia, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|St. Francis Hospital, Federal Way, Washington, United States|Cascade Cancer Center at Evergreen Hospital Medical Center, Kirkland, Washington, United States|Providence St. Peter Hospital Regional Cancer Center, Olympia, Washington, United States|Good Samaritan Cancer Center, Puyallup, Washington, United States|CCOP - Virginia Mason Research Center, Seattle, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Pacific Medical Center, Seattle, Washington, United States|Rockwood Clinic Cancer Treatment Center, Spokane, Washington, United States|Franciscan Cancer Center at St. Joseph Medical Center, Tacoma, Washington, United States|Allenmore Hospital, Tacoma, Washington, United States|CCOP - Northwest, Tacoma, Washington, United States|MultiCare Regional Cancer Center at Tacoma General Hospital, Tacoma, Washington, United States|St. Clare Hospital, Tacoma, Washington, United States|West Virginia University Health Sciences Center - Charleston, Charleston, West Virginia, United States|Mary Babb Randolph Cancer Center at West Virginia University Hospitals, Morgantown, West Virginia, United States|Langlade Memorial Hospital, Antigo, Wisconsin, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Bellin Memorial Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Mercy Regional Cancer Center, Janesville, Wisconsin, United States|Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States|Holy Family Memorial Medical Center Cancer Care Center, Manitowoc, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Vince Lombardi Cancer Clinic - Marinette, Marinette, Wisconsin, United States|Wheaton Franciscan Cancer Care - St. Joseph, Milwaukee, Wisconsin, United States|D.N. Greenwald Center, Mukwonago, Wisconsin, United States|Regional Cancer Center at Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|St. Nicholas Hospital, Sheboygan, Wisconsin, United States|Vince Lombardi Cancer Clinic - Sheboygan, Sheboygan, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Aurora Medical Center, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic - Two Rivers, Two Rivers, Wisconsin, United States|Waukesha Memorial Hospital Regional Cancer Center, Waukesha, Wisconsin, United States|University of Wisconcin Cancer Center at Aspirus Wausau Hospital, Wausau, Wisconsin, United States|Oncology Alliance, SC - Milwaukee - West, Wauwatosa, Wisconsin, United States|Riverview UW Cancer Center at Riverview Hospital, Wisconsin Rapids, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States",,https://ClinicalTrials.gov/show/NCT01107626,2,bevacizumab,pemetrexed disodium,1,1,False,False,False,False,bevacizumab,pemetrexed disodium,1,1
690,3000,3001,NCT00545948,Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer,TOP0703,Terminated,Has Results,"Carcinoma, Non-Small-Cell Lung",Drug: Vinorelbine followed by Cisplatin|Drug: Pemetrexed followed by Cisplatin,"2-Year Progression-Free Survival Rate in Patients With Completely Resected Stage IB, II, or IIIA NSCLC|Percentage of Patients With Completely Resected NSCLC Tumors That Can Be Analyzed and Used to Direct Adjuvant Chemotherapy|2-Year Overall Survival in Patients Treated for NSCLC|Patient Understanding and Perceptions of Participating in a Clinical Trial Evaluating Cancer Genomics for Adjuvant Treatment of Early Stage Lung Cancer|Compare Drug Sensitivity Patterns of Cisplatin and Pemetrexed in Both Treatment Arms",Duke University|Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,31.0,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pro00000657,December 2007,January 2012,January 2012,"October 18, 2007","June 9, 2014","July 21, 2014","Palm Beach Cancer Institute, West Palm Beach, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Presbyterian HealthCare, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Maria Parham Hospital, Henderson, North Carolina, United States|Scotland HealthCare System (Scotland Memorial Hospital), Laurinburg, North Carolina, United States|Southeastern Regional Medical Center, Gibson Cancer Center, Lumberton, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States|Johnston Memorial Hospital Authority, Smithfield, North Carolina, United States|Columbus County Hospital, Whiteville, North Carolina, United States|Beaufort Memorial Hospital, Beaufort, South Carolina, United States|Coastal Cancer Center, Myrtle Beach, South Carolina, United States|Community Memorial Health Center, South Hill, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00545948,2,vinorelbine followed by cisplatin,pemetrexed followed by cisplatin,1,1,False,False,False,False,vinorelbine followed by cisplatin,pemetrexed followed by cisplatin,1,1
693,3004,3005,NCT01116219,"Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).",,Completed,No Results Available,Lung Cancer,"Biological: bevacizumab, erlotinib|Drug: bevacizumab, pemetrexed, cisplatin",Progression-free survival at 6 months in stratum wtEGFR cohort 1|Progression-free survival|Overall survival|Best response (RECIST 1.1)|Adverse events (CTCAE v4.0)|Molecular markers in tumor tissue and blood,Swiss Group for Clinical Cancer Research,All,"18 Years and older   (Adult, Older Adult)",Phase 2,149.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SAKK 19/09|SWS-SAKK-19-09|EU-21026,June 2010,July 2014,May 2016,"May 4, 2010",,"May 15, 2019","Kantonsspital Aarau, Aarau, Switzerland|Kantonsspital Baden, Baden, Switzerland|Saint Claraspital AG, Basel, Switzerland|Clinical Cancer Research Center at University Hospital Basel, Basel, Switzerland|Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Spitalzentrum Biel, Biel, Switzerland|Kantonsspital Bruderholz, Bruderholz, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Kantonsspital Freiburg, Freiburg, Switzerland|Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland|Centre Pluridisciplinaire d' Oncologie, Lausanne, Switzerland|Kantonsspital Liestal, Liestal, Switzerland|Kantonsspital Luzern, Luzerne, Switzerland|Kantonsspital Olten, Olten, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland|Regionalspital, Thun, Switzerland|Spital Uster, Uster, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|UniversitaetsSpital Zuerich, Zurich, Switzerland|City Hospital Triemli, Zurich, Switzerland|Onkozentrum Hirslanden, Zürich, Switzerland",,https://ClinicalTrials.gov/show/NCT01116219,2,"bevacizumab, erlotinib","bevacizumab, pemetrexed, cisplatin",1,1,False,False,False,False,"bevacizumab, erlotinib","bevacizumab, pemetrexed, cisplatin",1,1
700,3028,3029,NCT00903292,Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma,,Unknown status,No Results Available,Non-Small Cell Lung Cancer,Drug: erlotinib (Tarceva)|Drug: pemetrexed (Alimta),"The primary analysis will be the overall best response rate, including a 95% confidence interval (Leemis and Trivedi 1996).",National Cheng-Kung University Hospital,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,52.0,Other,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,HR98004,March 2009,April 2010,December 2010,"May 18, 2009",,"May 18, 2009","National Cheng-Kung University Hospital, Tainan, Taiwan",,https://ClinicalTrials.gov/show/NCT00903292,2,erlotinib (tarceva),pemetrexed (alimta),1,1,False,False,False,False,erlotinib (tarceva),pemetrexed (alimta),1,1
704,3040,3041,NCT01236716,Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung,C-TONG1002,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Albumin paclitaxel plus carboplatin|Drug: Gemcitabine plus carboplatin,"Overall response rate(ORR)|Response duration, progression free survival, overall survival, safety profile",Chinese Society of Lung Cancer,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,126.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C-TONG1002,November 2010,December 2013,June 2014,"November 9, 2010",,"August 6, 2014","Guangdong General Hospital, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01236716,2,albumin paclitaxel plus carboplatin,gemcitabine plus carboplatin,1,1,False,False,False,False,albumin paclitaxel plus carboplatin,gemcitabine plus carboplatin,1,1
718,3075,3076,NCT02148380,Combination of Chemotherapy and Gefitinib as First-line Treatment,,Completed,No Results Available,Non-Small-Cell Lung Cancer,Drug: pemetrexed plus carboplatin|Drug: gefitinib,progression-free survival|overall survival|to evaluate the safety profile between three groups,Baohui Han|Shanghai Chest Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,121.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,chest20140001,May 2014,December 2014,December 2015,"May 28, 2014",,"April 20, 2016","Shanghai Chest Hospital, Shanghai, China",,https://ClinicalTrials.gov/show/NCT02148380,2,pemetrexed plus carboplatin,gefitinib,1,1,False,False,False,False,pemetrexed plus carboplatin,gefitinib,1,1
722,3096,3097,NCT00695994,The Effect of Docetaxel or Gemcitabine-based Chemotherapy in East Asian and Caucasian Patients,,Completed,No Results Available,Non Small Cell Lung Cancer|Breast Cancer,Drug: Docetaxel|Drug: gemcitabine and carboplatin,"Treatment toxicities|objective tumour response, survival, median time to progression, and duration of response","National University Hospital, Singapore",All,"18 Years and older   (Adult, Older Adult)",Phase 2,300.0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTRG-PG02/26/06,October 2006,September 2012,September 2012,"June 12, 2008",,"November 1, 2012","National University Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT00695994,2,docetaxel,gemcitabine and carboplatin,1,1,False,False,False,False,docetaxel,gemcitabine and carboplatin,1,1
729,3124,3125,NCT00354549,Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC,,Completed,No Results Available,Lung Cancer,Drug: bevacizumab + erlotinib hydrochloride|Drug: gemcitabine hydrochloride + cisplatin or carboplatin,"Disease stabilization (DS) (complete response [CR], partial response [PR], or stable disease [SD]) as assessed by RECIST criteria after 12 weeks of treatment with bevacizumab and erlotinib hydrochloride|DS as assessed by RECIST criteria after 6 and 18 weeks of treatment with bevacizumab and erlotinib hydrochloride|Objective response (CR or PR) as assessed by RECIST criteria after 6, 12, and 18 weeks of treatment with bevacizumab and erlotinib hydrochloride|Best overall response when treated with bevacizumab and erlotinib hydrochloride|Adverse events (AEs) when treated with bevacizumab and erlotinib hydrochloride|Time to progression (TTP) when treated with bevacizumab and erlotinib hydrochloride|Time to treatment failure (TTF) when treated with bevacizumab and erlotinib hydrochloride|Quality of life (QOL) when treated with bevacizumab and erlotinib hydrochloride|Objective response (CR or PR) when treated with chemotherapy|Unexpected adverse drug reaction|QOL when treated with chemotherapy|Overall survival (OS) in patients treated with bevacizumab and erlotinib hydrochloride and in patients treated with subsequent chemotherapy at disease progression",Swiss Group for Clinical Cancer Research,All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 2,104.0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SAKK 19/05|EU-20614,January 2006,April 2009,September 2010,"July 20, 2006",,"May 15, 2019","Universitaetsspital-Basel, Basel, Switzerland|Oncology Institute of Southern Switzerland, Bellinzona, Switzerland",,https://ClinicalTrials.gov/show/NCT00354549,2,bevacizumab + erlotinib hydrochloride,gemcitabine hydrochloride + cisplatin or carboplatin,1,1,False,False,False,False,bevacizumab + erlotinib hydrochloride,gemcitabine hydrochloride + cisplatin or carboplatin,1,1
739,3169,3170,NCT00198354,Stage I/II NSCLC Perioperative Chemotherapy,,Completed,No Results Available,Non-small Cell Lung Cancer Stage I and II|Peri-operative Chemotherapy,Drug: gemcitabine + cisplatine|Drug: Paclitaxel + Carboplatine,Compare 3-Years survival|Compare Objective response rate,Intergroupe Francophone de Cancerologie Thoracique,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,530.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IFCT-0002,May 2001,December 2009,December 2010,"September 20, 2005",,"March 10, 2016","CHU Besancon - Pneumologie, Besancon, France",,https://ClinicalTrials.gov/show/NCT00198354,2,gemcitabine + cisplatine,paclitaxel + carboplatine,1,1,False,False,False,False,gemcitabine + cisplatine,paclitaxel + carboplatine,1,1
740,3171,3172,NCT01326767,Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring,CEPAC-TDM,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Paclitaxel dosing according to SmPC|Drug: Individualized pharmacokinetically driven paclitaxel dosing,Grad 4 Neutropenia|Objective tumor response according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST v1.1)|Progression free survival|Overall survival|Overall neutropenia|Hematological / non-hematological toxicites|Cumulative dose and dose intensity of paclitaxel and platinum drug|Incidence of changes from cisplatin to carboplatin and reasons thereof|Overall rate of febrile neutropenia and hospitalization due to chemotherapy-associated adverse events|Health economic analysis using QoL Questionnaires,"Central European Society for Anticancer Drug Research|Saladax Biomedical, Inc.|Cantonal Hospital of St. Gallen|University Hospital, Basel, Switzerland|Assign Data Management and Biostatistics GmbH|Wake Forest University|University Hospital, Essen",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,366.0,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C-III-002|2010-023688-16,March 2011,December 2014,December 2014,"March 31, 2011",,"January 27, 2016","CESAR Study Center, Bochum, Germany|CESAR study center, Bonn, Germany|CESAR Study Center, Essen, Germany|CESAR study center, Gerlingen, Germany|CESAR study center, Großhansdorf, Germany|CESAR Study Center, Halle an der Saale, Germany|CESAR Study Center, Leer, Germany|CESAR Study Center, Löwenstein, Germany|CESAR Study Center, Munich, Germany|CESAR Study Center, Tübingen, Germany|Kantonsspital St. Gallen, St. Gallen, Switzerland",,https://ClinicalTrials.gov/show/NCT01326767,2,paclitaxel dosing according to smpc,individualized pharmacokinetically driven paclitaxel dosing,1,1,False,False,False,False,paclitaxel dosing according to smpc,individualized pharmacokinetically driven paclitaxel dosing,1,1
746,3186,3187,NCT00174772,Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC),,Completed,No Results Available,Lung Neoplasms,Drug: docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy|Drug: docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin,anti-tumor activity including overall response rate|all treatment related acute and chronic toxicity assessed according to the NCI-CTC scale|other adverse events not reported in the NCI-CTI scale|hematological and non-hematological toxicities,Sanofi,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,72.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XRP6976B_2505,March 2004,February 2009,February 2009,"September 15, 2005",,"February 17, 2010","Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Istanbul, Turkey|Sanofi-Aventis Administrative Office, Guilford, United Kingdom",,https://ClinicalTrials.gov/show/NCT00174772,2,docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy,docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin,1,1,False,False,False,False,docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy,docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin,1,1
759,3261,3262,NCT00269828,A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.,,Terminated,No Results Available,NSCLC,Drug: paclitaxel|Drug: paclitaxel poliglumex,"The primary objective of this study is to compare the overall survival of female patients randomized to CT-2103 to that of female patients randomized to paclitaxel.|Secondary objectives are to compare the progression-free survival, response rate, disease control, clinical benefit, quality of life, and the safety and tolerability of the treatment arms.",CTI BioPharma,Female,"18 Years and older   (Adult, Older Adult)",Phase 3,600.0,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PGT305|PIONEER,December 2005,,December 2006,"December 26, 2005",,"February 14, 2007","Desert Oasis Cancer Center, Casa Grande, Arizona, United States|Arizona Hematology Oncology, Tucson, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Heritage Physician Group, Oncology, Hot Springs, Arkansas, United States|Pacific Cancer Medical Center, Inc, Anaheim, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|Providence St. Joseph Medical Center, Burbank, California, United States|Hematology/Oncology Group of Fresno, Inc, Fresno, California, United States|Comprehensive Cancer Center-Research Office, Glendale, California, United States|Loma Linda University Cancer Institute, Loma Linda, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Medical Oncology Care Associates, Orange, California, United States|The Cancer Research and Prevention Center, Soquel, California, United States|Bethesda Research Center, Boynton Beach, Florida, United States|Broward Oncology Associates, Ft. Lauderdale, Florida, United States|Florida Wellcare, Inverness, Florida, United States|Cancer & Blood Disease Center, Lecanto, Florida, United States|Oncology-Hematology Associates of West Broward, Tamarac, Florida, United States|Hematology Oncology Speaclist, Tampa, Florida, United States|Joliet Oncology Hematology Associates, Ltd., Joliet, Illinois, United States|Loyola University Health Systems, Maywood, Illinois, United States|Mid-Illinois HEM & ONC Assoc., Normal, Illinois, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Associated Physicians & Surgeons Clinic, Terre Haute, Indiana, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|West Kentucky Hematology & Oncology Group, PSC, Paducah, Kentucky, United States|Cabrini Center for Cancer Care, Alexandria, Louisiana, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Oncology Care Associates, PLLC, St. Joseph, Michigan, United States|Troy, Michigan, United States|Hubert H. Humphrey Cancer Center, Robbinsdale, Minnesota, United States|St. Louis Cancer Care Center, Chesterfield, Missouri, United States|Columbia Comprehensive Cancer Care Clinics, Columbia, Missouri, United States|Bond Clinic, Rolla, Missouri, United States|Saint Louis University, St. Louis, Missouri, United States|Washington University Siteman Cancer Center Pharmacy, St. Louis, Missouri, United States|Montana Cancer Specialists, Missoula, Montana, United States|Sierra Nevada Oncology Care, Carson City, Nevada, United States|Essex Oncology of North Jersey, PA, Belleville, New Jersey, United States|Atlanta HEM ONC, Manasquan, New Jersey, United States|Oncology and Hematology Specialist, PA, Moutain Lakes, New Jersey, United States|San Juan Oncology Association, Farmington, New Mexico, United States|Our Lady of Mercy Medical Center, Bronx, New York, United States|Suny Downstate Medical Center, Brooklyn, New York, United States|Cancer Treatment Services, Corning, New York, United States|Interlakes Foundation, Inc., Rochester, New York, United States|Guthrie Clinic, Sayre, New York, United States|New York Medical Collegw, Valhalla, New York, United States|Alamance Cancer Center, Burling, North Carolina, United States|UNC Chapel Hill Oncology Protocol Office, Chapel Hill, North Carolina, United States|Leo Jenkins Cancer Center, Greenville, North Carolina, United States|Northwestern Carolina Oncology & Hematology, Hickory, North Carolina, United States|St. Alexius Medical Center, Bismark, North Dakota, United States|University of Cleveland, Cleveland, Ohio, United States|Metro Health Medical Center, Cleveland, Ohio, United States|The Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, Ohio, United States|Dayton Clinical Oncology Program, Dayton, Ohio, United States|Signal Point Hematology/Oncology, Inc., Middletown, Ohio, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|The Family Cancer Center, Collierville, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|JPS Center for Cancer Care, Ft. Worth, Texas, United States|Columbia Basin HEM/ONC, Kennewick, Washington, United States|Sanatorio Parque, Rosario, Santa Fe, Argentina|CETEN, Beunos Aires, Argentina|Hospital Privado de Comunidad, Buenos Aires, Argentina|Hospital General de Agudos ""Dr Teodoro Alvarez"", Buenos Aires, Argentina|Instituto Alexander Fleming, Ciudad de Buenos Aires, Argentina|Instituto Oncologico de Cordoba - IONC, Cordoba, Argentina|LUCEN, Cuidad Autonoma de Buenos Aires, Argentina|ISIS Clinica Especializada, Urquiza, Argentina|District Oncology Dispensary, Plovdiv, Bulgaria|District Oncolodispensary with Impatient sector, Rousse, Bulgaria|Military Medical Academy, Sofia, Bulgaria|Regional Oncology Dispensary with Inpatient Secot-Sofia District, Sogia, Bulgaria|Regional Oncology Dispensary with Inpatient Sector, Varna, Bulgaria|University Mulitprofile Hospital for Active Treatment ""Sveta Marina"", Varna, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sveta Marina"", Varna, Bulgaria|Regional Oncology Dispensary with Inpatient sector, Veliko Tarnovo, Bulgaria|Jewish General Hospital, Montreal, Quebec, Canada|Erzsebet Juhasz, Budapest, Hungary|University of Debrecen, Pulmonology Clinic, Debreen, Hungary|Hospital for Thoracic Diseases of Csongrad Country, Deszk, Hungary|Pulmonology Institute of Veszprem County, Farkasgyepu, Hungary|Hospital for Pulmonological Diseases of the Bekes County, Gyula, Hungary|Hospital of the Chest Desease of the Hungarian Reformed Church, Mosdos, Hungary|Karolina Hospital, Mosonmagyarovar, Hungary|Barany County Hospital, Pecs, Hungary|Erzsebet Hospital, Sopron, Hungary|Sanatorium for Pulmonological Diseases, Torokbalint, Hungary|Centenario Hospital Miguel Hidalgo, Aguascalientes, Ags., Mexico|CIMA Chihuahua, Chihuahua, Chih, Mexico|Hospital General, Durango, Dgo., Mexico|Instituto Estatal de Cancerologia ""Dr. Arturo Beltran Ortega"", Acapulco, Gro, Mexico|Hospital Dr. Angel Leano, Zapopan, Jalisco, Mexico|Hospital Star Medica Morelina, Morelia, Michoacan, Mexico|Monterrey International Research Center, Monterrey, N.l., Mexico|Centro Estatal de Canceologia, Jalapa, Veracruz, Mexico|Centro Anticanceroso de la Cruz Roja Mexicana de Merida, Merida, Yucatan, Mexico|Centro Estatal de Cancerologia, Chihuahua, Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"", San Luis Potosi, Mexico|Hospital General Regional, Veracruz, Mexico|Kujawsko-Pomorskie Centrum Pulmunologii, Bydgoszcz, Poland|Krakowski Szpital Specjelistyczny, Kawkow, Poland|Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland|Zaklad Opieki Zdrowotnej Ministerstaw Spraw Wewnetrznych i Administraeji, Olsztyn, Poland|Mazowleckie Centrum leczenia Chorob Pluc i Gruzlicy, Otwock, Poland|Wielkopolskie Centrum Chorob Pluc i Gruzlicy, Samodzielmy Publiczny ZOZ, Poznan, Poland|SPSK nr l im. Przemienienia AM w Poznaniu, Poznan, Poland|MSc Grezegorz Jedrejezak, Wroclaw, Poland|Dolnoslaskie Centrum Chorob Pluc ul. Grabiszynska 105, Wroclaw, Poland|Institutul Oncologie - Clinic de Oncologie Medicala, Bucharest, Romania|Prof. Dr. Al. Trestioreanu Institute of Oncology, Bucharest, Romania|""Prof. Dr. I. Chiricuta"" Institute of Oncology, Cluj-Napoca, Romania|Emergency Clinical County Hospital, Craiova, Romania|Oradea Clinical County Hospital, Oradea, Romania|Clinical County Hospital, Sibiu, Romania|Timisoara Emergency Clinical Municipal Hospital, Timisoara, Romania|Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation|Krasnodar City Oncology Center, Krasnodar, Russian Federation|Moscow Municpal Oncology Hospital #62, Moscow Region, Russian Federation|Moscow Oncology Clinical Dispensary #1, Moscow, Russian Federation|SI Russian Oncological Scientific Center after N.N. Blokhim RAMS, Moscow, Russian Federation|SI Russian Oncological Scientific Center after N.N. Blokhin RAMS, Moscow, Russian Federation|Centeral ClinicalHospital of the President o the Russian Federation, Moscow, Russian Federation|Omsk Regional Oncology Center, Omsk, Russian Federation|Orenburg Regional Oncology Clinical Center, Orenburg, Russian Federation|St. Petersburg City Clinical Oncology Center, Saint Petersburg, Russian Federation|Lenigrad Regional Oncology Center, St. Petersburg, Russian Federation|Leningrad Regional Clinical Hospital, St. Petersburg, Russian Federation|St. Petersbrug State Medical Pavlov University, St. Petersburg, Russian Federation|Donetsk Regional Antineoplastic Center, Donetsk, Ukraine|Ivano-Frankovsk Regional Oncology Center, Ivano-Frankovsk Medical University, Ivano-Frankovsk, Ukraine|Instiute of Oncology under AMS of Ukraine, Kiev, Ukraine|Volyn Regional Oncology Dispensary, Lutsk, Ukraine|Uzhgorod National University, Regional Clinical Oncology Dispensary, Uzhgorod, Ukraine|Vinnitsa State Medical University, Vynnytsya, Ukraine|Zaporizhzhya Regional Oncology Dispensary, Zaprizhzhya, Ukraine|The Royal Bournemouth Hospital, Bournemouth, United Kingdom|Oncology Pharmacy, London, United Kingdom|Wythenshaw Hospital, Pharmacy Department, Manchester, United Kingdom|Southhampton General Hospital, Southhampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT00269828,2,paclitaxel,paclitaxel poliglumex,1,1,False,False,False,False,paclitaxel,paclitaxel poliglumex,1,1
773,3342,3343,NCT00298415,Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC),,Completed,No Results Available,NSCLC,Drug: Paclitaxel + Carboplatin|Drug: Monotherapy (gemcitabine or vinorelbine),Overall survival|Objective response,Intergroupe Francophone de Cancerologie Thoracique,All,70 Years to 89 Years   (Older Adult),Phase 3,451.0,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IFCT-0501,March 2006,September 2010,December 2011,"March 2, 2006",,"October 25, 2013","CH - Pneumologie, Belfort, France|CHU Besancon - Pneumologie, Besancon, France|CHU - Pneumologie, Caen, France|CHU, Grenoble, France|Hôpital Tenon - Pneumologie, Paris, France",,https://ClinicalTrials.gov/show/NCT00298415,2,paclitaxel + carboplatin,monotherapy (gemcitabine or vinorelbine),1,1,False,False,False,False,paclitaxel + carboplatin,monotherapy (gemcitabine or vinorelbine),1,1
791,3426,3427,NCT02607592,A Prospective Multi-center Phase III Randomized Controlled Trial,NACA,Recruiting,No Results Available,Carcinoma，Non-Small-Cell Lung,Drug: cisplatin and pemetrexed|Drug: nadaplatin+pemetrexed,overall toxicity value|primary free-survival（PFS）|objective response rate （ORR）|overall survival（OS）,Sun Yat-sen University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,293.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,201507003,August 2015,August 2019,August 2020,"November 18, 2015",,"June 27, 2019","Sun Yat-sen University of cancer center, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02607592,2,cisplatin and pemetrexed,nadaplatin+pemetrexed,1,1,False,False,False,False,cisplatin and pemetrexed,nadaplatin+pemetrexed,1,1
802,3499,3500,NCT01347424,Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography,,Unknown status,No Results Available,Non Small Cell Lung Cancer|Nasopharyngeal Cancer|Liver Metastasis,"Drug: Paclitaxel , carboplatin, endostatin|Drug: Paclitaxel and Carboplatin",The changes of blood flow perfusion in secondary malignant neoplasm of liver|Comparing the difference of OS(Overall Survival) and ORR(Objective Response Rate) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria in the two different arms.|Number of Participants with Adverse Events in the two different arms,Sun Yat-sen University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,40.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XIANSHENG,January 2011,May 2014,October 2014,"May 4, 2011",,"December 9, 2013","SunYat-senU, GuangZhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01347424,2,"paclitaxel , carboplatin, endostatin",paclitaxel and carboplatin,1,1,False,False,False,False,"paclitaxel , carboplatin, endostatin",paclitaxel and carboplatin,1,1
803,3506,3507,NCT00432315,Docetaxel in Non Small Cell Lung Cancer (NSCLC),,Completed,No Results Available,"Carcinoma, Squamous Cell",Drug: Docetaxel + CDDP|Drug: docetaxel + CDDP,To assess the response rate to induction therapy with docetaxel in combination with CDDP|Resectability after induction therapy|Time to progression|Overall survival|Safety profile|Quality of life,Sanofi,All,"19 Years to 75 Years   (Adult, Older Adult)",Phase 2,80.0,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TAX_AT1_203,May 2001,October 2009,October 2009,"February 7, 2007",,"September 14, 2010","Sanofi-Aventis Administrative Office, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT00432315,2,docetaxel + cddp,docetaxel + cddp,1,1,False,False,False,False,docetaxel + cddp,docetaxel + cddp,1,1
821,3596,3597,NCT01769066,Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC,,Completed,No Results Available,NSCLC,Drug: Sequential Gefitinib With Pemetrexed/Platinum|Drug: Pemetrexed/Platinum,12 weeks of non-progression rate|PFS,Fudan University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,117.0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Gefitinib-2009-cjh,December 2009,February 2014,,"January 16, 2013",,"February 23, 2016","Cancer hospital Fudan University, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01769066,2,sequential gefitinib with pemetrexed/platinum,pemetrexed/platinum,1,1,False,False,False,False,sequential gefitinib with pemetrexed/platinum,pemetrexed/platinum,1,1
826,3627,3628,NCT00436332,S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma,,"Active, not recruiting",Has Results,Lung Cancer,Biological: bevacizumab|Drug: erlotinib hydrochloride,Overall Survival|Progression-free Survival|Response as Assessed by RECIST Criteria vs Central Computer-assisted Image-analysis System in Patients With Measurable Disease|Frequency and Severity of Toxicities,Southwest Oncology Group|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 2,84.0,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000529756|S0635|U10CA032102,July 2007,August 2016,August 2019,"February 19, 2007","December 22, 2016","November 8, 2018","Kaiser Permanente - Deer Valley, Antioch, California, United States|Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States|Peninsula Medical Center, Burlingame, California, United States|Kaiser Permanente - Fremont, Fremont, California, United States|Kaiser Permanente Medical Center - Hayward, Hayward, California, United States|Tibotec Therapeutics - Division of Ortho Biotech Products, LP, Marysville, California, United States|Kaiser Permanente Medical Center - Oakland, Oakland, California, United States|Valley Medical Oncology Consultants - Pleasanton, Pleasanton, California, United States|Kaiser Permanente Medical Center - Redwood City, Redwood City, California, United States|Kaiser Permanente Medical Center - Richmond, Richmond, California, United States|Kaiser Permanente Medical Center - Roseville, Roseville, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|South Sacramento Kaiser-Permanente Medical Center, Sacramento, California, United States|Kaiser Permanente Medical Center - Sacramento, Sacramento, California, United States|Kaiser Permanente Medical Center - San Francisco Geary Campus, San Francisco, California, United States|California Pacific Medical Center - California Campus, San Francisco, California, United States|Kaiser Permanente Medical Center - Santa Teresa, San Jose, California, United States|Kaiser Foundation Hospital - San Rafael, San Rafael, California, United States|Sutter Health - Western Division Cancer Research Group, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara Kiely Campus, Santa Clara, California, United States|Kaiser Permanente Medical Center - Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente Medical Center - South San Francisco, South San Francisco, California, United States|Kaiser Permanente Medical Facility - Stockton, Stockton, California, United States|Tahoe Forest Cancer Center, Truckee, California, United States|Kaiser Permanente Medical Center - Vacaville, Vacaville, California, United States|Kaiser Permanente Medical Center - Vallejo, Vallejo, California, United States|Sutter Solano Medical Center, Vallejo, California, United States|Kaiser Permanente Medical Center - Walnut Creek, Walnut Creek, California, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Piedmont Hospital, Atlanta, Georgia, United States|Northside Hospital Cancer Center, Atlanta, Georgia, United States|Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|WellStar Cobb Hospital, Austell, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Kennestone Cancer Center at Wellstar Kennestone Hospital, Marietta, Georgia, United States|Southern Regional Medical Center, Riverdale, Georgia, United States|Harbin Clinic Cancer Center - Medical Oncology, Rome, Georgia, United States|Kaiser Permanente - Moanalua Medical Center and Clinic, Honolulu, Hawaii, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|Regional Cancer Center at Memorial Medical Center, Springfield, Illinois, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Liberal, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas, United States|Cotton-O'Neil Cancer Center, Topeka, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Lucille P. Markey Cancer Center at University of Kentucky, Lexington, Kentucky, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Battle Creek Health System Cancer Care Center, Battle Creek, Michigan, United States|Mecosta County Medical Center, Big Rapids, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|Butterworth Hospital at Spectrum Health, Grand Rapids, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|Lacks Cancer Center at Saint Mary's Health Care, Grand Rapids, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Mercy General Health Partners, Muskegon, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Big Sky Oncology, Great Falls, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Mary Rutan Hospital, Bellefontaine, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|American Fork Hospital, American Fork, Utah, United States|Sandra L. Maxwell Cancer Center, Cedar City, Utah, United States|Logan Regional Hospital, Logan, Utah, United States|Jon and Karen Huntsman Cancer Center at Intermountain Medical Center, Murray, Utah, United States|Val and Ann Browning Cancer Center at McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center - Provo, Provo, Utah, United States|Dixie Regional Medical Center - East Campus, Saint George, Utah, United States|Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|St. Joseph Cancer Center, Bellingham, Washington, United States|Olympic Hematology and Oncology, Bremerton, Washington, United States|Columbia Basin Hematology, Kennewick, Washington, United States|Skagit Valley Hospital Cancer Care Center, Mount Vernon, Washington, United States|Harrison Poulsbo Hematology and Onocology, Poulsbo, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical, PLLC, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Group Health Central Hospital, Seattle, Washington, United States|Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Evergreen Hematology and Oncology, PS, Spokane, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States",,https://ClinicalTrials.gov/show/NCT00436332,2,bevacizumab,erlotinib hydrochloride,1,1,False,False,False,False,bevacizumab,erlotinib hydrochloride,1,1
